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THE EFFICACY OF SACRAL NERVE STIMULATION IN PATIENTS  
WITH NEUROPATHIC CONSTIPATION 
Usman Khan 
Rationale: 
Constipation is a common complaint in people with neurological diseases causing significant 
physical and psychological distress. Poor response to therapy is due to a number of factors: 
severe disruption to normal physiology (gut denervation); use of constipating drugs in the 
presence of immobility; and co-existence of faecal incontinence and constipation precluding 
treatment with standard oral laxatives.  
Sacral nerve stimulation (SNS) has been shown to have a beneficial effect in patients with 
functional constipation. It is a treatment with established efficacy for faecal incontinence, 
including that due to neurological disease. However, there are no studies on the efficacy of SNS 
in neuropathic constipation. Pilot work in this patient group was positive, thus a formal trial was 
indicated. 
This thesis reports a proof-of-concept trial examining the effectiveness of temporary SNS in 
neurological constipation. The study assessed efficacy over a three-week period of temporary 
SNS using an off-on-off design.  
Methods and principal evaluation criteria:  
The trial aimed to recruit 30 patients with constipation of neurological origin from the specialist 
clinic at the University Hospital North Durham, over a two-year period. For each patient, the trial 
lasted twelve weeks, including: a pre-SNS period of six weeks of baseline assessment, a three 
week period of stimulation and a three week period of post-treatment assessment.  The 
measurement schedule of symptoms and quality-of-life during the trial assessed symptom 
stability and the temporal effects of treatment. Physiological data was collected before and 
during treatment, in the form of transit studies and laser Doppler flow cytometry of rectal 
mucosal blood supply.  
The primary outcome measure was a global assessment of severity of constipation. Self-
administered questionnaires including patient assessment of symptoms (PAC-SYM) and patient 
assessment of quality of life (PAC-QOL), transit study, and laser Doppler flowcytometry (LDFC) 
constituted the secondary outcome measures. 
Patients responding to temporary SNS were offered implanted permanent SNS and long term 
response was evaluated. 
Results and possible implications:  
Twenty-two patients were recruited, including 8 men and 14 women with an average age of 51.5 
years (Range 38-69 yrs.). Four patients dropped out and were lost to follow-up; 18 patients 
completed the trial. Twelve patients (67%) had a successful response after three weeks of 
bilateral temporary stimulation and underwent permanent implant. The Global Assessment 
Score for constipation, PAC-SYM and PAC-QOL scores for these patients improved during 
treatment with temporary SNS (p<0.05). There was also an improvement in toileting time 
(p=0.04) and decrease in overall laxative use (p=0.03).  Physiological parameters did not change.  
The overall response rate during long-term follow-up (mean 20 mths) was 6/12 (50%, 95%CI: 
21% to 79%). 
Interpretation: 
Short term treatment with SNS helped two thirds of patients with neuropathic constipation in 
the short term. There was good symptom stability before treatment and rapid return to baseline 
after treatment. However, there were no improvements in the physiological measures used, so 
that a placebo response may have brought about the improvement in some patients.  Temporary 
SNS only identified 50% of long-term responders. 
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1. Introduction 
In this introduction constipation is described broadly as well as in terms of the more 
severe spectrum of patients referred to specialist clinics. The range of current 
treatment modalities are reviewed with their strengths and weaknesses. Particularly, 
attention is paid to the management of patient with neuropathic constipation, who are 
the subject of this thesis. Finally sacral nerve stimulation is introduced as a novel 
intervention requiring further evaluation in patients with severe neuroconstipation. 
Constipation is caused by a range of heterogeneous conditions many of which are 
poorly understood. Chronic constipation can be refractory to treatment and 
significantly affects quality of life. Constipation has a prevalence of 5% to 20 % in the 
general population. In one population survey of 10,000 people in United States its 
overall prevalence was found to be 14.7 % (Stewart, Liberman et al. 1999). In the UK, 
constipation is prevalent in less than 10% of the non-clinical population but this 
increases to up to 25% in those above 70 years of age (Campbell, Busby et al. 1993). A 
recent multinational survey of 13,000 participants showed that 12 % of women and 
5% of men in the United Kingdom have constipation (Wald, Scarpignato et al. 2008). 
The association with age is documented in the literature with constipation being more 
common in the very young and the very old. Similarly, women are affected more by 
constipation with an estimated female to male ratio of 2.2:1(Higgins and Johanson 
2004) . 
Constipation usually takes a chronic course with nearly half of the subjects having 
constipation for five or more years (Stewart, Liberman et al. 1999). Laxatives are used 
more often by those over 65 years of age but the overall use of laxatives has reduced in 
recent years (Heaton and Cripps 1993). A recent review has shown that laxatives fail to 
treat up to 40% of patients (Wald, Scarpignato et al. 2008). Although there is a 
shortage of studies directly looking at the reasons for poor quality of life with 
constipation, it seems to be a direct effect (O'Keefe, Talley et al. 1995).  
There are nearly half a million GP consultations each year arising from constipation. As 
a result constipation has a substantial economic impact on the health service with an 
expenditure of £65 million in prescription costs for laxatives in 2009 alone (The 
Prescription Cost Analysis, England - 2009). A proportion of patients with constipation 
will not respond to standard treatment and have refractory constipation. This can be 
due to anatomical defects, mechanical obstruction in the bowel wall, neurological 
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disease or side effects of medications. These patients are difficult to manage in the 
primary care setting and will often require referrals to secondary or tertiary care for 
further treatment. 
The Durham Constipation Clinic is a regional referral centre for patients with 
refractory disease. The clinic was established in 2001 at the University Hospital of 
North Durham. The clinic receives referrals from all over the Northeast of England for 
difficult constipation cases, receiving around 150 new patient referrals per year and 
with 400 currently being followed-up. In an audit of new referrals to the specialist 
constipation clinic at University Hospital North Durham, constipation was found to be 
idiopathic in 69% (Cowlam 2008).  Around 10% of patients had neurogenic 
constipation (see section 1.5), and the rest had drug induced or other secondary 
constipation.  These referrals represent a distinct group compared to those whose 
symptoms can be self-controlled or managed within primary care. The ability of the 
clinic to find solutions where others have failed is partly dependent on pursuing 
detailed assessment of patient symptoms, lifestyle and physiology, together with a 
multi-disciplinary approach to treatment.  
1.1 Definition 
Constipation is a condition caused by a variety of heterogeneous conditions. The 
American College of Gastroenterology described constipation as “a symptom based 
disorder defined as unsatisfactory defaecation and is characterised by infrequent 
stools, difficult stool passage, or both. Difficult stool passage includes straining, a sense 
of difficulty passing stool, incomplete evacuation, hard /lumpy stools, prolonged time 
to stool or need for manual manoeuvres to pass stool” (Ramkumar and Rao 2005). 
Due to the heterogeneity of the symptoms in constipation and disparity between 
patient and physician perceptions of constipation, it is important to classify 
constipation into subgroups. Constipation can be classified as either primary or 
secondary (Gattuso and Kamm 1993). Table 1-1 shows the classification of 
constipation and enlists some examples of causes of secondary constipation. 
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Table 1-1: Classification of Constipation 
Primary Constipation Secondary Constipation 
Functional constipation Intrinsic (neoplasms, diverticular disease) 
Irritable bowel syndrome (constipation 
predominant) 
Anorectal (anal fissures, anal strictures, 
proctitis) 
Pelvic floor disorders 
Neuropathic (spinal cord injury, multiple 
sclerosis, Parkinson’s, stroke) 
Chronic  pseudo-obstruction 
Metabolic (electrolyte imbalance, thyroid 
disease, coeliac disease) 
Hirschsprung’s disease 
Pharmacological (antidepressants, 
opiates, antipsychotics, iron 
supplements) 
Idiopathic megacolon or megarectum 
Psychological 
Lifestyle or Diet 
 
1.2 Normal Defaecation  
To understand the pathogenesis of constipation there is a need to understand the 
physiology of defaecation. Defaecation involves a complex sequence of events requiring 
coordination between smooth and striated muscles, central, enteric and autonomic 
nervous systems. The rectum acts as a reservoir for faeces, which is propagated from 
the colon into the rectum with help of colonic contractions. Distally, the rectum 
continues as the anal canal. The anorectal junction is controlled by puborectalis part of 
levator ani muscle. The tone of the internal anal sphincter, puborectalis and external 
anal sphincter help maintain continence (Figure 1-1). The external anal sphincter is the 
distal continuation of the levator ani and can be voluntarily controlled. Colonic mass 
contractions propel the stool forwards past the recto-sigmoid junction into the rectum 
(Sarna 1991). This leads to distension of the rectum with faeces and eventually leads to 
an urge to defaecate (Wester and Brubaker 1998). The intensity of this urge increases 
as more faeces is pushed into the rectum and causes further distension (Sun, Read et al. 
1990). This distension causes rectal contractions and involuntary relaxation of the 
internal sphincter which pushes the rectal contents into the distal anal canal. Also, 
  
13 
 
there is contraction of the external sphincter to prevent soiling. This reflex is known as 
the rectoanal inhibitory reflex (RAIR) and helps in the sampling of the rectal contents 
to establish the need for defaecation (Read, Timms, et al. 1986).  
The anal canal opens up during the defaecation reflex by straightening of the anorectal 
angle and blunting of the anal cushions. This is achieved by a rise in the rectal pressure 
and a drop in the anal canal pressure. Contraction of the abdominal muscles and a 
decrease in the tone of the pelvic floor musculature causes the expulsion of the rectal 
contents (Womack, Williams et al. 1985). As the anorectal angle opens, the stool can be 
pushed out by performing the Valsalva manoeuvre. If the time or place is 
inappropriate, the defaecation process can be voluntarily deferred.  
To maintain continence the anal canal must return to its closing position. This is 
achieved by restoration of the anorectal angle, internal sphincter tone and the anal 
cushions. 
 
 
Figure 1-1 Anorectal Angle 
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1.3 Assessment of Constipation 
1.3.1 Clinical Assessment  
At the Durham constipation clinic patients are assessed during a 45-minute long 
consultation, which includes quality of life and symptom assessment using validated 
questionnaires. Patients classified as having primary or secondary constipation are 
further subclassified predominantly into either functional constipation or irritable 
bowel syndrome (primary) or neuropathic or drug-induced (secondary). All patients 
undergo an abdominal and pelvic exam in addition to detailed history taking. At the 
end of the clinical assessment appropriate investigations are requested. 
1.3.2 Laboratory Blood Test 
These may include a full blood count, routine biochemistry profiles, liver function tests 
and thyroid function tests. There are no studies directly observing the utilization of 
laboratory blood tests for screening and managing constipation. Although there is lack 
of evidence in this regard, certain metabolic and biochemical disorders predisposing to 
constipation can be ruled out by employing specific blood tests. 
1.3.3 Endoscopic Assessment 
Constipation presenting in older patients may require endoscopic investigation. In a 
study looking at the yield of lower GI endoscopy in cases of constipation, the 
investigators found that the rates of colonic cancers and adenomas were similar to 
those seen in studies of screening in an asymptomatic general population (Pepin and 
Ladabaum 2002). Chronic constipation on its own may not be an appropriate 
indication for lower GI endoscopy. Age-appropriate screening should be pursued when 
patients present with constipation. 
1.3.4 Imaging 
Nearly all patients referred for constipation will at some point have some form of 
imaging to assess their large bowel. There are three types. 
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1.3.4.1 Colonic Transit and Plain Abdominal Films 
Plain abdominal films may be helpful in diagnosing constipation but are of limited 
value in assessing the severity of symptoms (Cowlam, Khan et al. 2008). Scintigraphic 
transit studies have been validated and are reproducible, but are not routinely used 
due to their cost. Radio-opaque marker transit studies are routinely used and have 
been validated. The estimation of transit time can be achieved by using a simple bolus 
technique and then performing plain abdominal films. Alternatively, segmental transit 
can be determined with a single plain abdominal X-ray taken after ingestion of radio-
opaque markers for three consecutive days (Metcalf, Phillips et al. 1987). This latter 
method allows a reduction in the number of x-ray exposures compared to previously 
described techniques. 
1.3.4.2 Proctography 
A defaecating barium proctogram can be utilized to rule out organic defects like 
rectoceles, intussusceptions, and enteroceles and to map out the function of the 
rectum. Measuring the anorectal angle, pelvic floor descent, rectal evacuation and time 
taken to initiate defaecation achieves these aims. There have been no recent reviews on 
the value of proctography for the initial assessment of constipation. Proctography has 
been shown to have no correlation with the severity of symptoms or transit times 
(Infantino, Masin et al. 1990) 
At the Durham constipation clinic we utilize a radioisotope defaecating proctogram to 
determine anorectal function and identify rectoceles or prolapse. This is done by 
measuring parameters that have already been validated and described 
(Papachrysostomou, Smith et al. 1994).  
1.4 Treatment options for constipation 
Constipation can be an intractable condition and the aim of the therapy is to achieve 
normal stool frequency and consistency without unnecessary complexity. The 
management of constipation follows a stepped therapeutic pathway starting from 
lifestyle modification. 
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1.4.1 Lifestyle Modification 
This includes increasing dietary fibre and fluid intake as well as exercise. However 
there is not much evidence for the use and efficacy of non-pharmacological measures 
and conflicting evidence concerning the role of fibre in chronic constipation. Some 
studies have shown a beneficial effect on constipation with improvements in symptoms 
where as others have shown little or no effect. (Bingham and Cummings 1989; Muller-
Lissner, Kamm et al. 2005; Johanson 2007; Pare', Bridges et al. 2007). 
1.4.2 Laxative Therapy 
Laxatives can be prescribed if lifestyle modification proves inadequate to control 
symptoms. Laxatives are one of the most commonly prescribed medications and the 
prescription costs of laxatives in 2009 in the NHS was £65 million (The Prescription 
Cost Analysis, England - 2009). Generally, there are four types of laxatives: bulk-
forming, stimulant, osmotic laxatives and stool softeners.  
Bulking agents like psyllium retain water inside stool and facilitate peristalsis. These 
have been shown to increase transit time and stool frequency in adults (Cheskin, Kamal 
et al. 1995). Osmotic laxatives like lactulose or polyethylene glycol work by retaining 
water inside the colonic lumen by osmosis to prevent the formation of hard stools. 
These have been shown to be beneficial in chronic constipation but can produce 
bloating due to fermentation in the colon. Sodium docusate and other stool softeners 
have an unknown efficacy and there is limited data available. Similarly, due to 
inadequate data, the efficacy of stimulant laxatives for treating chronic constipation is 
not known. However, prescribing stool softeners and a stimulant laxative has been 
shown to be appropriate and feasible (Larkin, Sykes et al. 2008). 
Newer agents like prucalopride (5-HT4 receptor agonist) have been approved for use in 
chronic constipation after failure of laxative treatment (NICE guidance 2010). (See 
Table 1-2) 
Constipation is managed in a stepwise fashion reflecting the invasiveness, complexity 
and in some cases cost of the available treatment. When all conservative options have 
been tried and exhausted, invasive treatment options may be offered to patients. 
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Table 1-2: Pharmacological agents for treating constipation 
Type Examples Recommendation * 
Bulking 
agents 
Methylcellulose, sterculia. 
Psyllium (Ispaghula husk) 
Unknown effectiveness 
Likely to be beneficial 
Stool 
softeners 
Arachis Oil, docusate,  
Liquid paraffin 
Unknown effectiveness 
Osmotic 
agents 
Lactulose 
Polyethylene glycol 
Magnesium salts 
Phosphate/Citrate Enemas 
Likely to be beneficial 
Beneficial with no side effects 
Unknown effectiveness 
Unknown effectiveness 
Stimulants 
Senna, Bisacodyl, glycerine 
suppositories 
Unknown effectiveness 
Newer Agents 
Lubiprostone 
Prucalopride 
Superior to placebo** 
Superior to placebo** 
*(Frank Frizelle and Barclay 2007), **(Ford and Suares 2011) 
1.4.3 Biofeedback 
Biofeedback involves neuromuscular retraining of the pelvic floor muscles to improve 
evacuatory dysfunction in chronic constipation (Bassotti and Whitehead 1994; 
Koutsomanis, Lennard-Jones et al. 1995). There is evidence of long-term response 
(Chiotakakou-Faliakou, Kamm et al. 1998) with a measurable response in physiological 
parameters as well (Emmanuel and Kamm 2001). Patients with pelvic floor 
dyssynergia have been shown to receive long-term benefit from biofeedback with 
improvements in straining, bloating, intestinal transit and stool (Chiarioni, Salandini et 
al. 2005) (Figure 1-2, Figure 1-3). A recent study has shown biofeedback to be effective 
in patients with MS with improvements in symptoms and squeeze pressures (Preziosi, 
Raptis et al. 2011). However, uncontrolled series are not able to differentiate 
therapeutic response and natural regression of symptoms. 
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Figure 1-2: Straining after biofeedback 
 
*(Chiarioni, Salandini and Whitehead 2005) 
  
Figure 1-3: Bloating after biofeedback 
 
*(Chiarioni, Salandini and Whitehead 2005) 
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1.4.4 Surgery 
Surgery is a last resort for patients with chronic constipation and significant symptoms 
affecting their quality of life. Antegrade Continence Enema (ACE Procedure) can be 
performed in younger patients, providing effective symptomatic relief in up to 90% of 
patients (King, Sutcliffe et al. 2005). Some patients with severe refractory constipation 
finally face major surgery involving colectomy and ileorectal anastomosis. Some prefer 
undergoing surgery to having a stoma, which provides relief from their symptoms and 
can be reversed.  
1.4.5  Novel therapies 
Sacral nerve stimulation is a novel treatment with established efficacy in faecal 
incontinence. It has shown promising early results in trials for idiopathic constipation 
thus far: a formal NICE approval is still awaited for its use in idiopathic constipation.  
In overview, a multidimensional approach is required in managing constipation with a 
progressive increase in treatment to formulate an appropriate bowel regimen 
according to the type and severity of constipation. See Figure 1-4: Treatment Algorithm 
for management of constipation. 
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Figure 1-4: Treatment Algorithm for management of constipation 
 
*Reproduced from (Tack et al. 2011)
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1.5 Neurogenic bowel dysfunction 
The enteric nervous system (ENS) is made up of neurons with cell bodies either in the 
submucosal layer (Meissner’s Plexus) or in the myenteric layer beneath the muscular 
coat of the bowel (Auerbach’s Plexus). These two are interconnected through inter-
neurons and work in unison through physiological mechanisms that are unclear. ENS 
mediates reflexes that control internal sphincter relaxation during defaecation. 
The extrinsic nerve supply to the gut is partly controlled by the autonomic nervous 
system (ANS). The ANS consists of both parasympathetic and sympathetic innervation. 
The parasympathetic nerve fibres innervating the proximal gut arise from the vagus 
nerve and the left colon, sigmoid colon and the rectum are supplied by the outflow 
from the ventral sacral roots (S2-S4). Parasympathetic innervation is mainly excitatory 
and accelerates transit and controls propulsion during defaecation. Sympathetic 
outflow arises from the spinal cord (T9-L2) via the lumbar ventral roots and lumbar 
splanchnic nerves. These provide an inhibitory input to the colon and excitatory fibres 
to the internal anal sphincter (IAS).  
Pudendal nerves provide the somatic innervation to the external anal sphincter (EAS). 
The motor neuron cell bodies reside in the Onuf’s nucleus in the spinal cord. The 
somatic innervation is both sensory and motor. Rectal afferent fibres terminate in the 
dorsal horn of the lumbosacral cord. Unmyelinated C fibre afferents express 
neuropeptides and carry the noxious and painful stimuli from the rectum. Myelinated 
Aδ fibres carry the sensations of rectal fullness and discomfort from the rectal 
mechanoreceptors. See Figure 1-5. 
In spinal cord disease or injury the distal colon is the most affected segment of the 
large bowel. In lesions above the L2 segment (supraconal) sympathetic inhibition is 
lost. The injury pattern is similar to an upper motor neuron lesion and causes hyper-
reflexia and hypertonia of the rectum (Lynch, Anthony et al. 2000). The whole gut 
transit is slowed. This can cause reflex defaecation and can lead to incontinence.  
In cauda equina lesions, there is a lower motor neurone type presentation as the sacral 
reflex arc is disturbed leading to hypotonia and hyporeflexia (Krogh, Olsen et al. 2003). 
Both suparconal and conal injuries lead to faecal loading and impaction. This results in 
severe constipation leading to faecal incontinence and soiling. The most severe 
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dysfunction is seen in complete SCI. In incomplete SCI the level of the lesion does not 
correlate with the bowel dysfunction as the ENS plays some part in moderating the 
bowel function after the injury. The inhibitory parasympathetic input and excitatory 
sympathetic innervation to the IAS is lost. In complete SCI voluntary control is lost as 
the somatic innervation to the EAS via the pudendal nerves is disturbed. 
In multiple sclerosis (MS), the pathophysiology is similar to spinal cord disease but the 
lesions can occur at multiple levels resulting in variable presentations in patients with 
MS. Previous studies have described colonic dysfunction in severe MS patients (Glick, 
Meshkinpour et al. 1982) and patients with spinal cord injury (Glick, Meshkinpour et al. 
1984; Vallès, Vidal et al. 2006) secondary to visceral neuropathy causing severe 
constipation. According to one study, constipation, incontinence and nausea are all 
very common in spinal cord injury patients(Glickman and Kamm 1996).  
 
Figure 1-5: Nerve supply of the Alimentary tract 
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1.6 Neuroconstipation 
The term neuroconstipation refers to constipation due to neurological disease in the 
brain, spinal cord or the nerves supplying the bowel. Constipation is a major physical 
and psychological problem in patients with spinal cord disease and Multiple Sclerosis 
(MS).  The prevalence of MS is 100 to 120 per 100,000 of the population; 
approximately 52,000 to 62,000 people in England and Wales (NICE 2003). The 
prevalence of constipation is between 43% and 58% in patients with MS or spinal cord 
injury (SCI)(Hinds, Eidelman et al. 1990; De Looze, Van Laere et al. 1998), being a 
significant cause of physical and emotional distress in these patients. According to a 
study by Glickman, 95% of patients require some form of treatment for their 
constipation and more than half have psychological distress caused by their symptoms  
(Glickman and Kamm 1996). 
Neuroconstipation is a difficult condition to treat because of the complex pathological 
mechanisms involved. Thus, there are a number of factors contributing to constipation 
in patients with neurological disorders. A large proportion of these patients are either 
bed-bound or wheel chair bound. This reduced mobility has an adverse effect on their 
bowel habit causing severe constipation and faecal impaction. A poor diet with 
insufficient fluid intake and the lack of exercise, often compounds these problems. 
Patients are usually on long-term medication that can cause constipation as a side 
effect thus worsening their already poor bowel habit. Some patients on laxatives start 
experiencing diarrhoea which can cause incontinence.  
1.6.1 Treatment Options for neuroconstipation. 
Managing neuroconstipation is difficult in this heterogeneous group of patients with 
multiple aetiologies. The goal of therapy is to provide effective symptom relief while 
maintaining patient dignity and independence. The treatment also has to be cost-
effective for it to be sustainably provided. 
The options for managing neuroconstipation include manual evacuation with digital 
stimulation, pharmacological management with laxatives, suppositories and/or 
enemas, transanal irrigation and faecal diversion by formation of stomas. 
Patients with SCI suffer from unplanned evacuations leading to faecal incontinence and 
urinary tract infections. Presence of hard stools leads to prolonged toileting times in 
patients with SCI. In a multi-centre cross-sectional study of 837 patients with SCI, Haas 
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et al found manual evacuation to be effective in patients with hard stools (Haas, Geng et 
al. 2005). Manual evacuation also decreased the frequency of unplanned bowel 
movements and duration of toileting time. There was no evidence of injury to the anal 
canal sustained during manual evacuation. Although effective in patients with SCI, 
manual evacuation is very labour intensive and takes several hours to complete. The 
procedure has to be repeated every two to three days and carries a significant carer 
associated cost. 
Laxatives are associated with significant unplanned evacuations resulting in faecal 
incontinence. Soft or liquid stools result from laxative use and may lead to increased 
toileting time as well. Patients taking laxatives over a period of time often require 
increasing amounts of laxatives which may cause more difficulty in bowel evacuations. 
However, some patients with incomplete SCI having some control over their bowel 
function do seem to benefit positively form laxative therapy. (Harari, Sarkarati et al. 
1997; Lynch, Wong et al. 2000) 
For those patients undergoing surgery, a systematic review published in 2008 did not 
identify any functional or QOL related advantages in patients undergoing a colostomy 
when compared to SCI patients with an ileostomy. Toileting time was shown to 
significantly reduce in patients with a stoma (colostomy or ileostomy) and patients 
were satisfied with their stomas. (Hocevar and Gray 2008) 
Surgery for diversion carries a significant risk of early or late complications. A 
retrospective study in 32 patients with SCI recorded increased patient satisfaction and 
a decrease in toileting time (from 10.3 hrs/week to 1.9 hrs/week). However, 44% of 
patients suffered from complications (6% early, 37.5% late). These included diversion 
colitis, faecal fistula, parastomal hernias and adhesional bowel obstruction. (Branagan, 
Tromans et al. 2003) 
Transanal irrigation (TAI) is another treatment modality which has been shown to be 
effective and safe in patients with neuroconstipation. There is no standard protocol for 
TAI and treatment depends on individual response. TAI involves using a pump for 
irrigating the large bowel with tap water which results in evacuation of large bowel. 
Scintigraphic studies during TAI have shown that patients with SCI manage to evacuate 
most of their left colon and that TAI is more effective in patients with SCI (Christensen, 
Olsen et al. 2003).  
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A randomized controlled trial in 87 patients with SCI and neurogenic bowel 
dysfunction compared ten weeks of TAI with ten weeks of conservative management. 
The patients with SCI had both complete and incomplete spinal injuries. Subjective 
scoring methods were used to analyze the outcomes (Cleveland clinic constipation 
scoring system, St. Mark’s FI score, NBD score). Patients receiving TAI reported 
improved QOL, a decrease in toileting time (from 74 mins/day to 47 mins/day), a 
decrease in the frequency of urinary infections and improved overall satisfaction. The 
study period was extended to include another 20 patients in the TAI group but the 
investigators did not identify any predictors of response to TAI (Christensen, Bazzocchi 
et al. 2006). The evidence for TAI in patients with MS is limited to observational studies 
with mixed reports.  
In a 10 year follow-up study carried out in Denmark in 348 patients with different 
aetiologies, TAI was successful in 47% (145/348) of patients and treatment failure 
occurred in 53% (203/348) of patients. Patients with neurogenic bowel dysfunction 
had a better response to TAI than patients with other aetiologies. TAI was effective in 
62% of patients with SCI (n=68) and 50% of patients with MS (n=10). The reported 
frequency of TAI was daily (36%), every other day (35%), two to three times per week 
(25%) and once per week (14%). A significant number of treatment failures ended up 
having surgery (23%, n=81) with 18 patients undergoing SNS. TAI was shown to be 
very safe with a perforation rate of 1 per 55000 irrigations (0.002%). Other side effects 
included abdominal pain, sweating and general discomfort but overall TAI was well 
tolerated. (Christensen, Krogh et al. 2009) 
TAI is a safe and effective treatment option but requires a high frequency of treatment 
(every 2nd day in the Christensen study) and significant duration of toileting time. In 
contrast sacral nerve stimulation (SNS) offers a potential minimally invasive but 
unevaluated alternative. 
1.7 Sacral Nerve Stimulation 
Although not assessed in neuro-constipation, sacral nerve stimulation (SNS) has been 
extensively evaluated as a minimally invasive treatment option for patients with 
idiopathic constipation and/or faecal incontinence who have failed maximal 
conservative therapy. It involves continuing low-level stimulation of the sacral nerves 
to affect the hindgut, pelvic floor and the anal sphincters. It is a two-stage procedure 
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with a temporary (diagnostic) and permanent (therapeutic) stage and has been 
directly adapted from its use in treating urinary dysfunction (Figure 1-6). 
 
 
Figure 1-6: Sacral Nerve Stimulation 
 
 
1.7.1 Background 
The origin of SNS lies in the 1950s when research work was carried out to find new 
treatment modalities for urinary dysfunction. Early studies involved direct stimulation 
of the spinal cord, followed by work on the detrusor muscle and the striated sphincter. 
Results of these studies were unsatisfactory, so the focus shifted towards SNS. It was 
observed that bowel function improved in patients undergoing SNS for urinary 
dysfunction, prompting interest in treating functional bowel disorders with SNS (Pettit, 
Thompson et al. 2002). The first permanent implant for SNS was reported in 1981 by E. 
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Tanagho and R. Schmidt, for the treatment of bladder dysfunction such as urge 
incontinence and non-obstructive urinary retention (Tanagho and Schmidt 1982). 
1.7.2 Technique 
Diagnostic or temporary SNS (TSNS) involves percutaneous placement of a needle 
inside the sacral foramina followed by the use of a stimulator to evaluate muscle 
responses in the pelvic floor. This helps to identify the sacral foramen offering the most 
appropriate response. The procedure requires a short general anaesthetic and has no 
major complications. 
After evaluation and identification of an adequate response, the needle is substituted 
with a temporary nerve electrode, which is connected to an external stimulator for a 
short evaluative period typically two to three weeks. Functional response can then be 
assessed using objective measures such as transit time and subjectively by patient 
symptoms. Temporary SNS provides a diagnostic and screening stage and helps to 
identify patients who may benefit from a permanent implant. The temporary electrode 
can later be replaced with a permanent electrode placed surgically (under a general 
anaesthetic) inside the foramen of choice (usually S3) with an implantable pulse 
generator (IPG) placed subcutaneously. See Figure 1-7, Figure 1-8, Figure 1-9, Figure 
1-10. 
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Figure 1-7: S3 foramen electrode placement for SNS 
 
Figure 1-8: TSNS with helical lead 
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Figure 1-9: TSNS with tined lead 
 
 
Figure 1-10: Implantable pulse generator (IPG) 
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1.7.3 Mechanism of Action 
SNS is thought to modulate the sacral outflow thus affecting the bowel through 
mechanisms which are still not clear. It is thought to have its effect at local, central and 
even molecular levels. Somatic efferent nerves of S2, S3 and S4 innervate the external 
sphincters and pelvic floor. It appears that the effects of SNS on the pelvic floor are due 
to afferent fibre activation and by a sacral reflex arc which leads to better pelvic 
control. This in turn improves bladder and bowel function. 
SNS may act on the central cortico-anal pathways to modulate bowel activity. It has 
been shown to have an inhibitory effect on motor cortical pathways to the external anal 
sphincter in incontinent patients after two weeks of stimulation(Sheldon, Kiff et al. 
2005). Also, SNS seems to have some effect on cerebral somatosensory evoked 
potentials in both incontinence and constipation(Giani, Novelli et al. 2011; Griffin, 
Pickering et al. 2011). This suggests that in addition to the localized effect on spinal 
cord pathways, SNS may bring about dynamic changes in cortico-anal excitability via a 
central mechanism of action influencing the motor cortex. 
Neurotransmitters like 5-HT and substance P interact with the enteric nervous system 
at mucosal and submucosal levels, affecting gut sensitivity, peristalsis and secretion. 
Recent studies have shown increased rectal mucosal levels of Substance P in 
incontinent patients and conversely decreased rectal mucosal levels in patients with 
slow transit constipation(Gooneratne, Facer et al. 2008). It is possible that SNS 
modulates neurotransmitter activity at a molecular level thus bringing about its effects 
on the gut. 
1.7.4 SNS in neuroconstipation  
The National Institute of Clinical Excellence has approved SNS for use in faecal 
incontinence and voiding dysfunction. In addition to the extensive work on SNS in 
relation to faecal incontinence, there is a limited body of evidence for the role of SNS in 
constipation.  
A pan-European multi-centre study of SNS in functional constipation has now been 
completed with preliminary results presented at conference showing efficacy in two 
thirds of patients in terms of symptom improvement (Kamm, Dudding et al. 2010). No 
study to date has involved constipation due to neurological disease alone, though 
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theoretically this would seem the most obvious cohort to study, since the treatment 
may restore the compromised parasympathetic supply to the hindgut.  
1.7.5 Rationale for SNS work in neuro-constipation 
McDonagh et al demonstrated that complete control of defaecation is possible in spinal 
injury patients after sacral nerve stimulation by an intradural catheter(MacDonagh, 
Sun et al. 1990). This was reported in a series of 12 consecutive spinal injury patients 
with a success rate of 50%. The investigators employed a technique that stimulated the 
anterior roots of the sacral nerves by surgically placing an intradural catheter. 
However, this was a very invasive surgical procedure involving implantation of a 
Brindley-Finetech root stimulator along the anterior sacral nerve roots along with 
deafferentation of the posterior sacral nerve roots. The operative time was long and 
the patients underwent a complex procedure requiring significant surgical exposure. 
The rate of morbidity and complications from the procedure was high.  
In contrast, SNS is a minimally invasive and very safe procedure with promising 
results. Theoretically speaking, SNS augments the extrinsic nerve supply to the bowel 
which is impaired in patients with neurogenic bowel dysfunction. Recent results have 
been promising: a recently concluded study of SNS for faecal incontinence has shown 
that patients with a neurological cause had the best outcome (Gourcerol, Gallas et al. 
2007).  
Autonomic Dysreflexia (AD) was a concern in patients with spinal cord injury. Noxious 
and non-noxious stimuli can lead to AD in patients with SCI above T5-T6 segments. It 
can cause headache, dysrhythmias, flushing and sweating above the lesion and 
vasoconstriction below the lesion. This may be associated with a sudden bout of 
hypertension. Patients can also experience piloerection, stuffy nose, anxiety, malaise 
and diaphoresis. This is due to widespread activation of sympathetic activity below the 
lesion and release of catecholamines. This can occur several times a day and can be 
asymptomatic. 
Patients with high cord injuries had been thoroughly assessed at the regional spinal 
injury unit before referral to the constipation clinic. All patients with SCI had stable 
injuries older than at least six months. All patients with SCI were asked about 
symptoms and signs of AD at their first clinic visit. None of the patients recruited had a 
previous history of AD and they were advised to inform the clinical team in case of any 
adverse event. At the University Hospital of North Durham, SNS was offered to five 
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patients with neurogenic bowel dysfunction and four of them responded positively to 
the test stage of SNS. Three out of these four patients had a permanent stimulator 
implanted and reported marked improvement in their symptoms. Based on these 
experiences a formal study was planned to assess SNS and develop further knowledge 
in this field. 
1.7.6 Rationale for this PhD 
Neuroconstipation is a significant problem. This thesis brings together existing 
knowledge on SNS in neuroconstipation to assess the construct validity of this 
approach to care. It reports a trial of the efficacy of SNS in neurological constipation 
after temporary and permanent implantation. It substantially advances knowledge 
regarding SNS in neuroconstipation informing the future research agenda and future 
application in clinical practice. In the Chapter 2 a systematic review of the available 
literature on SNS is provided. In Chapter 3 the protocol and the methods used to 
conduct the trial are described. Chapters 4, 5 and 6 provide and explore the trial 
findings.  An interpretation of trial findings, strengths, weaknesses and future direction 
are provided in Chapter 7. 
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2. Systematic Literature Review 
2.1 Aim 
This review summarises current published evidence addressing the use and efficacy of 
sacral nerve stimulation (SNS) in constipation. 
2.2 Methods for review 
2.2.1 Search Strategy 
Electronic systematic literature searches were carried out using the databases 
provided by the National Library for Health website. Searching identified studies 
evaluating SNS used in constipation. Search terms utilizing Boolean logic were used to 
retrieve citations from the databases. Duplicates were removed. All studies were 
searched individually and relevant references were identified and retrieved. MEDLINE, 
EMBASE, CINAHL, OVID and Cochrane databases were searched for relevant studies. 
Mesh terms included constipation, defecation, anorectal disorders, rectal diseases, anus 
diseases, anal canal, rectum, stimulation, electric stimulation, electrostimulation, 
electric stimulation therapy, neuromodulation, sacral spinal cord, lumbosacral spine, 
sacrum and lumbosacral plexus.  
2.2.2 Inclusion criteria for the studies 
Types of studies included were randomised controlled trials, case series, case reports, 
systematic reviews and narrative reviews. 
Participants included were adults with constipation. The primary purpose of this 
review was to determine the efficacy and safety of SNS in a subgroup of patients with 
spinal cord disease or central neurological disease suffering from constipation by 
identifying studies describing the use of SNS in adults with neuroconstipation. Due to 
the paucity of adequate data, all studies of SNS in constipation were included 
regardless of underlying pathology or cause. 
The only type of intervention considered is sacral nerve stimulation for constipation. 
Studies solely addressing SNS only in faecal incontinence were excluded. Reports 
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containing data on patients with both faecal incontinence and constipation were 
included.  
Outcomes were considered in the following categories. 
Improvement in Constipation: This was demonstrated by the proportion of 
participants who were cured or improved symptomatically, a decrease in use of 
laxatives, an increase in bowel movements, a decrease in episodes of straining and 
decrease in time with pain and bloating.  
Quality of life: Both disease-specific and generic measures were considered. 
Physiological measures: measures of anorectal physiology (resting pressure, maximal 
squeeze pressure, rectal sensory threshold to balloon distension, sensation of urgency 
to balloon distension and maximal tolerated rectal volume to balloon distension) were 
included in addition to transit studies. 
Adverse effects: infection at the electrode site, pain at the implant site, electrode 
dislodgement, and technical failure of the device. 
2.2.3 Exclusion criteria for the studies 
Studies not meeting the inclusion criteria and non-English studies were excluded. 
Studies including patients with faecal incontinence only were excluded; as were studies 
on magnetic or cutaneous sacral nerve stimulation. 
2.2.4 Data Extraction 
The titles and abstracts of all the relevant studies were screened and then full text 
copies were requested for studies that were considered to be relevant. The references 
of the retrieved papers were checked to identify further relevant reports.  
2.2.5 Analysis 
If sufficient trials of a certain methodological quality were available (for example 
randomized controlled trials), these were analysed without reference to weaker study 
designs. In the absence of adequate high quality data, all evidence was described, 
analysing improvements in the context of whatever reference or control assessments 
are available. Since patients are offered SNS after a long period of chronic constipation, 
then persistent benefit from SNS treatment is likely to be an attributable treatment 
effect.  
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2.2.6 Data synthesis 
Where studies of similar design and method reported comparable outcomes these 
were pooled using fixed effects methods, reporting findings and interpreting indicators 
of heterogeneity and consistency of treatment effect with study size.  
2.3 Results 
Number of studies found was as follows: 
MEDLINE (1950 to date): Forty-eight citations on SNS and bowel disorders, which 
were reduced to nine studies addressing SNS and constipation. 
EMBASE (1974 to date): Ten studies were found addressing SNS and bowel disorders. 
CINAHL (1982 to date): Two studies found. 
OVID: none. 
COCHRANE: There were no relevant reviews or reports found.  
A detail of the search strategy is attached in the appendix B (Page 171-173). 
2.3.1 Studies predating SNS 
Three papers were more than ten years old and described different techniques for 
stimulating either the spinal cord or the anterior sacral nerve roots. The results and 
techniques reported in these papers describe the origins underpinning the 
development of SNS. Both procedures preceded the modern technique of sacral nerve 
stimulation.  
A study published in 1982 (Pescatori and Meglio 1982) presented data on two patients 
with neuroconstipation who were treated with spinal cord stimulation for chronic 
constipation. This was achieved by placing epidural electrodes under local anaesthesia 
at the level of T8 and T9 respectively. Low frequency electrical current stimulated 
these electrodes and the patients were assessed using physiological and clinical 
parameters. There was improvement in the transit time after the procedure and both 
patients achieved spontaneous defaecation without the use of laxatives within 12 
hours of stimulation. The authors suggested that neuro-stimulation was improved 
propulsion in the distal colon in addition to activating neural pathways leading to 
improvement in bowel frequency.  
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Shafik demonstrated that controlled defaecation was possible in a canine model after 
stimulation of S2 ventral nerve root with electric current (Shafik 1995). The use of 
electrical stimulation of sacral roots was suggested for both incontinence and neuro-
constipation.  
Binnie and colleagues implanted a Brindley Fine-tech catheter, stimulating the S234 
anterior sacral nerve roots, in seven patients with spinal cord injury (SCI) (Binnie, 
Smith et al. 1991).  Data from a control group of SCI patients was compared with the 
group with SCI and Brindley implants. When compared to the control group, patients 
with the Brindley stimulator had more frequent bowel movements and decreased 
colonic transit time. This was attributed to the motor influence of the sacral root 
stimulation on the left colon and rectum. These studies were instrumental in 
developing the basic knowledge on nerve stimulation and led to further work that has 
shaped the way SNS is being utilized in modern clinical practice. 
2.3.2 Number and type of studies and enrolled patients 
Fourteen  studies matched the inclusion criteria for this review. There was one double-
blind placebo controlled trial, ten case series, one abstract, and two reviews. The two 
reviews included the studies covered in this chapter and did not identify any new 
studies (Jarrett, Mowatt et al. 2004; Kenefick 2006)  
Overall one hundred and ninety eight patients were enrolled with a median age of 45.8 
years and a range between 17-79 years, and including one hundred and seventy 
women and twenty eight men. The symptom duration ranged between 2-47 years, but 
this finding was only reported in 3 studies. The patients recruited in these studies were 
followed up over a period of time ranging from 2 weeks to 2 years. Six patients were 
reported as being lost to follow-up. The characteristics of these patients are shown in 
Table 2-1.  
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Table 2-1: Demographics 
Study id No. Age (range) Gender 
Symptom 
Duration 
Follow-up 
(m,w,d) 
FU range 
(m,w,d) 
Lost 
to FU 
Dinning 2007 8 43(20-59 y) 8 F 24 (2-45 y) 3 w 0 2 
E Ganio 2001 12 47(27-75 y) 9 F 3M - 9.9 d 7 - 30 d 2 
E Ganio 2002 16 49.2(30-72y) 13 F 3M - 12 m - - 
Hetzer et al. 2006 2 68(60-74y) 2 F - 2 w - - 
Holzer 2008 19 - 19F - 11 m 2-20 m - 
Maeda et al. 2010 38 45.6(21-66) 32F 6M - 25.7 m 0-70 - 
Malouf 2002 8 47(35-68 y) 8 F 31 (9-47 y) 3 w 0 0 
Kamm 2010 62 40(17-79y) 55F 7M - 28 m 1 – 55 m - 
Naldini et al. 2010 15 45.7(25-64) 13F 2M - 42 m 24-60 m - 
Kenefick, C Vaizey 2002* 2 36 y 2 F - 2+2 w - - 
Kenefick, Nicholls 2002** 4 33.5(27-36y) 4 F 22 (8-32 y) 8 m  1-11 m 2 
Lombardi et al. 2010 12 39 +/- 10y 5F 7M - 38 m - - 
Total 198 45.8 (17-79) 
170 F 28 
M 
- - - 6 
*Unclear if patients from previous studies were included (Malouf, Kenefick) 
** Included 2 patients from the Malouf study, going forward to P-SNS 
 
For the 198 patients, there were 146 cases of temporary SNS and 134 cases of 
permanent SNS. Kenefick enrolled four patients who all received a permanent implant 
after temporary stimulation (Kenefick, Nicholls et al. 2002) . In this study, two patients 
out of the four enrolled were lost to follow-up and did not complete the six-month 
assessment. Maeda reported 38 patients receiving a permanent implant although the 
number receiving temporary SNS was not reported (Maeda, Lundby et al. 2010). 
Similarly, Lombardi reported 12 patients with constipation receiving permanent SNS 
out of a total of 23 (11 FI patients)(Lombardi, Del Popolo et al. 2010). See Table 2-2. 
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Table 2-2: Permanent and temporary SNS in neuroconstipation 
Study id Enrolled T-SNS P-SNS 
Dinning 2007 8 8 - 
E Ganio 2001 12 12 - 
E Ganio 2002 16 16 16 
Hetzer et al. 2006 2 2 - 
Holzer 2008 19 19 8 
Maeda et al. 2010 38 - 38 
Malouf,2002 8 8 - 
Kamm 2010 62 62 45 
Naldini et al. 2010 15 15 9 
Kenefick, C J Vaizey 2002 2 - 2 
Kenefick, R J Nicholls 2002 4 4 4 
Lombardi et al. 2010 12 - 12 
Total 198 146 134 
Where estimates were consistently reported, meta-analysis was attempted to describe 
changes in measures of constipation. A fixed effect model was utilised, describing 
heterogeneity and vulnerability to bias. 
2.3.3 SNS in neuroconstipation 
One retrospective case series for neurogenic bowel dysfunction was identified. 
Lombardi and colleagues performed temporary SNS in 39 patients with incomplete 
spinal cord injury (SCI) suffering from neurogenic bowel dysfunction(Lombardi, Del 
Popolo et al.). Patients suffered from both faecal incontinence and constipation. Twenty 
three of the thirty nine patients received a permanent implant. Of these, only 12 
patients suffered from constipation. The median number of bowel movements per 
week increased from 1.65 (1.5-2) to 4.98 (4.5-7) per week. The Wexner score improved 
from 19.91 (17-23) to 6.55 (4-9). The toileting time per defaecation also improved 
from 45.85 min (20-80 min) to 10.81 (5-15 min). 
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A European multi-centre study enrolled the largest number of cases (Kamm, Dudding 
et al. 2010), with 62 patients undergoing T-SNS and 45 subsequently receiving P-SNS. A 
case-series of sixteen patients presented at a conference in Italy in 2002 (Ganio 2002), 
has not subsequently been published in detail. 
A double-blind placebo controlled crossover design included two women who received 
an SNS implant 12 months previously (Kenefick, Vaizey et al. 2002). Both the 
investigators and the patients were blinded by giving sub-sensory stimulation in “on” 
or “off” mode for two 2-week intervals. Diary cards were kept during those weeks and 
anorectal physiology was assessed. 
Naldini performed SNS in 15 patients with slow transit constipation. Nine of the fifteen 
patients had a good response with a sustained improvement in constipation symptom 
scores and quality of life (SF-36)(Naldini, Martellucci et al. 2010). 
There were two further reports of SNS that were considered relevant and are included. 
Hetzer described the technique of video-assisted SNS on six patients by using a fibre 
optic camera to monitor pelvic responses at the time of electrode insertion(Hetzer, 
Hahnloser et al. 2006). This enabled them to completely separate the pelvic area with a 
drape and potentially decrease the chance of infection. Two of the six patients 
recruited in this study had idiopathic constipation. Dinning demonstrated that SNS 
produces pan-colonic propagating pressure waves in patients with refractory 
constipation, which are essential for defaecation. This coincided with symptomatic 
improvement in six of the eight participants in the trial(Dinning, Fuentealba et al. 
2007). 
2.3.4 Improvement in constipation 
There were no standardized assessment criteria to define improvement and different 
tools were employed in each study. For example, ‘response’ rates were variously 
assessed using visual analogue scores, bowel frequency, percentage time with 
abdominal bloating/pain and use of laxatives. Patient responses assessed as an 
improvement in symptoms were recorded for one hundred and fifty three patients in 
these studies. A response to SNS occurred in one hundred and two of one hundred and 
thirty eight patients (67%), documented by symptoms scores and diaries. This is 
similar to the finding from the largest study: 45 out of the 62 patients within the 
multicentre trial (73%) had satisfactory clinical improvement defined as a >50% 
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improvement in symptoms(Kamm, Dudding et al. 2010). These patients went on to 
receive a permanent implant. See Table 2-3. 
 
Table 2-3: Response rates 
Study id Improved  
Dinning 2007 6/8  (75%) 
E Ganio 2001* 9/10(90%) 
E Ganio 2002 15/16(94%) 
Hetzer et al. 2006** 5/6 (83%) 
Holzer 2008 8/19(42%) 
Malouf,2002 2/8 (25%) 
Kamm 2010 45/62(73%) 
Naldini 2010 9/15(60%) 
Kenefick, C J Vaizey 2002 2/2(100%) 
Kenefick, R J Nicholls 2002 3/4 (75%) 
*10 of the 12 patients completed the necessary period of stimulation 
** Results were given collectively, only 2 patients had constipation 
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Figure 2-1: Analysis of Reported Response Rates to SNS (Random Effects) 
 
These findings can be shown visually on a forest plot (see Figure 2.1). Using a fixed 
effects model the pooled proportion was 0.677 (95% CI = 0.600 to 0.750).  However 
there was substantially heterogeneity between studies Q, p=0.005; I²= 63.4%.  A 
random effects model (DerSimonian-Laird) assumes that the true underlying value is 
distributed rather than taking a single value and is a more appropriate summary when 
heterogeneity is present: proportion [DL] = 0.696 (95% CI = 0.547 to 0.827). 
Unfortunately it does not identify the reason for heterogeneity and the studies are too 
few and small to meaningfully explore the variations in design and conduct. Although 
the number of studies is small, there was no evidence that the response rate varied 
with study size (Egger: bias p = 0.86), which might occur due to publication bias or 
study quality varying with study size. Malouf recorded a response rate of 25% in eight 
patients with longstanding slow-transit constipation undergoing T-SNS (Malouf, Wiesel 
et al. 2002). Thus, these patients might be considered more severe than other patient 
groups. 
 
 
 
0.0 0.2 0.4 0.6 0.8 1.0
Combined 0.68 (0.55, 0.80)
Kenef ick, R J Nicholls 2002 0.75 (0.19, 0.99)
Kenef ick, C J Vaizey 2002 1.00 (0.16, 1.00)
Naldini 2010 0.60 (0.32, 0.84)
Kamm 2010 0.66 (0.53, 0.77)
Malouf ,2002 0.25 (0.03, 0.65)
Holzer 2008 0.42 (0.20, 0.67)
Hetzer et al. 2006 0.83 (0.36, 1.00)
E Ganio 2002 0.94 (0.70, 1.00)
E Ganio 2001 0.90 (0.55, 1.00)
Dinning 2007 0.75 (0.35, 0.97)
proportion (95% conf idence interval)
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2.3.5 Outcomes 
2.3.5.1 Bowel Frequency 
There was evidence of improvement in frequency of bowel movements. At latest 
follow-up the bowel frequency improved from a baseline of 3.3 (0.5-28) before 
stimulation to 8.04 (1-21) after SNS. There was good correlation between temporary 
and permanent stages of SNS. Crude average rates are reported as it was not possible 
to abstract measures of variance consistently to permit meta-analysis of findings. See 
Table 2-4 
 
Table 2-4: Bowel frequency 
Study id Pre SNS BMs/wk (Range) After SNS (Range) 
Dinning 2007 0.8 7.4 +/- 2.7 
E Ganio 2001 9.5(2-28) 6.4(2-14) 
E Ganio 2002 2.1(0.5-10) 3.5 (1-9) 
 11.5 (5-21) 
Malouf,2002 4.5(1-9) 6(2-13) 
Kamm 2010 2.3 6.6 
Naldini et al. 2010 1.7 3.3 
Kenefick, R J Nicholls 2002 PSNS 3.25(1-6) 23(20-26) 
Kenefick, R J Nicholls 2002TSNS 3.25(1-6) 8.25(9-13) 
Lombardi et al. 2010 1.65 (1.5-2) 5.40 (4.5-7) 
 
The data from the double-blind placebo controlled trial suggests that SNS has an effect 
greater than placebo (Kenefick, Vaizey et al. 2002). The two women received the 
implant 12 months before the study and the number of bowel movements during the 
inactive period was less than the number of defaecations during the stimulation period. 
See Table 2-5 
Table 2-5: Bowel frequency 
N J Kenefick, C J Vaizey, et al. 2002 
BM/week (range) Stimulation off Stimulation On 
3.5(1-6) 3(2-4) 9(8-10) 
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Hetzer reported the safety of Video-assisted SNS and did not provide detailed outcome 
information (Hetzer, Hahnloser et al. 2006). Two patients in the Kenefick trial were lost 
to follow-up and the long-term figures were only available for two patients (Kenefick, 
Vaizey et al. 2002). 
2.3.5.2 Constipation Scores 
A variety of scores were reported in studies. The Wexner scale [6 studies] and  Visual 
analogue score (VAS) [3 studies] were used variously before and after stimulation. 
Each score had its own scale: VAS 0: severe symptoms, 100: no symptoms; Wexner 0: 
best, 30: worst. Kenefick used both Wexner and VAS scores (Kenefick, Vaizey et al. 
2002): both scores showed an improvement after TSNS in all four patients. Six month 
follow-up data after receiving implants was only available for two patients showing 
improvement in both Wexner and VAS. There was improvement in VAS and Wexner 
scores in all studies. One study utilized weekly laxative use as a score showing a 
reduction in the use of laxatives (Dinning, Fuentealba et al. 2007). See Table 2-6,Table 
2-7. 
The change in Wexner score is shown visually on a forest plot (see Figure 2.2). Using a 
random effects model the change in score was 12.03 (95% CI = 10.05 to 14.00).  There 
was substantially heterogeneity between studies Q= 25.22; I²= 80.17%.  A random 
effects model (DerSimonian-Laird) assumes that the true underlying value is 
distributed rather than taking a single value and is a more appropriate summary when 
heterogeneity is present. 
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Figure 2-2 Change in Wexner score (random effects model) 
 
  
7 9 11 13 15 17
Combined 12.03 (10.06, 14.01)
Lombardi et al. 13.36 (11.29, 15.42)
Kenef ick, Nicholls 12.00 (8.60, 15.40)
Kenef ick, C Vaizey 12.00 (7.20, 16.80)
Naldini et al. 10.00 (8.40, 11.60)
Holzer 15.00 (13.25, 16.74)
E Ganio 10.00 (8.45, 11.55)
Change in Wexner Score (95% conf idence interval)
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Table 2-6: Constipation scores 
Study id Constipation scores Baseline (Range)  After SNS (mean) 
Dinning 2007 Laxative use (days/week) 4.7+/- 3 1.5 +/- 1.9 
E Ganio 2001 - - - 
E Ganio 2002 Wexner (0-30) 14.6 (8-20) 4.6 (0-14) @3mths 
  2.7 (3-16)@12 mths 
Holzer 2008 Wexner (0-30) 23 (18-27) 8(4-13) )@12 mths 
Malouf 2002 VAS 15 (4-33) 30.3(2-88) 
Kamm 2010 Wexner (0-30) 18 10.2 
VAS 18 66 
Naldini et al. 2010 Wexner (0-30) 21(11-27) 11 (3-20) 
Kenefick, R J Nicholls 2002 PSNS 
Wexner (0-30) 16 (8-24) 5.5 (1-10) 
VAS [0-100] 16.5 (10-21) 90 (80-100) 
Kenefick, R J Nicholls 2002 PSNS 
Wexner (0-30) 21.5 (20-23) 13.7 (7-14) 
VAS [0-100] 22.5 (15-30) 67 (35-88) 
Lombardi et al. 2010 Wexner (0-30) 19.91 (17-23) 6.55 (4-9) 
VAS, 0=severe symptoms 100= no symptoms;  
Wexner 0= Best 30= Worst;  
 
 
In the double-blind crossover trial there was considerable difference in the Wexner 
and VAS scores during the two periods. There was a visible improvement in both 
scores while the stimulation was “on”.  
Table 2-7: Constipation scores 
Kenefick, C J Vaizey 2002 
Score Baseline (range) Stimulation off Stimulation On 
Wexner 
(0-30) 
21 (22 & 30) 14 (15&13) 9(5&13) 
VAS 
(0-100) 
30 (32 &28) 31.5(30 & 33) 74 (88 & 60) 
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2.3.5.3 Anorectal physiology 
Recent studies have not emphasised anorectal physiology. Seven studies in this review 
reported data on anorectal physiology. Generally there was a reduction in both the 
sensory threshold and sensation of urgency due to balloon distension across all studies 
but findings were generally not statistically significant. The sphincter pressures at rest 
and on squeezing improved as well. This suggests a change in rectal sensitivity during 
SNS preventing an excessive rise in endorectal pressure. There was poor symptom 
correlation with Anorectal physiology findings. See Table 2-8 and Table 2-9. 
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Table 2-8: Anorectal Physiology 
Study id E Ganio 2001 E Ganio 2002 Malouf 2002 Kamm 2010 
Kenefick, R J 
Nicholls 2002 
PSNS 
Lombardi  
et al. 2010 
RP mean BL 73 mm Hg - - - 75 cm H2O 31.58 cm H2O 
BL range  - - - 52-99 25-42 
After SNS mean 80 - - - 91 32.25 
After SNS range 29.3 - - - 72-114 27-45 
MSP BL 120  - - - 42 cm H2O 57.41 cm H2O 
BL range 33.1 - - - 32-102 45-70 
After SNS mean 126 - - - 63 58.25 
After SNS range 33.8 - - - 40-119 45-70 
Sens. Threshold 
Vol. BL 
106 mls 106 mls 47 mls - 59 mls 68.58 mls 
BL range 33.5 - 10-110 - 45-71 40-90 
After SNS mean 89 mls 10 mls 25 mls - 38 mls 67.33 mls 
After SNS range 39 - 10-30 - 30-45 40-90 
Urgency Vol BL 189 mls 214 mls - Reduced 115 mls 111.66 mls 
BL range 52.99 0 - - 90-185 90-140 
After SNS mean 139 mls 95 mls - - 85 mls 105 mls 
After SNS range 52.3 - - - 50-95 80-130 
Max. Tolerated 
Vol  BL 
- - - Reduced 157 mls 158.30 mls 
BL range - - - - 130-245 135-190 
After SNS mean - - - - 125 156.91 mls 
After SNS range - - - - 63-130 135-180 
BL: Baseline; RP: Resting pressure; MSP:Maximum squeeze pressure 
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Table 2-9: Anorectal physiology 
Kenefick, C J Vaizey 2002 
Baseline 
(Range) 
Stimulation off  
(Range) 
Stim. On 
Anal Resting Pressure (cms H20) 74.5 (65 & 84) 51 (63 & 69) 76 (68 & 84) 
Anal Squeeze pressure (mls) 39 (32 & 46) 54 (51 &57) 93 (41 &145) 
Sens. Threshold to balloon distension (mls) 46 (45 & 47) 35 (30 & 40) 17.5 (2 & 15) 
Urgency to balloon distension (mls) 130 (185 & 75) 70 (60 & 80)  34 (33 & 35) 
Max. tolerated Volume to distension (mls) 194 (245 & 143)  102.5 (85 &120) 67.5 (65 & 70) 
 
2.3.5.4 Other outcomes 
2.3.5.4.1   Time needed for toileting 
Time spent on toilet decreased from 17.6 to 9.3 minutes in one study (Kamm, Dudding 
et al. 2010) and from 12.5 minutes (5-20 min) to 9.3 minutes (5-30 min) for each 
bowel movement in another(Ganio, Masin et al. 2001). Lombardi reported an 
improvement from 45.85 (20-80) minutes per week to 10.41(5-15) minutes per week 
after SNS(Lombardi, Del Popolo et al. 2010). Other studies did not record this data. 
2.3.5.4.2   Abdominal pain and bloating 
Three studies provided findings. Malouf et al reported improvement in abdominal pain 
and bloating together with improvement in the VAS score although they failed to 
publish the data (Malouf, Wiesel et al. 2002). Kenefick documented percentage time 
with bloating before and after SNS (Kenefick, Vaizey et al. 2002) while Kamm recorded 
the number of days with abdominal pain and bloating during the week (Kamm, 
Dudding et al. 2010). 
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2.3.5.4.3   Unsuccessful evacuation 
Both studies by Ganio documented numbers of unsuccessful visits to the toilet before 
and after SNS. In the 2001 study the episodes of unsuccessful visits to the toilet 
decreased from 29.2 (7-24) per week before stimulation to 6.7 (0-23) per week after 
SNS(Ganio, Masin et al. 2001). Similarly there was improvement noted in the 2002 
study from 4.5 (2-14) episodes every week to 2.1 (0-7) at 3 months following SNS 
(Ganio 2002). There was no available data in other studies did not report changes in 
unsuccessful evacuations. 
2.3.5.4.4   Difficulty with rectum emptying 
Improvement in difficult evacuation was reported in three studies. Kamm et al 
reported a reduction in the proportion of straining from 75% of successful bowel 
movements to 46% of all successful evacuations at last follow-up. There was also an 
improvement in perception of incomplete evacuation. (Kamm, Dudding et al. 2010). 
See also Table 2-10. 
Table 2-10: Improvements in evacuation 
Study id Difficult evacuation Pre-SNS After SNS 
E Ganio 2001 7 (2-21) episodes 2.1(0-6) episodes 
Kenefick, R J Nicholls 2002 4 (0-4)*  1 (0-4)* 
* evacuation score 
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2.3.5.4.5   Transit Time 
Only three studies addressed transit time before and after SNS. Malouf et al included 
eight patients with slow-transit constipation. Only 2 out of the eight patients 
responded positively to T-SNS. The transit time did not normalize in the responders 
and stayed prolonged (Malouf, Wiesel et al. 2002). Kenefick documented prolonged 
transit time in two out of the four participants before permanent SNS that normalized 
in one after stimulation (Kenefick, Vaizey et al. 2002). In the European multi-centre 
trial, transit time normalized in half of patients who had slow transit before SNS 
(Kamm, Dudding et al. 2010). 
2.3.5.4.6   Quality of Life (QOL) 
The reporting of quality of life data was minimal across all studies. Several studies 
mentioned documenting QOL data but findings were not adequately reported. The 
double blind placebo-controlled cross-over trial utilized Short Form 36 to measure 
quality of life before and a year after stimulation. It reported marked improvement in 
both participants but no specific numbers were given. In their second report, Kenefick 
et al recorded improvement in all subscales of SF-36 except health transition after 
temporary and permanent SNS (Kenefick, Vaizey et al. 2002). Similar improvements in 
subsets of SF-36 were noticed in the multi-centre trial (Kamm, Dudding et al. 2010).  
2.3.5.4.7   Safety/ Adverse Effects 
Ganio enrolled 40 patients with functional anorectal and urinary disturbances. There 
were no infections but four patients had electrode displacement within the first 24 
hours (Ganio, Masin et al. 2001). Two of these patients had repositioning of the 
electrodes. Kenefick and Malouf did not report any infections. There were no reported 
adverse events in the crossover trial (Kenefick, Vaizey et al. 2002). 
Hetzer et al performed video-assisted SNS in six patients. They suggested that by 
separating the operative field with the help of a camera between the patient’s legs, to 
observe stimulation responses in the pelvic floor, infection rates could be reduced for 
SNS. There was no infection in any of the six patients and five of the six screenings 
were successful. In their four-year experience of 36 SNS procedures, explantation was 
necessary in only one patient.(Hetzer, Hahnloser et al. 2006) 
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Table 2-11: Complications 
Study id Enrolled Infection 
Electrode 
Displacement 
Implant 
Removal 
E Ganio 2001 40 No infection 4 (10.8 %) - 
Hetzer et al. 2006 36 No infection - 1 (2.8%) 
Malouf 2002 8 None None None 
Kenefick, C J Vaizey 2002 2 None None None 
Kenefick, R J Nicholls 2002 PSNS 4 - - None 
Kenefick, R J Nicholls 2002TSNS 4 None - - 
 
2.3.6 A critique of the Kamm Study 
The largest study (with 62 patients) of the use of SNS in idiopathic constipation was 
published by Kamm and colleagues in 2010. It is the only study with a (clearly) 
prospective design, following 62 patients who underwent temporary SNS and 45 
patients who proceeded to permanent SNS, with follow-up ranging from 1 to 55 
months. Long term clinical outcomes are analysed using the last recorded observation 
carried forward. The study reported a 73% response from temporary SNS and an 87% 
response from permanent SNS. However there are several limitations within the 
analysis that reduce the quality of inference that can be made from the study. Firstly 
the primary endpoint of response to treatment depends on meeting one of three 
conditions: increased defecation frequency (≤2/wk to ≥3/wk), decreased straining 
(≥50% reduction) or decreased sensation of incomplete evacuation (≥50% reduction). 
This presents a very low bar for success, e.g. a patient might improve defecation 
frequency from 2 to 3 per week but experience worse straining and sensation of 
incomplete evacuation but still be marked as a success.  Unfortunately this study 
provides no patient reported outcomes which can be correlated against the clinical 
assessments. When different definitions are applied then treatment response looks 
very variable. For example only 33% of patients reported improvement in all three 
components of the primary endpoint. Another concern is the uncritical use of a last 
observation carried forward analysis. The paper does not report whether the duration 
of follow-up for subjects was determined by censoring (running out of time) or loss to 
follow-up (which might be outcome related). This could have been explored by 
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reporting outcomes by duration of follow-up, e.g. outcomes for those patients with 1,2 
and 3 years of follow-up. 
2.4 Discussion 
There are few studies in the literature which evaluate SNS for constipation and these 
studies are small. The data from the pan-European trial is the most significant having 
the largest number of patients (Kamm, Dudding et al. 2010). This review identified no 
adequate randomised controlled trials on use of SNS in constipation or faecal 
incontinence. Most studies are retrospective case-series reports with relatively few 
patients. 
In some studies it was not apparent whether the data collection was prospective or 
retrospective. Furthermore, the small number of patients and absence of long-term 
data for some patients due to loss to follow-up raises the issue of selective reporting.  
This systematic review is unable to provide definitive findings due to the lack of 
sufficient quality data. There was a different case-mix of patients in each study but the 
results were aggregated collectively within each. The outcome measures vary between 
reports, which in turn used different assessment criteria. As a result, there was little 
value in aggregated results within a meta-analysis.  
2.4.1 Efficacy results 
About half of patients having SNS respond to temporary stimulation and go on to 
receive a permanent implant. The only reliable reported data comes from the pan-
European study in which 45 of the 62 participants (73%) received a permanent 
implant (Kamm, Dudding et al. 2010). Across all studies, there was no reliable 
information on cure rates but 67% of all participants receiving temporary SNS 
improved symptomatically. 
The range of outcome measures showed consistent improvement in bowel frequency 
after SNS. Almost every study utilized bowel frequency as an outcome measure. 
Overall, about seventy percent of the patients showed improvement in bowel 
frequency from an average of three movements/week before stimulation to eight 
bowel movements/week during stimulation. This effect of SNS was reproducible 
during both temporary and permanent stages. The small double-blind placebo 
controlled trial included patients who had an implant for almost 12 months (Kenefick, 
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Vaizey et al. 2002). These patients had a significant decrease in number of bowel 
movements during the off phase that rapidly improved in frequency when the 
stimulation was turned on. This suggests a genuine treatment effect for SNS. 
A range of constipation scores including VAS, Wexner and CCCS were used 
inconsistently in these studies making it difficult to combine results. There was an 
improvement in constipation scores during stimulation in all studies regardless of the 
type of score used or duration or type of stimulation. 
When reported, there was reduction in time with bloating and abdominal pain as well 
as in time required for toileting. SNS improved the number of unsuccessful evacuation 
and straining and squeezing episodes during defaecation. 
SNS may improve transit times in constipation but the mechanism of action is not clear 
yet. Of the ten patients with prolonged transit reported by Malouf and Kenefick, transit 
normalized in only one patient (Kenefick, Vaizey et al. 2002; Malouf, Wiesel et al. 
2002). In the pan-European trial half of the patients with prolonged transit had 
improved transit times after SNS (Kamm, Dudding et al. 2010). Long-term data for a 
larger number of patients is required to characterise the impact of SNS on transit times. 
SNS appears to improve QOL in patients with constipation but more studies are needed 
to examine this more closely. Anorectal physiology results were inconclusive although 
these suggest improvements in sphincter pressures, reduction in sensory threshold 
and sensation of urgency to balloon distension during SNS. Anorectal physiology does 
not affect patient selection for SNS. 
2.4.2 Safety results 
Due to the small number of patients in the studies and inconsistent reporting, the 
extent and severity of adverse events is poorly understood. However, in the literature 
the reported infection rate for temporary electrodes is between 2-5%. In this review 
there were no reports of electrode infection. In case of permanent implants common 
adverse effects include infection and pain at implant site (2%), lead pain (4%), lead 
migration or displacement (5%).(NICE 2004) 
As use and understanding of SNS has progressed, pain at the site of implantation has 
been reduced or avoided all together by placing the implant in the buttock instead of 
the abdominal wall. Lead migration and displacement has been improved by 
introduction of a helical lead design. The lead is also easier to remove, without sedation 
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or anaesthetic, in cases of superficial skin infections at the electrode site. There are no 
reported long-term problems from temporary or permanent stimulation. 
2.5 Conclusions/ Limitations 
Limited evidence from this review suggests that SNS may be an effective treatment for 
constipation based on short term improvements in symptoms and quality of life from 
case-series data. Firm conclusions are not possible in an absence of adequate 
randomised trial evidence and long term data. Furthermore, there are no comparisons 
with other forms of treatment that may be effective in constipation. Each patient in 
these case-series acted as their own control with improvements over baseline readings 
suggesting a positive effect. This raises the possibility of bias and selective reporting as 
well as the scope for a placebo response to SNS (particular in the short term). However, 
the persistence of improvement over time and good correlation between temporary 
and permanent stimulation makes it very unlikely that just a simple placebo response 
is being observed. Studies included different subgroups of patients in varying 
proportions and these have been reported collectively: it is possible that different 
subgroups may benefit more or less from SNS. This thesis will specifically cover the 
efficacy of SNS in patients with neuroconstipation and advance current understanding 
of the use of SNS in constipation caused by neurological diseases. 
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Table 2-12: Study Summary 
Authors Year Methods Sample Interventions Outcomes Results/Notes 
Dinning  2007 Type of study: Case 
series 
Follow-up: 3 weeks 
Setting: Single centre 
 
Enrolled: 8 
Gender: 8 F 
Age:43 +/-14.6 yrs 
(Range 20-59) 
 
T-SNS at S2 and S3 
over 3 weeks 
Colonic Manometry: pan-
colonic antegrade and 
retrograde propagating 
sequence (PS), Bowel 
Frequency, 
Laxative use 
S3 stimulation significantly increased PS frequency (5.4 ± 4.2 vs 11.3 ± 6.6 PS/h, 
p= 0.01).  
S2 Stimulation significantly increased retrograde PS (basal 2.6 ± 1.8 vs SNS 
5.6 ± 4.8 PS/h, p= 0.03).  
Six of eight enrolled: improved bowel frequency with a reduction in laxative 
usage. 
Ganio 2001 Type of study: Case 
series 
Follow-up: 3 weeks 
Setting: Single centre 
Lost to follow-up: 2 
Enrolled: 40 (12 with 
constipation) 
Gender: 9M 3F 
Age: 50.2 yrs (Range 
26-79) 
 
T-SNS at S3 or S4 
over 3 weeks 
Anorectal Manometry 
Bowel Diary 
 
Reduction in difficult evacuations from 7 (range, 2-21) episodes/week to 2.1 
(range, 0-6) episodes/week, P < 0.01). 
Reduction in unsuccessful evacuations from 29.2 (7-24) to 6.7 (0-28) per week 
(p = 0.01).  
Manometric findings: increase in maximum squeeze pressure during SNS (from 
63 +/- 0 mm Hg to 78 +/- 1 mm Hg; p=0.009). Reduction in urge threshold 
(from 189 +/- 52 ml to 139 +/- 45 ml; p=0.004). 
Ganio 2002 Type of study: Case 
series 
Follow-up: 1 yr. 
Setting: Single centre 
Enrolled: 16  
Gender: 3M 13F 
Age: 49.2 yrs (Range 
30-72) 
P-SNS at S3 Anorectal Manometry 
Transit study 
Wexner Score 
 
One treatment failure (15/16 responded) 
Wexner’s score improved from 14.6 (range 8-20) to 4.6 at 3 months (range 0-
14) and to 2.7 at 12 months (range 3-16, p<0.01) 
Voluntary bowel movements/week increased 2.1 (range 0.5-10) to 3.5 (range 
1-9) at 3 months and to 11.5 (range 5 – 21) at one year. 
Unsuccessful evacuations/week decreased from 4.5 (range 2-14) to 2.1 (range 
0-7) at 3 months. 
Anorectal manometry: Rectal sensitivity improved. Sensory threshold to 
balloon distension decreased from 106 to 10 cc at 12 months. Urge volume 
decreased from 214 to 95 cc. 
Hetzer et 
al. 
2006 Type of study: Case 
series 
Follow-up: 8 weeks 
Setting: Single centre 
Enrolled: 6 
Gender: 6F 
Age: 68 yrs(Range 
60-72). 
2 (constipation) 
Video assisted P-
SNS 
Wound infection Combined success rate of 5 out of 6 patients reported. 
Bowel symptoms not reported. 
Holzer  2008 Type of study: Case 
series 
Follow-up: 11 mths 
(Range 2-20) 
Setting: Single centre 
Enrolled: 19 
Gender: 6F 
Patients with STC 
and FDD 
T-SNS over 3 
weeks: 19 pts. 
P-SNS: 8 pts. 
Wexner score 
QOL scores (SF-36) at 1 
and 6 mths. 
8/19 (42%) received permanent implants. 
Wexner score: improved from 23 (range 18-27) to 8(range 4-13) at 12 mths. 
Significant improvement in quality of life. 
 
Maeda et 
al. 
2010 Type of study: 
Retrospective case 
series 
Follow-up: 25.7 mths 
Enrolled: 38 
Gender: 32F  6M 
Age: 45.6  yrs (Range 
21-66) 
P-SNS Suboptimal outcome 
Adverse events 
Failure of treatment 
22/38 (58%) patients experienced at least one reportable event. 
58 events in total including loss of efficacy, pain, and undesired change of 
sensation.  
Most managed by reprogramming 28/58(48%). 
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(Range 0-70) 
Setting: Single centre 
19/58 (33%) required surgery. 
3 treatment failures. 
Malouf  2002 Type of study: Case 
series 
Follow-up: 3 weeks 
Setting: Single centre 
Enrolled: 8 
Gender: 8F   
Age: 47  yrs (Range 
35-68) 
T-SNS for 3 weeks Anorectal manometry 
Colonic Transit  
Bowel Diary 
 
2/8 (25%) patients showed a response. 
Bowel frequency: from 4.5(1-9) per week to 6(2-13) per week. 
VAS: from 15 (4-33) to 30.3(2-88). 
Rectal threshold to distension decreased. 
Colonic transit did not improve. 
Kamm et 
al. 
2010 Type of study: 
Prospective  
Follow-up: 
28mths.(Range 1-55) 
Setting: Multi-centre 
Enrolled:62 
Gender: 55F 7M   
Age: 40 yrs. (Range 
17-79) 
T-SNS: 62 
P-SNS: 45 
Defaecation frequency 
Straining 
Incomplete evacuation 
45/62 (73%) had P-SNS. 39/45 (87%) treatment success. 
Defaecation frequency: From 2.3 to 6.6/week (p<0.001) 
Straining: From 75 to 46% of evacuations. 
Incomplete evacuation: From 71.5 to 46% of successful evacuations. 
Colonic transit normalized in half with STC at 6 mths (p=0.014) 
QOL improved significantly. 
Naldini et 
al.  
2010 Type of study: 
Retrospective case 
series 
Follow-up: 42 mths. 
(Range 24-60)  
Setting: Single centre 
Enrolled:15 
Gender: 13F 2M   
Age: 45.7 yrs. (Range 
25-64) 
T-SNS over 3 
weeks: 15 pts. 
P-SNS: 9 pts. 
Defaecogram 
Colonic transit 
Wexner score 
QOL score (SF-36) 
9/15 had P-SNS (60%) 
Wexner score improved from 21 (range 11–27) to 11 (range 3–20) at 
one month. 
SF-36 increased from 95.8 (range 88–104) to 102 (range 96–113) at six months. 
Bowel frequency increased from 1.7 to 3.3 per week, p=0.003, at 6 months. 
Transit times not reported. 
Kenefick, 
C Vaizey 
2002 Type of study: Double-
blind placebo-
controlled crossover 
trial  (On/Off design) 
Follow-up: 12 mths 
Setting: Single centre 
Enrolled:2 
Gender: 2F   
Age: 36 yrs. 
P-SNS implanted 
12months before the 
study 
P-SNS for two 2-
week intervals 
with subsensory 
stimulation either 
on or off. 
Anorectal manometry 
QOL assessment (SF-36) 
Wexner score 
Bowel diary 
Symptom analogue score 
(0-100) 
Anorectal manometry inconclusive. 
SF-36 improved at 12 months. 
Marked difference in bowel frequency, pain and bloating, and the symptom 
analogue score in the ‘on’ compared with ‘off’. 
No change in Wexner score in both ‘on’ and ‘off’ phase. 
Kenefick, 
Nicholls 
2002 Type of study: Case 
series 
Follow-up: 8 mths. 
(Range 1-11)  
Setting: Single centre 
Enrolled:4 
Gender: 4F 
Age: 33.5 (Range 27-
36). 
T-SNS: 4 
P-SNS: 4 
Anorectal manometry 
QOL assessment (SF-36) 
Wexner score 
Bowel diary 
Symptom analogue score 
(0-100)  
3/4 showed marked improvements with P-SNS 
Bowel frequency: From 1-6 to 6-28 evacuations/3 weeks. Evacuation score: 
From 4 (0-4) to 1 (0-4) at 8 mths. 
Time with abdominal pain: From 98 (95-100)to 12 (0-100) % 
Time with bloating: From 100 (95-100) to 12 (5-100) % at 8 mt. 
Wexner score: From 21 (20-22) to 9 (1-20) at 8 mths. 
Analogue score: From 22 (16-32) to 80 (20-98) at 8mths. 
Maximum anal resting and squeeze pressures increased.  
Transit time normalized in one patient. 
Lombardi 
et al. 
2010 Type of study: Case 
series 
Follow-up: 38 mths. 
Setting: Single centre 
Enrolled:39 with 
incomplete SCI. 
Gender: 5F 7M 
Age: 39 +/- 10 yrs. 
12 (constipation) 
P-SNS 
 
Neurogenic bowel 
symptoms 
Wexner score 
Bowel movements per week:  from 1.65 (1.5-2) to 4.98 (4.5-7)/ week.  
Wexner score: from 19.91 (17-23) to 6.55 (4-9). 
Toileting time /defaecation: from 45.85 (20-80 min) to 10.81 (5-15 min). 
 
STC: slow transit constipation, FDD: Functional defaecation disorder VAS: visual analogue scale 
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3. Materials and methods 
3.1 Study objectives 
3.1.1 Primary 
The primary objective was to investigate short-term efficacy of temporary (test) SNS in 
neurological constipation, using a global measure of constipation symptom severity.  
3.1.2 Secondary 
Secondary objectives were to 
Assess the severity of constipation and incontinence before and during and after 
treatment using disease specific symptom and QOL measures. 
Profile changes in generic health status of the participants by using standardized self-
completion questionnaires (EuroQOL EQ-5D and EQ-VAS). 
Quantify changes in intestinal transit before and during SNS. 
Quantify changes in parasympathetic stimulation of the hindgut using laser Doppler 
flow cytometry before and during treatment. 
Record side effects of SNS. 
Establish the long-term efficacy in the subgroup of patients receiving permanent SNS. 
3.1.3 Design 
A within group off-on-off trial design was selected divided into three consecutive 
periods with patients acting as their own controls. Firstly, pre-treatment severity of 
constipation was assessed over a period of six weeks before SNS insertion. The 
participants then had the SNS wire placed bilaterally and were assessed over a period 
of three weeks. Finally the wires were removed and the participants underwent a final 
assessment period of three weeks post-SNS. 
3.1.3.1 Rationale for the study design 
Careful consideration was given to the most appropriate study design to explore the 
value of SNS in constipation of neurological origin. It was concluded that a controlled 
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trial was not feasible at this stage in the development of the use of SNS in this patient 
group. Patients were unlikely to be willing to be allocated to, and remain in, a 
treatment as usual group that continued to provide a failed pattern of care. The 
possibility of a controlled trial comparing active and sham SNS was considered but 
considered technically out of scope for the current study. When it is not possible to get 
an adequate control group, the attribution of treatment outcome can be improved by 
manipulating the use of the intervention over time. In this instance it was possible to 
demonstrate the chronic stability of the condition using a six-week run in period. The 
off-on-off design thus allows a high level of attribution where the temporal symptoms 
pattern follows the SNS stimulation pattern, and when the impact of SNS upon patient 
symptoms is anticipated to be large. 
3.1.3.2 Patient involvement in the design 
The trial was developed after discussion with four patients in the specialist 
constipation clinic who have neurological constipation, two of whom have already had 
insertion of an implant. The opinions of patients who have neurological disorders were 
canvassed to determine those investigations and interventions that would be 
acceptable to potential participants.  
3.1.4 Number of subjects 
The study involved planned prospective data collection from 30 patients with severe 
constipation caused by neurological disorders. A sample size of 30 had 94% power to 
detect a difference in means of 2.0 in a global symptom assessment scale (change from 
baseline), assuming a standard deviation of the differences of 3.0, using a two-group 
paired t-test with a 0.05 two-sided significance level. 
3.1.5 Duration of Study 
Participants were recruited over a two-year period. For each participant the total 
duration of the temporary SNS study was twelve weeks, from the point when consent 
was confirmed. 
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3.1.6 Primary outcome 
The primary outcome was a weekly global assessment of symptoms using a five-point 
Likert scale. This recorded any changes in both constipation and faecal incontinence on 
a weekly basis. 
3.1.7 Secondary outcomes 
Secondary outcome measures included i) a daily defaecation and laxative diary; ii) 
weekly self-administered questionnaires to measure symptoms (PAC-SYM); iii) weekly 
self-administered questionnaires to assess quality of life (PAC-QOL); iv) self-
administered questionnaires to assess generic status of patient health (EuroQOL EQ-5D 
and EQ-VAS) v) transit study; and vi) laser Doppler flowcytometry. Copies of all 
measures are reported in Appendix A. 
3.1.8 Definitions  
Multiple Sclerosis (MS): A progressive diffuse neurological disease characterised by 
areas of demyelination in the central nervous system. These lesions produce a variety 
of sensory and neurological disorders including constipation. Diagnosis of MS was 
made on clinical, radiological and electrophysiological grounds. All patients seen in the 
clinic were under the care of neurologists.  
Spinal Cord Disease: Referring to damage to the spinal cord following trauma, surgical 
intervention, diseases of the spinal cord or as a result of abnormalities of the bony 
spine including congenital defects that result in spinal cord dysfunction. 
Spina Bifida: A congenital defect that causes hydrocephalus and other neurological 
problems. These arise because of protrusion of the spinal cord or it’s covering 
(meninges) through a defect caused by incomplete closure of the bony spinal column. 
Constipation: For research purposes the "Rome III Criteria" were accepted and used 
in the study (Longstreth, Thompson et al. 2006). 
The diagnosis of constipation required at least 2 of the following: 
 Straining during at least 25% of defaecations 
 Lumpy or hard stools in at least 25% of defaecations 
 Sensation of incomplete evacuation for at least 25% of defaecations 
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 Sensation of anorectal obstruction/blockage for at least 25% of defaecations 
 Manual manoeuvres to facilitate at least 25% of defaecations (e.g., digital 
evacuation, support of the pelvic floor) 
 Fewer than 3 defaecations per week 
3.2 Subject selection and withdrawal 
3.2.1 Inclusion criteria 
All of the following criteria had to be met to qualify the patient for inclusion: 
 Males and females age 16 years or older 
 Neurological disorder (MS or spinal disease)  
SCI injury patients had been seen at the regional spinal injury unit at James Cook 
University Hospital. The level of the lesion had been graded using the American 
Spinal Injury Association (ASIA) impairment scale. MS patients were referred from 
the regional neurology service to the constipation clinic. They had been diagnosed 
and classified before being seen at the constipation clinic by a neurologist. Only 
patients with significant bowel dysfunction and failed conservative management 
were referred. 
 Constipation according to the above definition 
 At least 6-month-old SCI at any level with at least one of the following 
o Spending 30 minutes or more attempting defaecation everyday or every 
other day 
o Faecal Incontinence episodes once or more a month 
o Abdominal discomfort before or during defaecation 
o Symptoms not adequately relieved by standard treatments (lifestyle 
modification, laxative, suppository, enema and rectal irrigation) 
3.2.2 Exclusion criteria 
The presence of any of the criteria disqualified the patient for inclusion: 
 Age less than 16 years 
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 Unfit for general anaesthetic 
 Severe psychiatric disease 
 Persistent diarrhoea (except when due to laxative use) 
 Uncontrolled or decompensated cardiac, respiratory, endocrine, renal, or 
hepatic diseases 
 Rapid progression of neurological disease 
 Active systemic infection 
 Known pregnancy, suspected pregnancy or trying to conceive 
 Subjects currently (or within one month) of any other study 
 Severe incapacity of higher mental function such that informed consent can not 
be achieved  
 Severe incapacity of higher mental function or physical abilities such that 
questionnaires cannot accurately be completed.  
3.2.3 Recruitment 
Potential subjects for recruitment were patients with neurological disorders (MS, spina 
bifida and spinal disease) causing severe constipation refractory to treatment with diet 
changes, laxatives, suppositories, enemas and rectal irrigation. Participants were 
recruited from the Specialist Constipation Clinic at the University Hospital North 
Durham. This clinic receives referrals from a wide area in the North-East (150 new 
patients per year; 350 under follow-up, 10-15 neuro referrals per year), and we 
anticipated adequate numbers to allow recruitment of the required number of patients 
over a two-year period. Aside from the presence of neurological disorders, these 
patients represent an unselected group of individuals with symptoms severe enough to 
justify specialist referral. Those considered suitable, according to standard definitions 
and the inclusion/exclusion criteria, were asked to participate. 
3.2.3.1 The consent process 
Participants were required to give written consent where possible. The investigators 
explained verbally and in writing if needed, the nature of the study. A copy of the 
information sheet (See Appendix B) was given for consideration by the patient before 
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consent was obtained. Patients were allowed to deliberate for at least 24 hours after 
the initial discussions before the consent process was completed. Patients were 
advised that they were free to withdraw from the study at their own request. It was 
explained that the study had been designed in line with the International Conference of 
Harmonisation – Good Clinical Practice (ICH-GCP) and that they were protected by the 
2000 Declaration of Helsinki ensuring their rights, safety and well being. Arrangements 
were made to ensure adequate consent for participants who may have had difficulty 
understanding English or who had impairments (e.g. visual or hearing) that could 
influence the consent process. Independent witnesses were available to confirm 
consent in those unable to do so in writing. 
3.2.3.2 Patient subgroups 
Patient subgroups included multiple sclerosis (MS), spinal cord injury (SCI) and others 
(including patients with polio and spinal myoclonus). 
After recruitment, all the participants with SCI were classified according to 
international standards for classification of spinal cord injury based on the affected 
spinal segments. Patients were roughly divided into three groups according to their 
affected segments. 
 High supraconal injury (T9 & above) 
 Low supraconal injury (T10- S1) 
 Conal or cauda equina lesion (S2-S4) 
These were further subdivided into those with complete and incomplete injuries. All 
patients had been seen at the regional spinal injury unit and were classified according 
to the American spinal injury association (ASIA) impairment scale. 
Patients with neurological disorders were not a heterogeneous group and a subgroup 
analysis was planned based on the groups described. Differences between subgroups 
might help inform hypotheses for future studies of SNS. 
3.2.4 Patient withdrawal 
Patients were provided with contact details allowing them to contact one of the 
investigators if they were considering withdrawal. Participants were able to terminate 
participation immediately at any point. Participants were offered the opportunity to 
meet an investigator within 48hrs if they wished, following withdrawal. Data gathered 
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from patients who withdrew were kept; this fact was included in the patient 
information sheet.  
3.2.5 Study monitoring 
The study was monitored by a monthly audit of adherence to protocol and review of 
participants. Additionally, a six monthly interim report was made to the Project Review 
Board at the University Hospital of North Durham as well as an annual report to 
Regional Ethics Committee.  
The purpose of these arrangements was to identify any significant developments as the 
research proceeded that may necessitate alterations to the protocol and to protect the 
safety and wellbeing of participants. Although it was not expected, the arrangements 
were there to identify hazards to research participants. Complications, adverse events, 
adverse reactions occurring as a result of participation could be used as criteria to 
terminate the study. 
3.3 Study procedures  
3.3.1 Standard patient assessment in the Constipation Clinic 
The Durham Constipation Clinic is a regional referral centre for patients with 
refractory disease. The ability of the clinic to find solutions where others have failed is 
partly dependent on pursuing detailed assessment of patient symptoms, lifestyle and 
physiology. The intensity of this assessment is discussed with patients at the outset, 
though we usually find that patients attending this clinic (often from some distance 
away) are highly motivated and very keen to have these assessments. 
The following are standard for patients attending with neurological constipation: 
 History taking 
 Physical examination including PR examination 
 Blood test including full blood count, urea and electrolytes, calcium, blood 
sugar and thyroid function tests. 
 Symptom and Quality of Life (QOL) assessment is performed in all patients 
referred to the Constipation Clinic using self-administered questionnaires 
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 Transit Study. This is recommended in all patients and is part of standard 
clinical practice. Transit time is determined following a single plain abdominal 
X-ray taken after ingestion of radio-opaque markers. The markers are inert, 
easy to swallow and are taken on days 1, 2 and 3. The X-ray is taken on day 4 
(Metcalf, Phillips et al. 1987). This method allows a reduction in the number of 
x-ray exposures compared to previous techniques.  
 Flexible Sigmoidoscopy is recommended in nearly all patients. It helps in ruling 
out or diagnosing any structural pathology causing constipation in these 
patients. Random rectal mucosal biopsies are taken and assessed histologically 
to further rule out any pathology. 
3.3.2 Standard management in the Constipation Clinic 
The individual needs of patients with neurological disorders were taken into account 
when planning management. Standard approaches like dietary manipulation, laxatives, 
suppository and enema therapy were used as required. Should these therapies fail to 
control symptoms, a trial of rectal irrigation was considered. However, patients usually 
had symptoms that were refractory to all these interventions. In these difficult cases 
SNS was offered.   
3.3.3 Assessments  
The patients were assessed using the following measures: 
3.3.3.1 Global Assessment of Symptoms 
This addressed changes in symptoms of constipation and/or faecal incontinence. 
Weekly assessments were recorded throughout the 12-week study period. This helped 
quantify any changes in participants’ symptoms before, during or after SNS. At the end 
of each week participants answered the following questions. 
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Table 3-1: Global assessment of symptoms 
How has your constipation been this 
week? 
Tick the appropriate box 
How has your faecal incontinence been this 
week? 
Tick the appropriate box. 
 
1. No problem  1. No problem  
2. Mild problem 
(Can be ignored with effort) 
 
 
2. Mild problem 
(Can be ignored with effort) 
 
 
3. Moderate problem 
(Cannot be ignored but does not 
influence my daily activities) 
 
 
 
3. Moderate problem 
(Cannot be ignored but does not 
influence my daily activities) 
 
4. Severe problem 
(Cannot be ignored and often limits 
my concentration on daily activities) 
 
4. Severe problem 
(Cannot be ignored and often limits my 
concentration on daily activities) 
 
5. Very severe problem 
(Cannot be ignored and markedly 
limits my daily activities and often 
requires rest) 
 
5. Very severe problem 
(Cannot be ignored and markedly limits 
my daily activities and often requires 
rest) 
 
 
3.3.3.2 Diary 
In addition to weekly global assessments of symptoms, participants were asked to fill 
in daily diary cards on a weekly basis from week four to week nine (covering three 
weeks of pre-treatment assessment and 3 weeks of treatment). The diary included 
daily stool frequency, episodes and type of faecal incontinence, laxative intake and 
laxative score. 
Patients with neurological constipation often suffer from faecal incontinence due to 
lack of sphincter control. Inability to open the bowels for a long period of time will lead 
to a more than average laxative use by the patient causing episodic faecal incontinence 
due to runny stools. Documentation of incontinence in the diary was based on a 
standardized scoring system (Wexner score). 
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3.3.3.2.1   Laxatives and laxative score 
Each participant documented the intake of laxatives in the diary on a daily basis. Use of 
new laxative agents was limited in order to preserve continuity during the trial.  
In our experience the dosage and type of laxatives vary in patients with neurological 
constipation and it is very difficult to quantify the laxative intake over a period of time. 
To account for this, weekly laxative use was averaged out for each participant and then 
documented with the help of a simple daily laxative score. Patients recorded in their 
diaries whether their laxative intake was more, same or less than their average use 
with the help of a simple scale. 
3.3.3.3 PAC-SYM and PAC-QOL 
The Patient Assessment of Constipation (PAC) tool consists of two separate scales, 
PAC-SYM (12 item measure of symptom severity) and PAC-QOL (28-item measure of 
health related quality of life). The questionnaire could be administered by patients or 
by investigators. This tool was designed to specifically assess constipation. The robust 
psychometric properties of the system have been demonstrated in community dwelling 
younger adults(Frank, Kleinman et al. 1999; Marquis, De La Loge et al. 2005). Both of 
theses questionnaires were administered on a weekly basis throughout the trial. 
3.3.3.4 EuroQOL 
EuroQOL is a standardized instrument for measurement and valuation of health status. 
It is used to determine the global or generic status of a person’s health and health 
related quality of life. It is designed for self-completion and has been applied widely to 
a variety of health conditions and treatments(Rabin and de Charro 2001). It can be 
easily completed in a few minutes and has five dimensional (EQ-5D) descriptive profile 
(each dimension has 3 levels) and a visual analogue scale (EQ-VAS). EuroQOL has been 
applied in clinical, economical and population-based studies. The performance of 
EuroQOL in IBS and inflammatory bowel disease has been evaluated previously(König, 
Ulshöfer et al. 2002; Bushnell, Martin et al. 2006). As an outcome measure it can also 
help conduct an economic valuation of treatments by calculating quality adjusted life 
years (QALY) (estimating differences between treatments in quality of life over time). 
The EuroQOL tool was repeated before, during and after the treatment at three-week 
intervals. The potential differences in the profiles over this time period were to help 
assess changes in patients. A copy of EuroQOL is included in Appendix B. Although it 
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was recognised that neither EQ-5D nor EQ-VAS would be sensitive enough to detect 
changes in a small number of patients it was included to obtain estimates of variance to 
help design future studies. 
3.3.3.5 Transit study 
Transit time was one of the physiological parameters tested during this study and was 
also part of standard assessment in the constipation clinic. In addition to subjective 
assessments of the effect of SNS (QOL and symptoms), objective measures are helpful 
in ascertaining the effectiveness of treatment and extending understanding of who 
benefits from treatment. Findings may help advise future patients when they are 
making a decision regarding SNS treatment. Patients participating in the study 
underwent a further abdominal radiograph. This additional radiation exposure was 
however minimal and was not felt to constitute a significant risk to participants in 
either the short or long term. The issue of radiation exposure was carefully discussed 
with participants and an explanation of the justification for repeating the transit study 
given. Special attention was paid to certain groups to minimize radiation exposure.    
3.3.3.6 Laser Doppler flowcytometry 
Laser Doppler flow cytometry (LDFC) measures the change in frequency of light 
reflected off moving objects: in this instance red blood cells flowing within capillaries. 
The equipment consists of a fibre optic probe producing a low intensity coherent 
monochromatic light beam. This light is reflected off moving blood cells and the 
frequency shift is measured and evaluated by a photocell and computer software. This 
measured frequency shift gives the volume flow (flux) through the respective tissue in 
millilitres of blood per minute per 100 grams of tissue.  
A DRT4 laser Doppler flow meter (Moor Instruments, Devon, UK) with a bandwidth of 
14.9 Hz was used. The area of measurement corresponds to 1 mm2 of rectal mucosa up 
to a depth of 1 mm from the tip of the probe. Readings were taken with the help of a 
sigmoidoscope approximately 10 cm from the anal verge with the patient in a left 
lateral position. The first reading was taken after 30 seconds when the trace becomes 
more stable and was recorded over 3 minutes. Built-in software limits any movement 
artefacts. Four circumferential readings, 90 degrees apart, were taken at the same level 
in order to reduce the variability coefficient to less than 10%, thus making the 
measurements reliable (Emmanuel and Kamm 1999). Two separate measurements 
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were taken at 3 weeks and 9 weeks. There was one measurement before SNS and one 
during SNS.  
LDFC provides a validated quantitative measure of extrinsic autonomic nerve activity 
of the GI tract. Patients with slow-transit constipation have less mucosal flux assessed 
by LDFC when compared to normal controls (Emmanuel and Kamm 2000). Laser 
Doppler measurements of rectal mucosa have shown improvement in blood flow after 
SNS suggesting a potentially positive autonomic neuromodulatory role for SNS. It has 
been suggested that sacral parasympathetic efferents, in response to direct stimulation, 
activate a cholinergic mediated vasodilator response that improves mucosal blood flow 
(Emmanuel and Kamm 1999). The use of LDFC may help quantify any potential 
changes in the autonomic input of the gut by performing LDFC before and during 
treatment.  
 
Figure 3-1: LDFC Probe in rectum during measurement 
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3.3.3.7 Selection for Permanent implant (P-SNS) 
Criteria for receiving a permanent implant after T-SNS included the following 
 GA Constipation:  An improvement of 2.0 on the GA scale for constipation 
 PAC-SYM: improvement in overall score of PAC-SYM from baseline  
 Patients were also asked to report any associated subjective improvements in 
their symptoms and quality of life.  
 Absence of any adverse events associated with T-SNS. 
Patients were considered for permanent implants if they fulfilled any of the above 
criteria and both the investigator and the patient felt that there was a significant 
improvement during T-SNS. 
3.3.4 Adverse events 
All untoward events that arose from participation in the study (whether or not they 
were considered serious or related to participation) were recorded. The following 
information was entered in the medical notes and in an adverse event database.  
 Description of the event 
 Severity 
 Date 
 Relationship to participation in the study 
 Outcome 
3.4 Analysis Plan 
3.4.1 Baseline Data 
Demographic data including, but not limited to age, race, gender and ethnicity and 
baseline characteristics were recorded for each subject. In addition, diagnosis, stage of 
the disease and effects on mobility were also included in the baseline data. 
3.4.2 Grouping of measurements and analysis 
Observations were grouped within SNS study phases (pre: weeks 1-6; during: weeks 7-
9 and post: weeks 10-12) and included primary and secondary outcomes measured on 
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a weekly basis. Pre-intervention baseline scores were averaged for the first six weeks, 
forming the pre-SNS measure. The scores from week 8 and week 9 were used for the 
intervention phase, forming the SNS intervention measure. Week 12 scores were used 
for the post-stimulation of phase. Weeks 7, 10 and 11 were excluded from the planned 
analysis because of the prior expectation that changes in SNS stimulation would have a 
transient effect before change was stable. The scores for the pre-intervention period 
were compared with scores during and after temporary SNS, using a paired Student’s t-
test. The validity of parametric testing was explored by non-parametric testing 
usingbootstrapped estimates.  Non-parametric findings were reported when they were 
divergent from parametric findings. The Mann Whitney U test was applied to compare 
responders and non-responder rates to SNS. Non-parametric findings were reported 
when they were divergent from parametric findings. 
3.4.3 Primary outcome 
3.4.3.1 Global assessment of Constipation (GA Constipation) 
This was measured once weekly over the course of twelve weeks during the trial.  The 
GA score for constipation is a 5 point Likert scale ranging from 1-5 (1= no symptoms, 
5= very severe symptoms). For a description see Table 3-1. 
3.4.4 Secondary Outcomes 
3.4.4.1 Global Assessment of Faecal Incontinence (GA F.I.) 
The GA score for faecal incontinence, like the constipation measure, is a 5 point Likert 
scale ranging from 1-5 (1= no symptoms, 5= very severe symptoms). 
3.4.4.2 Patient Assessment of Constipation Symptoms (PAC-SYM)  
The PAC-SYM questionnaire was used on a weekly basis during each trial phase. It is a 
12 item measure of symptom severity. A sub domain analysis of measured changes in 
the three sub domains of PAC-SYM questionnaire was planned. 
3.4.4.3 Patient Assessment of Constipation (PAC-QOL) 
PAC-QOL score was measured weekly throughout the trial. PAC-QOL is a 28 point 
questionnaire self-administered by patients. This quantified constipation specific QOL 
for each patient during the trial. PAC-QOL has five sub domains. A sub domain analysis 
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of measured changes was planned. 
3.4.4.4 Euro QOL Health Questionnaire (EQ-5D) 
EQ-5D is a five domain health questionnaire designed to measure the general quality-
of-life (QOL) of recruited patients.  It was measured during weeks 3 and 6 (pre-
intervention), week 9 (during SNS) and week 12 (post intervention). Responses were 
converted to a single health-related quality-of-life score using the social tariffs 
provided by the EuroQol group.  Weeks 3 and 6 were combined to form the pre-
intervention measure and compared with week 9 and week 12 using a paired student’s 
t-test. 
3.4.4.5 EuroQOL Visual Analogue Score (EQ-VAS) 
EQ-VAS is a self administered score between 0 and 100 (0 poor state of health, 100 best 
state of health). This was administered at the same time as EQ-VAS and was analysed 
accordingly. 
3.4.4.6 Daily Dairy 
During weeks 4 to 9 patients completed a daily diary. This daily diary included bowel 
frequency, episodes of faecal incontinence, type of incontinence (flatus, liquid or solid), 
time spent during toileting in minutes and laxative score. This entailed documenting in 
the diary whether their laxative intake was more, the same or less than average use 
with the help of a simple scale.  
Manual manoeuvres during toileting such as abdominal massage, digital stimulation 
and manual evacuation of rectum were measured on a daily basis as well. The average 
pre-intervention and during intervention scores were compared for each variable of 
the diary utilizing a paired t-test. 
3.4.4.7 Stimulation Thresholds 
The Stimulation thresholds were recorded at the time of insertion of the temporary 
electrodes. These were also measured at the end of the temporary trial. Differences 
between responders and non-responders were estimated using an unpaired Student’s 
t-test. 
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3.4.4.8 Physiological Outcomes 
3.4.4.8.1 Laser Doppler Flowcytometry (LDFC) 
LDFC is a determinant of the autonomic innervation of the hindgut (Emmanuel and 
Kamm 2000) and has been shown to improve during SNS. LDFC was measured pre and 
during intervention. This was done by sigmoidoscopy at four sites in the rectum 10 
cms from the anal verge. The average LDFC score for each site was analysed during and 
before treatment to measure any improvements in the autonomic innervation of the 
hindgut. 
3.4.4.8.2 Colonic Transit time 
As part of standard assessment of constipation each patient underwent a transit 
marker study at the start of the trial utilizing a previously described modified 
technique (Metcalf, Phillips et al. 1987). Patients underwent a repeat transit study 
during temporary SNS and any changes from the pre-intervention phase were 
analysed. 
3.4.4.9 Correlation between outcomes 
Correlation coefficients between primary and secondary trial endpoints were 
estimated. The purpose was to understand the relationship between outcomes. 
3.4.5 Permanent SNS implantation 
Patients who had a successful trial of bilateral SNS received an implantable pulse 
generator (IPG). The medium to long-term data from these patients was collected and 
compared to their pre-intervention baseline scores to quantify the extent to which the 
effect of SNS was sustained. 
The longer term follow-up data included GA scores for constipation, PAC-SYM scores 
and PAC-QOL scores. 
3.4.6 Predictors of Outcome 
A linear regression analysis was planned, to explore the determinants of response to 
SNS during the temporary and permanent phases. This included exploration of 
stimulation thresholds at the time of procedure, baseline characteristics including the 
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diagnosis and mobility criteria and long-term data.  The dependent variables included 
primary and secondary outcomes.  
3.4.7 Other Analyses 
3.4.7.1 Subgroup analyses 
A subgroup analysis was planned for patients with Multiple Sclerosis (MS) recruited to 
the trial. MS patients have a different aetiology and presentation than spinal cord 
diseases or injuries and may respond differently to SNS. We anticipated a majority of 
participants would have MS. 
3.4.8 Missing Data 
Patients not commencing SNS or having a failed trial at the time of wire placement did 
enter the treatment phase (weeks 7-9) of the study. These patients were documented 
and reported separately from the main analyses.  
For each outcome, any patient with missing data was omitted from the analysis of that 
outcome without imputation. 
3.5 Ethical Considerations 
The decision to offer SNS was made on clinical grounds and did not form part of the 
study protocol. However, the ethics of SNS are considered here. SNS for neurological 
constipation is a novel therapy and experience is still limited. Therefore, patients were 
counselled and consented in a rigorous fashion so that they were fully aware of the 
issues surrounding the procedure. The alternatives to SNS for patients with refractory 
symptoms are invasive surgical interventions with recognized complications and 
without guarantee of success. By actively studying the effect of SNS in this group we 
hoped to improve our understanding of how best to manage these patients who are 
severely disabled by their symptoms.  
Following the decision to offer SNS, patients were free to choose whether to participate 
in the study without prejudice to their routine care. Ethical questions could be raised 
regarding repeat transit study and laser Doppler: two investigations that would not 
normally be routinely performed. However, it was felt that subjects would find these 
tests acceptable and tolerate them well. The additional radiation exposure of the 
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transit study was minimal and was not considered to contribute to long-term 
problems. These tests were crucial to improve our understanding of the efficacy of SNS. 
3.5.1 Confidentiality 
Identification within the study was by a pseudonymous coded number effectively 
ensuring anonymisation. However, using this number the principle investigators were 
able to identify subjects rapidly to react to research related information that may 
influence a patient’s management or involvement in the study.  A subject’s inclusion in 
the study was made clear in their medical notes. Other medical practitioners involved 
with the non-research related care of the subjects (for example in a medical emergency 
unrelated to the study) were able to use the information recorded in the notes about 
study participation and contact the investigators if needed.   
3.5.2 Information to GPs 
General Practitioners were informed of their patient’s decision to participate. The 
letter to GPs provided information about the study. The GP was invited to contact the 
investigators at the University of North Durham if they had questions or objections. 
3.5.3 Information to carers 
Carers (both formal and informal) were made aware of the patient’s decision to 
participate. An information leaflet for carers was available (see Appendix B). This letter 
provided information about the study. Carers were invited to contact the investigators 
at the University Hospital of North Durham if they had enquires or objections.  
3.5.4 Radiological Procedures 
Patients with constipation due to neurological disorders required radiological 
investigation including a Transit Study. This forms part of the standard approach. In 
this study there was a research need to repeat the Transit Study following SNS 
insertion. We believe that the additional radiation exposure was small and carried 
negligible risk to the individual. Using the current technique at the University Hospital 
of North Durham (Metcalf, Phillips et al. 1987). Only one abdominal radiograph per 
transit study was required thus reducing radiation exposure. To avoid exposure in any 
individual who maybe pregnant certain precautions were observed: 
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 All patients were warned verbally and in writing of the potential risk of 
radiation exposure to a developing foetus 
 Patients were excluded from the study at the initial assessment if they were 
pregnant; thought they might be pregnant or were trying to conceive. 
 All women of childbearing age were asked to give written consent to for each 
individual radiological procedure in the study. 
 Subjects at high risk included pre-menopausal women who were sexually 
active and were not using regular reliable contraception. All such patients had 
radiological procedures timed to coincide with the first 10 days of their 
menstrual cycle. Patients who had irregular periods were offered the option of 
a pregnancy test on the day of the procedure. 
3.5.5 Additional Radiation exposure as part of the study 
Study participants underwent an additional abdominal X ray as part of the second 
Transit Study three weeks after SNS insertion (at week nine of the study). The 
additional exposure had been calculated as 0.5mSv.  
The dose constraint (ED) set for this research exposure by the Radiation Protection 
Officer was 1.0 mSv. The associated additional excess lifetime mortality risk was 
therefore approximately 1 in 13,000. The radiation dose was comparable with the 
annual dose from natural sources in the United Kingdom. The risk was less than the 
annual risk of a fatal road accident and at least 25 times less than the natural annual 
cancer risk. An ED of 1.0 mSv equates to approximately 4.5 months natural background 
radiation in the UK. This represented a very small additional risk. The written patient 
information included reference to this additional radiation exposure, with the risk put 
into context for the patient.  
3.5.6 Magnetic Resonance Imaging (MRI) following SNS 
Patients with an established diagnosis of multiple sclerosis may require further MRI 
scans in case of disease progression. They may require brain and/or spine MRI scans 
depending on the site of lesions in each patient.  
MR scanning in patients with implanted pulse generators (IPG) for SNS can cause 
excessive and painful stimulation and heating during the MR exam as well as decreased 
function of the IPG after the MRI. Medtronic have published guidelines regarding the 
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interstim system of implants for patients undergoing MRI scans. Patients implanted 
with the MR conditional type of pulse generators can have head scans providing that 
certain conditions have been met. They recommend using MR scanners up to 1.5Tesla 
with the stimulator turned off and the magnetic switch disabled. They also recommend 
withholding sedation during the MR to get reliable patient feedback.(Medtronic) 
There have been a number of papers published on the safety of MRI scans in patients 
with neurostimulators. In a series of 15 patients with P-SNS, Chermansky et al. 
reported device failure in only one patient after MRI scans. They followed the 
manufacturer’s guidelines and did not have any adverse events in the rest of the 
patients after re-programming (Chermansky, Krlin et al. 2010). Elkelini reported 
similar findings in another series of patients with interstim implants (Elkelini and 
Hassouna 2006). Kainz et al. reported a temperature rise of 2.1 degree Celsius at the 
lead tip and only 1.8 degree Celsius over the implant casing during MRI. This was 
reproduced with both 1.5Tesla and 3Tesla MR scanners (Kainz, Neubauer et al. 20022). 
However, most of the patients with stable MS may not require any MR scans after 
implantation. The field of view of MR scans in MS is the brain and/or the spinal cord 
which is away from the pelvis where the leads and the implant are sited. The threshold 
for irreversible thermal injury is more than 45 degree Celsius and a change of 2-3 
degree Celsius during MR seems to be clinically safe in these patients. The functionality 
issue can be managed by switching the IPG off for the scan and re-programming after 
scanning. 
3.6 Study schedule 
The study schedule is set out in Table 3-2 and assessment schedule in Figure 3-2. 
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Table 3-2: Study schedule 
(Blue boxes denote research activity; Green boxes represent standard clinical 
management) 
1. Patient referred to Constipation clinic at University Hospital of North Durham 
History, examination, Symptom & QOL assessment, Transit study, Flexible 
sigmoidoscopy. 
Standard treatments  
2. Patients not responding offered SNS and referred to surgeons 
3. Patients seen in surgical clinic by Consultant Surgeon 
4. Patient consented to SNS and referred to constipation clinic 
5. Patient consents to inclusion in study & is recruited               Week 0 
6. Patient fills weekly global symptom assessment (GA) diary, 
PAC-SYM and PAC-QOL      Week1-3 
7. Patient fills EuroQOL and undergo laser Doppler flowmetry              Week 3 
8.   Daily stool and laxative diary cards (Pre-SNS)                  Week 4-6 
9.   Repeat weekly GA, PAC-SYM & PAC-QOL                    Week 4-6 
10. Repeat EuroQOL in clinic      Week 6 
11. Temporary SNS, 12-24 hour hospital admission   Week 7 
12. Daily stool and laxative diary cards (during SNS)   Week 7-9 
13. Repeat weekly GA, PAC-SYM & PAC-QOL      Week 7-9 
14. Repeat EuroQOL, transit study and laser Doppler flowmetry                 Week 9 
      in clinic    
15. Temporary SNS removed      Week 9 
16. Repeat weekly GA, PAC-SYM & PAC-QOL      Week 10-12 
17. Final reassessment of EuroQOL and end of trial appointment                Week 12 
Monthly meetings of investigators to review and audit data 
Interim report to Project Review Board at 6 months following start of study 
Completion of result analysis and preparation of final report predicted at 30 months 
following start of study 
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Figure 3-2: Assessment schedule 
 
 
                 Recruitment            3 wk visit            3wk visit                3wk visit 
 
 
Phases Pre-SNS SNS Post-SNS 
Assessments Wk01 Wk02 Wk03 Wk04 Wk05 Wk06 Wk07 Wk08 Wk09 Wk10 Wk11 Wk12 
Global 
assessment 
                        
Diary        
PAC-SYM                         
PAC-QOL                         
EuroQOL                 
Transit              
LDFC                
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4. Findings 
4.1 Recruitment and Baseline Data: 
The trial recruited 22 patients over 2 years (December 2007 to December 2009) from 
one tertiary care centre: the specialist constipation clinic at the University Hospital 
North Durham. There were 8 men and 14 women with an average age of 51.5 years 
(Range 38-69 yrs.). Of 22 patients: 14 patients had Multiple Sclerosis; 5 had Spinal Cord 
Injury (2 cauda equina lesions, 1 incomplete lumbar spine injury, 1 complete thoracic 
spine injury and 1 incomplete cervical spine injury); 1 patient had autonomic dystonia; 
1 had spinal myoclonus; and, 1 had a history of myelitis secondary to polio. During the 
study, 4 patients dropped out before temporary SNS; 18 patients completed the trial. 
Reasons for drop-out were not recorded. See Table 4-1. 
The referral route for the majority of patients seen in the constipation clinic at the 
University hospital of North Durham is through local GP practices and regional 
hospitals. The trial aimed to recruit 30 patients with neuroconstipation, however 
during the second year the referral rates from local practices and hospitals dropped 
significantly. One major contributing factor was the retirement of a local collaborator 
which led to a decrease in the frequency of outpatient clinics at the local neurology 
unit. Hence, the trial was unable to meet the recruitment target within the two year 
trial time frame. 
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 Age Sex Diagnosis Mobility Successful trial IPG implanted 
SNS001 39 M Autonomic Dystonia RM Dropped out - 
SNS002 61 M SCI cervical  Normal Yes Yes 
SNS003* 50 F MS WB Yes Yes 
SNS004 69 M MS RM Yes Yes 
SNS005 38 M MS RM Yes Yes 
SNS006 58 F SCI thoracic WB No No 
SNS007 63 M MS WB Yes Yes 
SNS008 45 M Cauda Equina Normal Yes Yes 
SNS009 40 F MS WB Yes Yes 
SNS010 54 F MS WB No No 
SNS011 50 F MS RM No No 
SNS012 55 F SCI RM No No 
SNS013 60 F Spinal Myoclonus WB Yes Yes 
SNS014 67 F MS Normal Dropped out - 
SNS015 64 F MS Normal Dropped out - 
SNS 016 53 F MS WB Yes Yes 
SNS 017 41 M MS Normal Yes Yes 
SNS018 55 F MS WB No No 
SNS019 47 F MS Normal Dropped out - 
SNS020 64 F Polio/ Hemiplegia Normal Yes Yes 
SNS021 58 F MS Normal Yes Yes 
SNS022** 50 M Cauda Equina RM No No 
Key:  
* Sigmoid Volvulus; has loop colostomy now 
** Patient died midtrial in RTA 
MS= Multiple Sclerosis 
SCI=Spinal cord Injury 
IPG= Implantable pulse generator  
Mobility= WB wheelchair bound, RM reduced mobility, N normal. 
Table 4-1: Demographics and Participation 
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4.2 Primary outcome 
4.2.1 Global assessment of Constipation 
Table 4-2 shows the average scores for GA constipation from week 1 to week 12 of the 
trial. The Likert scale ranges from 1 (normal bowel habit) to 5 (very severe 
constipation). One of the patients failed to respond to SNS at the time of wire insertion; 
and the data were not included. Complete data were available for 15 patients as 2 
patients did not report complete data. 
The weekly mean scores and confidence intervals are reported in Table 4-2 and 
visualized in Figure 4-1. 
Figure 4-1: Mean GA scores for constipation 
 
Table 4-2: Mean weekly scores for global assessment of constipation 
Week 1 2 3 4 5 6 7 8 9 10 11 12 
Mean  3.75   3.88   3.94   3.75   3.75   3.63   2.75   2.75   2.63   2.94   3.38   3.63  
95%CI-  3.44   3.55   3.53   3.29   3.18   3.11   2.15   2.22   1.93   2.44   2.90   3.15  
95%CI+  4.06   4.20   4.35   4.21   4.32   4.14   3.35   3.28   3.32   3.43   3.85   4.10  
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The mean GA score for constipation during the first six weeks was 3.78 (95% CI 3.44 to 
4.12). It improved during intervention (week 8-9) to 2.69 (95% CI 2.12 to 3.25) and 
post intervention (week 12) increased to 3.63 (95% CI 3.15 to 4.10).  
There was an improvement in GA score for constipation during the intervention phase 
when compared to the pre-intervention stage (Table 4-3 p= 0.0003, paired t-test).  
Alternative use of the non-parametric Wilcoxon signed-rank test supported a 
statistically significant difference (p=0.001). There was a gradual washout of effect 
after the removal of stimulation (see Figure 4-1). At week 12 symptoms were similar to 
baseline (p=0.40). Individual patient data reported in appendix A. 
 
Table 4-3: Changes in GA Constipation during each phase of the study 
 Int-Pre End-Pre 
Mean -1.09 -0.16 
95% CI- -1.59 -0.54 
95% CI+ -0.59 0.23 
p 0.0003 0.40 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
End: Post-intervention (wk 12) 
 
4.2.2 Permanent Implant Decision 
All patients demonstrating a positive response (12 of 18, 67%) were offered and 
received a permanent implant (see Table 4-1).  Four of the original sample of 22 
patients did not proceed to temporary implant.  
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4.3 Secondary Outcomes 
4.3.1 Global Assessment of Faecal Incontinence 
The Likert scale ranged from 1 (no incontinence) to 5 (very severe incontinence). One 
of the patients failed to respond to SNS at the time of wire insertion and was not 
included in the final analysis. Complete data were available for 15 patients. 
The mean GA score for faecal incontinence during the first six weeks was 1.29 (95% CI 
0.61 to 1.97), during intervention (week 8-9) was 1.13 (95% CI 0.41 to 1.84) and post 
intervention was 1.25 (95% CI 0.35 to 2.15). The mean weekly scores and confidence 
intervals for GA FI are given in Figure 4-2 and Table 4-4. 
 
Figure 4-2: GA of Faecal Incontinence 
 
Table 4-4: Mean weekly scores for GA FI 
Week 1 2 3 4 5 6 7 8 9 10 11 12 
Mean  1.81  2.00 1.88 1.88 1.63 1.88 1.75 1.88 1.56 1.56 1.63 1.81 
95%CI- 1.19 1.22 1.18 1.26 0.95 1.18 1.15 1.30 0.98 1.13 1.05 1.13 
95%CI+ 2.43 2.78 2.55 2.49 2.30 2.57 2.35 2.45 2.12 2.00 2.18 2.49 
 
The change in mean GA score of FI during the intervention phase of the study was 
neither clinically important nor statistically significant (p = 0.36, see  Table 4-5). The 
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lack of response in this measure was consistent with prior expectation, since FI was not 
an important symptom in this patient group. 
 
Table 4-5: Changes in GA FI during each phase of the study 
 Int-Pre End-Pre 
Mean -0.13 -0.03 
95% CI- -0.41 -0.44 
95% CI+ 0.16 0.37 
p 0.36 0.87 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
End: Post-intervention (wk 12) 
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4.3.2 Patient Assessment of Constipation Symptoms (PAC-SYM) 
The aggregate PAC-SYM score ranges from 0 (no constipation) to 4 (severe 
constipation). The overall score is calculated as the average of 12 items, each scored 
from 0 to 4. Missing values were subtracted from the denominator during the 
calculation of the overall score. Complete data were available for 15 patients. 
The mean PAC-SYM score during the first six weeks was 1.83 (95% CI 1.49 to 2.17). It 
improved during intervention (week 8-9) to 1.10 (95% CI 0.67 to 1.54) and post 
intervention increased to 1.54 (95% CI 1.13 to 1.94). The mean weekly scores and 
confidence intervals for PAC-SYM are given in Figure 4-3 and Table 4-6. 
Figure 4-3: PAC-SYM Score 
 
 
Table 4-6: Weekly mean scores for PAC-SYM 
Week 1 2 3 4 5 6 7 8 9 10 11 12 
Mean  1.81   1.88   1.91   1.86   1.78   1.73   1.25   1.17   1.04   1.10   1.23   1.54  
95%CI-  1.38   1.50   1.55   1.50   1.40   1.36   0.81   0.72   0.61   0.76   0.92   1.13  
95%CI+  2.24   2.26   2.28   2.22   2.16   2.11   1.69   1.61   1.47   1.43   1.55   1.94  
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There was a clinically important improvement in PAC-SYM score during the 
intervention phase when compared to the pre-intervention stage (p=0.003). There was 
a gradual diminution of effect after the removal of stimulation (see Table 4-7 and 
Figure 4-3), although symptoms had not fully returned to baseline at week 12 (p=0.04).  
 
Table 4-7: Change in PAC-SYM during each phase of the study 
  Int-Pre End-Pre 
Mean -0.73 -0.29 
95% CI- -1.06 -0.58 
95% CI+ -0.39 -0.01 
p 0.0003 0.04 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
End: Post-intervention (wk 12) 
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4.3.2.1 PAC-SYM Domain Analysis 
The PAC-SYM12-item self-report measure is divided into three symptom subscales (i.e. 
abdominal, rectal and stool). Items are scored on a four-point Likert scale, with 4 
indicating the worst symptom severity. A sub-domain analysis was carried out to check 
variations in each domain during each phase of the trial. In summary, over the 12 week 
period, each sub-domain qualitatively reflected the pattern found in the overall PAC-
SYM score. 
4.3.2.1.1 Abdominal Domain 
There are four items in the abdominal domain which include abdominal discomfort, 
abdominal pain, abdominal cramping and abdominal bloating. Table 4-7 shows the 
average scores for the abdominal domain of PAC-SYM from week 1 to week 12 of the 
trial. The mean score during the first six weeks was 2.00 (95% CI 1.60 to 2.41). It 
improved during intervention (week 8-9) to 1.16 (95% CI 0.65 to 1.67) and post 
intervention increased to 1.64 (95% CI 1.16 to 2.13). The weekly mean scores and 
confidence intervals are given in Table 4-8 and visualized in Figure 4-4.  
Figure 4-4: PAC-SYM Abdominal score 
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Week 1 2 3 4 5 6 7 8 9 10 11 12 
Mean 1.94 2.12 2.02 2.05 1.93 1.93 1.34 1.12 1.20 1.24 1.36 1.64 
95%CI- 1.41 1.64 1.57 1.62 1.45 1.45 0.88 0.62 0.67 0.81 0.92 1.16 
95%CI+ 2.48 2.59 2.47 2.48 2.41 2.41 1.80 1.62 1.72 1.68 1.79 2.13 
 
There was an improvement in the PAC-SYM abdominal domain score during the 
intervention phase when compared to the pre-intervention stage (Table 4-9, 
p=0.0009). There was a trend from week 10 to 12 of the score returning to baseline 
after removal of wires (see Figure 4-4).  
 
 Int-Pre End-Pre 
Mean -0.84 -0.36 
95% CI- -1.27 -0.77 
95% CI+ -0.41 0.06 
p 0.0009 0.09 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
End: Post-intervention (wk 12) 
 
  
Table 4-8: Weekly mean scores for PAC-SYM abdominal domain 
Table 4-9: Change in PAC-SYM abdominal domain 
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4.3.2.1.2 Rectal domain 
There are 3 items related to the rectal domain. These include painful bowel 
movements, rectal burning and bleeding or tearing during or after bowel movements. 
Table 4-10 shows the average scores for the rectal domain of PAC-SYM from week 1 to 
week 12 of the trial. The mean score during the first six weeks was 1.42 (95% CI 1.06 
to 1.78). It improved during intervention (week 8-9) to 0.78 (95% CI 0.42 to 1.14) and 
post intervention increased to 1.15 (95% CI 0.70 to 1.60). The weekly mean scores and 
confidence intervals are given in Figure 4-5.  
 
Figure 4-5: PAC-SYM Rectal score 
 
 
Week 1 2 3 4 5 6 7 8 9 10 11 12 
Mean 1.38 1.31 1.48 1.54 1.38 1.42 0.85 0.88 0.69 0.65 0.88 1.15 
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Table 4-10: Mean scores for rectal domain of PAC-SYM 
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There was an improvement in PAC-SYM rectal domain score during the intervention 
phase when compared to the pre-intervention stage (p=0.003). There was a trend from 
week 10 to 12 of the score returning to baseline after removal of wires (see Figure 4-5 
and Table 4-11). 
 
 Int-Pre End-Pre 
Mean -0.64 -0.27 
95% CI- -1.03 -0.75 
95% CI+ -0.24 0.21 
p 0.003 0.25 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
End: Post-intervention (wk 12) 
 
 
4.3.2.1.3 Stool Domain 
The stool domain has five items which include bowel movements that require straining 
or squeezing, bowel movements that are too hard, bowel movements that are too small, 
bowel movements that result in a sensation of incomplete evacuation and having false 
alarms. 
The mean score during the first six weeks was 1.94 (95% CI 1.48 to 2.40). It improved 
during intervention (week 8-9) to 1.27 (95% CI 0.76 to 1.77) and post intervention 
increased to 1.67 (95% CI 1.16 to 2.18). The weekly mean scores and confidence 
intervals are given in Figure 4-6 and Table 4-12. 
Table 4-11: Change in Rectal domain of PAC-SYM 
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Figure 4-6: PAC-SYM Stool score 
 
 
 
Week 1 2 3 4 5 6 7 8 9 10 11 12 
Mean 1.98 2.02 2.11 1.88 1.89 1.75 1.47 1.44 1.09 1.22 1.30 1.67 
95%CI- 1.41 1.46 1.57 1.38 1.35 1.32 0.87 0.94 0.56 0.81 0.90 1.16 
95%CI+ 2.56 2.58 2.65 2.37 2.43 2.18 2.07 1.94 1.63 1.63 1.69 2.18 
 
There was an improvement in the stool domain of PAC-SYM during intervention. This 
was statistically significant (p<0.0001). There was a gradual diminution of benefit after 
the removal of wires and the symptoms reverted towards the pre-treatment stage 
(Table 4-13 p=0.12). 
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Table 4-12: Mean scores for Stool domain of PAC-SYM 
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 Int-Pre End-Pre 
Mean -0.67 -0.27 
95% CI- -0.92 -0.61 
95% CI+ -0.43 0.08 
p <0.01 0.12 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
End: Post-intervention (wk 12) 
 
4.3.3 Patient Assessment of Constipation (PAC-QOL) 
The PAC-QOL is a 28-item subject self-administered instrument that measures the 
severity of constipation-related quality of life. Items are rated on a 5-point scale: 0=not 
at all/none of the time, 1=a little bit/a little of the time, 2=moderately/some of the 
time, 3=quite a bit/most of the time and 4=extremely/all of the time. 
The aggregate average score similarly ranges from 0 (best QOL) to 4 (Worst QOL). 
Missing values are subtracted from the denominator during the calculation of overall 
score. Complete data were available for 15 patients. 
The mean PAC-QOL score during the first six weeks was 2.26 (95% CI 1.96 to 2.55). It 
improved during intervention (week 8-9) to 1.58 (95% CI 1.11 to 2.05) and post 
intervention increased to 2.16 (95% CI 1.82 to 2.51) almost returning to baseline value 
by the end of week 12. The mean weekly scores and confidence intervals for PAC-QOL 
are given in Figure 4-7 and Table 4-14. 
 
Table 4-13: Change in Stool domain of PAC-SYM 
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Figure 4-7: PAC-QOL Score 
 
Table 4-14: Weekly mean score for PAC-QOL 
Week 1 2 3 4 5 6 7 8 9 10 11 12 
Mean  2.42   2.34   2.32   2.23   2.17   2.07   1.77   1.61   1.55   1.64   1.99   2.16  
95%CI-  2.04   2.00   2.01   1.96   1.91   1.70   1.33   1.16   1.05   1.27   1.66   1.82  
95%CI+  2.80   2.67   2.64   2.49   2.43   2.44   2.21   2.06   2.06   2.01   2.33   2.51  
The improvement in PAC-QOL during SNS was statistically significant during the 
intervention phase (p=0.0008) and was similar to baseline by week 12 (p=0.43), after 
cessation of SNS (Table 4-15). 
 
 Int-Pre End-Pre 
Mean -0.68 -0.10 
95% CI- -1.02 -0.35 
95% CI+ -0.33 0.16 
p 0.0008 0.43 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
End: Post-intervention (wk 12) 
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Table 4-15: Change in PAC-QOL during intervention 
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4.3.3.1 PAC-QOL Domain Analysis 
PAC-QOL has four subscales which include physical, psychosocial, worries and 
concerns and satisfaction domains.  
4.3.3.1.1 Physical Discomfort 
Physical discomfort has 4 items which include the following: bloated to the point of 
bursting, felt heavy because of constipation, felt any physical discomfort and false 
alarms. 
The mean score during the first six weeks was 2.51 (95% CI 2.09 to 2.92). It improved 
during intervention (week 8-9) to 1.59 (95% CI 1.03 to 2.15) and post intervention 
increased to 2.31 (95% CI 1.80 to 2.83). The weekly mean scores and confidence 
intervals are given in Figure 4-8 and Table 4-16.  
 
Figure 4-8: PAC-QOL Physical discomfort domain 
 
 
Week 1 2 3 4 5 6 7 8 9 10 11 12 
Mean 2.67 2.73 2.56 2.42 2.38 2.28 1.66 1.58 1.59 1.64 2.09 2.31 
95%CI- 2.18 2.28 2.11 2.02 1.94 1.77 1.14 1.01 1.00 1.10 1.59 1.80 
95%CI+ 3.16 3.18 3.01 2.82 2.81 2.79 2.17 2.14 2.19 2.18 2.59 2.83 
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Table 4-16: Mean weekly score for PAC-QOL physical discomfort 
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There was an improvement in the PAC-QOL physical discomfort domain score during 
the intervention phase when compared to the pre-intervention stage (p value <0.01), 
which had largely disappeared by week 12 (Table 4-17, p=0.41) 
 
 Int-Pre End-Pre 
Mean -0.92 -0.20 
95% CI- -1.41 -0.68 
95% CI+ -0.43 0.29 
p 0.0012 0.41 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
End: Post-intervention (wk 12) 
 
 
4.3.3.1.2  Psychosocial Discomfort 
Psychosocial discomfort has 8 items which include the following: 
1. been embarrassed to be with other people 
2. been eating less and less because of not being able to have bowel movements 
3. had to be careful about what you eat 
4. had a decreased appetite 
5. been worried about not being able to choose what you eat 
6. been embarrassed about staying in the toilet for so long when you were away 
from home 
7. been embarrassed about having to go to the toilet so often when you were 
away from home   
8. been worried about having to change your daily routine 
The mean score during the first six weeks was 1.40 (95% CI 1.02 to 1.79). It improved 
during intervention (week 8-9) to 1.10 (95% CI 0.58 to 1.62) and post intervention 
Table 4-17: Change in PAC-QOL physical discomfort 
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increased to 1.34 (95% CI 0.79 to 1.79). The weekly mean scores and confidence 
intervals are given in Figure 4-9 and Table 4-18. 
 
Figure 4-9: PAC-QOL Psychosocial discomfort 
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There was an improvement in PAC-QOL psychosocial discomfort domain score during 
the intervention phase when compared to the pre-intervention stage (Table 4-19, 
p=0.039). The score returned to baseline after removal of wires. 
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Table 4-18: Weekly scores PAC-QOL Psychosocial domain 
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 Int-Pre End-Pre 
Mean -0.30 -0.07 
95% CI- -0.58 -0.36 
95% CI+ -0.02 0.23 
p 0.039 0.63 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
End: Post-intervention (wk 12) 
 
4.3.3.1.3 Worries and Concerns 
Within the PAC-QOL measure, worries and concerns has 11 items which include the 
following: 
1. felt irritable because of your condition 
2. been upset by your condition 
3. felt obsessed by your condition 
4. felt stressed by your condition 
5. felt less self-confident because of your condition 
6. felt in control of your situation 
7. been worried about not knowing when you are going to be able to open your 
bowels 
8. been worried about not being able to open your bowels when you needed to 
9. been more and more bothered by not being able to open your bowels 
10. been afraid that your condition will get worse 
11. felt that your body was not working properly 
The mean score during the first six weeks was 2.35 (95% CI 1.96 to 2.74). It improved 
during intervention (week 8-9) to 1.69 (95% CI 1.15 to 2.23) and post intervention 
Table 4-19: Change in PAC-QOL Psychosocial domain 
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increased to 2.20 (95% CI 1.79 to 2.62). The weekly mean scores and confidence 
intervals are given in Figure 4-10 and Table 4-20.  
 
 Figure 4-10: PAC-QOL Worries and Concerns 
 
 
Week 1 2 3 4 5 6 7 8 9 10 11 12 
Mean 2.49 2.41 2.39 2.31 2.32 2.18 1.89 1.70 1.68 1.62 2.00 2.20 
95%CI- 2.05 2.01 1.98 1.88 1.94 1.71 1.42 1.19 1.09 1.27 1.59 1.79 
95%CI+ 2.93 2.80 2.81 2.74 2.69 2.65 2.36 2.20 2.26 1.97 2.41 2.62 
 
There was a statistically significant improvement during the intervention phase 
(p=0.002), that did not persist to week 12 (Table 4-21, p=0.36), after cessation of SNS. 
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Table 4-20: Weekly scores for PAC-QOL worries and concerns 
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 Int-Pre End-Pre 
Mean -0.66 -0.15 
95% CI- -1.04 -0.47 
95% CI+ -0.29 0.18 
p 0.002 0.36 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
End: Post-intervention (wk 12) 
 
4.3.3.1.4 Dissatisfaction 
The dissatisfaction domain has 5 items: 
1. fewer bowel movements than you would like 
2. satisfied with how often you open your bowels 
3. satisfied with the regularity with which you open your bowels 
4. satisfied with your bowel function 
5. satisfied with your treatment 
The mean score during the first six weeks was 3.09 (95% CI 2.81 to 3.36). It improved 
during intervention (week 8-9) to 2.11 (95% CI 1.49 to 2.73) and post intervention 
increased to 3.26 (95% CI 3.01 to 3.51). The weekly mean scores and confidence 
intervals are given in Figure 4-11 and Table 4-22. 
 
Table 4-21: Change in PAC-QOL worries and concerns 
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Figure 4-11: PAC-QOL Dissatisfaction domain score 
 
 
Week 1 2 3 4 5 6 7 8 9 10 11 12 
Mean 3.26 3.31 3.09 3.13 2.90 2.83 2.51 2.15 2.08 2.39 3.18 3.26 
95%CI- 3.00 3.02 2.75 2.78 2.52 2.22 1.91 1.55 1.40 1.88 2.87 3.01 
95%CI+ 3.53 3.61 3.43 3.47 3.28 3.43 3.12 2.75 2.75 2.90 3.48 3.51 
There was a statistically significant improvement during the intervention phase 
(p=0.005), that did not persist to week 12 (Table 4-23, p=0.19), after cessation of SNS. 
 Int-Pre End-Pre 
Mean -0.97 0.18 
95% CI- -1.60 -0.10 
95% CI+ -0.35 0.46 
p 0.005 0.19 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
End: Post-intervention (wk 12) 
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Table 4-22: Weekly score for PAC-QOL dissatisfaction score 
Table 4-23: Change in PAC-QOL Dissatisfaction score 
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4.3.4 Euro QOL Health Questionnaire (EQ5D) 
EQ5D is a descriptive system of health-related quality of life states consisting of five 
dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) 
each of which can take one of three responses. The responses record three levels of 
severity (1=no problems 2=some or moderate problems, 3=extreme problems) within 
each EQ-5D dimension. Responses are converted to ‘utility’ scores (0-1) using a lookup 
algorithm provided by the EuroQoL group and based on societal values. Assessments 
were made pre-intervention phase (week 3, 6), one during SNS (week 9) and one after 
SNS (week 12). 
The average EQ5D pre-intervention score was 0.22 (95% CI 0.07 to 0.37). It increased 
during intervention to 0.32 (95% CI 0.15 to 0.49) and post intervention decreased to 
0.25 (95% CI 0.08 to 0.43). The mean scores and confidence intervals are given in Fig 
4-12 and Table 4-24. 
Figure 4-12: EQ5D Scores 
 
 
 Week 3 Week 6 Week 9 Week 12 
Mean 0.22 0.22 0.32 0.25 
95%CI- 0.06 0.06 0.15 0.08 
95%CI+ 0.39 0.38 0.49 0.43 
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Table 4-24: Mean scores for EQ5D 
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Although qualitatively there seems to be an improvement during intervention this was 
not a statistically significant change from baseline (Table 4-25, p=0.16). 
 Int-Pre End-Pre 
Mean 0.10 0.03 
95% CI- -0.04 -0.12 
95% CI+ 0.24 0.18 
p 0.16 0.68 
Int: Intervention (wk 9) 
Pre: Pre-intervention (wks3,6) 
End: Post-intervention (wk 12) 
 
 
4.3.5 EuroQOL Visual Analogue Score (EQ-VAS) 
EQ-5D is a standardised instrument for use as a proxy measure of health. It uses a 
standard vertical 20 cm visual analogue scale (similar to a thermometer) for recording 
an individual’s rating for their current health-related quality of life. The maximum 
score is 100 (best state of health) and the minimum score is 0 (worst state of health). 
Two readings were taken in the pre-intervention phase (week 3, 6); one during SNS 
(week 9) and the last measurement was taken after SNS (week 12). 
The average pre-intervention score was 45.5 (95% CI: 38.5 to 52.4). It increased 
marginally during intervention to 47.7 (95% CI: 35.8 to 59.5) and post intervention the 
score was 45.0 (95% CI: 38.4 to 51.6). The weekly mean scores and confidence 
intervals are given in Figure 4-13 and Table 4-26. 
Table 4-25: Change in EQ5D during each phase 
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Figure 4-13: EQ-VAS scores 
 
 
 Week 3 Week 6 Week 9 Week 12 
Mean 45.6 45.3 47.7 45.0 
95%CI- 36.8 36.8 35.8 38.4 
95%CI+ 54.4 53.9 59.5 51.6 
 
There was no change in the overall EQ-VAS scores during the intervention phase (Table 
4-27, p >0.05) or subsequently. 
 Int-Pre End-Pre 
Mean 2.2 -0.47 
95% CI- -9.2 -6.1 
95% CI+ 13.6 5.2 
p 0.69 0.86 
Int: Intervention (wk 9) 
Pre: Pre-intervention (wks3,6) 
End: Post-intervention (wk 12) 
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Table 4-26: Mean weekly EQ-VAS score 
Table 4-27: Change in EQ-VAS 
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4.3.6 Daily Diary 
A daily dairy was administered during the pre-intervention phase (week 4 to week 6) 
and the intervention phase (week 7 to week 9) of the study. 
Patients kept a daily record of their bowel movements, episodes of faecal incontinence, 
time spent toileting and laxative score: these were aggregated to weekly averages for 
the analysis.  
4.3.6.1 Bowel Movements  
Complete diary data were available for 15 subjects. The mean number of pre-
intervention bowel movements was 1.46 per week (95% CI 0.78 to 2.33) and during 
intervention was 1.15 per week (95% CI 0.73 to 1.78). The mean scores and confidence 
intervals are given in Figure 4-14 and Table 4-28. 
Figure 4-14: Bowel Movements 
 
 
 Week 4 Week 5 Week 6 Week 8 Week 9 
Mean 1.57 1.58 1.22 1.20 1.10 
95%CI- 0.78 0.82 0.68 0.77 0.63 
95%CI+ 2.57 2.56 1.99 1.75 1.84 
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Table 4-28: Mean weekly bowel movements 
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Comparing intervention and pre-intervention phases, changes in bowel movement 
were not statistically significantly different (Table 4-29, p=0.29).  
 
 Int-Pre 
Mean -0.31 
95% CI- -0.77 
95% CI+ 0.01 
p 0.29 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks 4,5,6) 
 
4.3.6.2 Faecal Incontinence Episodes 
Complete diary data were available for 15 subjects. Patients with neuropathic 
constipation may suffer from faecal incontinence (FI) as well. The median FI score was 
zero, being reported in 9 patients consistently throughout the diary period. A related 
samples Wilcoxon signed rank test comparing intervention and pre-intervention found 
no statistically significant change in FI: p=0.345. 
Table 4-29: Change in bowel movement during intervention 
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4.3.6.3 Time spent toileting 
Complete diary data were available for 15 subjects. Before SNS, an average of 20 
minutes per visit (95% CI 11 to 31) was spent on toileting. This decreased during 
intervention to 13 minutes per visit (95% CI 8 to 19). The mean scores and confidence 
intervals are given in Figure 4-15 and Table 4-30. 
 
 Figure 4-15: Time spent toileting (minutes) 
 
 
 Week 4 Week 5 Week 6 Week 8 Week 9 
Mean 22.3 20.2 15.6 14.8 11.3 
95%CI- 10.5 10.7 9.6 9.5 7.0 
95%CI+ 38.0 32.1 23.1 21.7 16.3 
 
There was a suggested (non-statistically significant) mean reduction of 6 minutes in 
the time spent toileting per visit during intervention (p=0.126, Table 4-31). 
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Table 4-30: Mean time spent toileting (minutes) 
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 Int-Pre 
Mean -6.5 
95% CI- -13.3 
95% CI+ 1.5 
p 0.126 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks 4,5,6) 
 
4.3.6.4 Laxative Score 
Complete diary data were available for 16 subjects. The dosage and type of laxatives 
vary in patients with neurological constipation and it is very difficult to quantify the 
laxative intake over a period of time. Weekly laxative use was averaged for each 
participant and then documented with a daily laxative score. The participants 
documented whether their laxative intake was more, same or less than their average 
daily use on a scale (0=same, +1 =more, -1=less than the usual dose). 
The pre-intervention laxative score was 0.10 (95% CI -0.03 to 0.22). It decreased 
during intervention to -0.06 (95% CI -0.24 to 0.10). The mean scores and confidence 
intervals are given in Figure 4-16 and Table 4-32. 
Table 4-31: Change in time spent toileting (minutes) 
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Figure 4-16: Mean Laxative score 
 
 
 Week 4 Week 5 Week 6 Week 8 Week 9 
Mean 0.14 0.04 0.11 -0.06 -0.06 
95%CI- -0.28 -0.09 -0.10 -0.27 -0.23 
95%CI+ 0.32 0.14 0.30 0.13 0.08 
 
Laxative score decreased during intervention: the mean decrease in use was 0.16 
(Table 4-33, p=0.032). 
 Int-Pre 
Mean -0.16 
95% CI- -0.29 
95% CI+ -0.04 
p 0.032 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks 4,5,6) 
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Table 4-32: Mean weekly laxative score 
Table 4-33: Change in Laxative score 
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4.3.7 Physiological Outcomes 
Two physiological measures were included in the study: the colonic transit time and 
laser Doppler flow cytometry.  For an explanation of these methods see sections 3.3.3.5 
and 3.3.3.6. 
4.3.7.1 Transit Study 
Transit time measurements were completed at recruitment and towards the end of the 
intervention phase. Transit studies were completed by 13 patients, with transit times 
shown in Fig 4-17. 
Figure 4-17 Transit times 
 
The pre-intervention transit time (TT) was 58.5 hours (95% CI 49.4 to 67.6). During 
SNS intervention the transit time was 62.1 hours (95% CI 53.5 to 70.6). The transit 
times were not significantly different: SNS – Pre SNS = 4.23 hours (95% CI -1.11, 9.57, 
p=0.11). 
Patients who had a positive response during SNS (responders) were offered permanent 
stimulation. Patients who failed to respond during temporary stimulation were 
identified as non-responders. At baseline both groups had delayed transit times. The 
mean transit time before SNS was lower in responders when compared to the non-
responders, although not statistically significantly different (p= 0.10). During SNS, 
although the transit times of both groups increased, there were no significant 
differences between the two groups (p=0.16, Figure 4-18. 
0 
10 
20 
30 
40 
50 
60 
70 
80 
1 2 3 4 5 6 7 8 9 10 11 12 13 
Tr
an
si
t 
ti
m
e 
in
  h
rs
 
Patient number 
TT Pre SNS 
TT SNS 
  
110 
 
Figure 4-18: Transit time in responders and non-responders 
 
4.3.7.2 Laser Doppler Flowcytometry (LDFC) 
LDFC provides a direct measure of the autonomic innervation (nerve activity) of the 
hind gut, which should be improved by SNS. Two separate measurements were taken 
at 3 weeks and 9 weeks, before and during SNS.  LDFC was completed by 14 patients, 
with scores shown in Figure 4-18. 
Figure 4-19: LDFC Scores 
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The mean cumulative LDFC score was 50.4 flux units (95% CI 35.1 to 65.7) before 
intervention and 44.8 flux units (95% CI 35.9 to 53.6) during SNS: the reduction of 5.6 
flux units (95% CI -18.1 to 6.8) was not statistically significant. LDFC scores were 
expected to improve during stimulation in response to an expected increase in the 
rectal mucosal blood flow.  However, the cumulative flux was similar before and during 
treatment. This might be explained by the different pathophysiological processes 
involved in neuroconstipation when compared to idiopathic disease.  
The LDFC score for responders decreased during intervention but was comparably 
higher than the non-responders. See below. 
Figure 4-20: LDFC in responders and non-responders 
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4.3.8 Stimulation Thresholds 
The temporary pulse generator can produce a maximum current of 10 volts during the 
first temporary stage of SNS. The correct positioning of the electrode is confirmed by 
observable anal sphincter contraction and toe dorsiflexion at the time of the operation. 
The current threshold at which this occurs was found to be variable across different 
patients. Dudding reported that a low motor threshold at the time of wire insertion is a 
predictive factor for better long-term response. This was reported in a cohort of 
patients treated with faecal incontinence who received SNS (Dudding, Parés et al. 
2008). 
The motor stimulation threshold of the participants was measured at the time of 
insertion of the electrodes at week 7 and at the time of removal at the end of week 9. At 
the time of insertion the mean threshold on the right side was 2.90 volts (95% CI 1.81 
to 4.01) and 6.54 volts (95% CI 4.17 to 8.92) at the time of removal. On the left side, the 
mean threshold was 2.64 volts (95% CI 1.46 to 3.81) and 6.55 volts (95% CI 3.90 to 
9.19) at the time of removal.  
The motor stimulation threshold at the time of electrode siting was 2.87 volts (95% CI 
1.56 to 4.16) in the responders and 2.50 volts (95% CI -0.36 to 6.21) in the non-
responders (p=0.35). At the time of removal, this increased to 6.31 volts (95% CI 3.90 
to 8.73) in the responders and to 7.16 volts (95% CI 0.07 to 15.04) in the non-
responders. Although the current at the time of electrode removal was lower in 
responders when compared to non-responders, this difference was statistically not 
significant (p= 0.27). See Figure 4-19. 
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Figure 4-21 Stimulation Thresholds in responders and non-responders 
 
The motor response observed during T-SNS at the time of electrode placement under 
general anaesthetic is due to afferent fibre activation within the sacral nerve root. This 
acts as a valuable assessment tool for electrode placement but its value in predicting a 
successful outcome is uncertain. The stimulation threshold was noted to change from 
week 7 to week 9 for all patients. There was a gradual increase in the current value 
required for a satisfactory sensation of stimulation between weeks 7 and 9. This 
change in amplitude could be due to the neuroplasticity of the sacral roots, asymmetric 
innervation of the pelvic floor muscles, mechanical and/or patient factors. 
The distance of the electrode tip from the nerve is crucial. Ideally, the tip should be just 
anterior to the sacral cortex during placement and confirmed with an image intensifier 
during the procedure. There is a strong case for placing these leads under local 
anaesthetic to get valuable patient feedback during placement. Lead migration during 
T-SNS can change the stimulation requirements as the distance between the electrode 
and the nerve root increases. Loose connections and breakage of electrode fibres are 
other important factors which affect the helical single leads used for T-SNS in this trial. 
Future research trials are utilizing tined leads with a 4-electrode tip which should be 
more reliable when compared to helical leads. Patient factors such as change in 
perception of stimulation and behavioural changes also affect the stimulus threshold 
for a sustained response. 
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4.3.9 Correlation of outcomes 
The relatedness of outcome measures was explored by examining bivariate 
correlations. The purpose is to demonstrate that conceptually related outcomes report 
similar trends, thus providing supporting evidence about the principle findings. Each 
variable is analysed as its change score comparing the intervention and pre-
intervention period.  It is recognised that the numbers of patients contributing data is 
small and the correlations tentative. 
It should be noted that a lower global assessment scores (incontinence, constipation), 
PAC-SYM, PAC-QOL, laxative score, bowel movement and toileting time denote 
improvement, whereas higher EQ-5D and EQ-VAS denote improvement. 
The global assessment of constipation was strongly and positively correlated with the 
PAC-QOL measure but was only weakly positively correlated with PAC-SYM.  
Interestingly EQ-VAS was strongly negatively correlated with the global assessment of 
constipation (lower constipation score, higher quality of life) although EQ-VAS did not 
independently record a benefit from intervention (see 4.3.5). There were few other 
significant correlations, although in line with expectation frequency of bowel 
movement and toilet time were positively correlated. 
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Table 4-34 Correlation Matrix 
 
GA 
constipation 
GA 
incontinence 
PAC-sym PAC-Qol EQ 5D EQ VAS 
Laxative 
Score 
Bowel 
Movement 
Toilet 
Time 
GA 
constipation 
Pearson Correlation 1 .355 .357 .868
**
 -.097 -.715
**
 -.492 -.366 -.081 
Sig. (2-tailed)  .177 .174 .000 .730 .003 .053 .179 .775 
N 16 16 16 16 15 15 16 15 15 
GA 
incontinence 
Pearson Correlation .355 1 -.055 .247 -.180 -.172 -.100 -.309 .100 
Sig. (2-tailed) .177  .839 .356 .522 .540 .712 .263 .722 
N 16 16 16 16 15 15 16 15 15 
PAC-sym 
Pearson Correlation .357 -.055 1 .626
**
 .381 -.393 -.058 -.116 .070 
Sig. (2-tailed) .174 .839  .010 .161 .147 .832 .680 .803 
N 16 16 16 16 15 15 16 15 15 
PAC-Qol 
Pearson Correlation .868
**
 .247 .626
**
 1 -.050 -.705
**
 -.450 -.273 -.010 
Sig. (2-tailed) .000 .356 .010  .859 .003 .080 .324 .971 
N 16 16 16 16 15 15 16 15 15 
EQ 5D 
Pearson Correlation -.097 -.180 .381 -.050 1 .234 .200 .012 -.112 
Sig. (2-tailed) .730 .522 .161 .859  .401 .475 .966 .703 
N 15 15 15 15 15 15 15 14 14 
EQ VAS 
Pearson Correlation -.715
**
 -.172 -.393 -.705
**
 .234 1 .470 .172 -.222 
Sig. (2-tailed) .003 .540 .147 .003 .401  .077 .556 .446 
N 15 15 15 15 15 15 15 14 14 
Laxative 
Score 
Pearson Correlation -.492 -.100 -.058 -.450 .200 .470 1 .453 .191 
Sig. (2-tailed) .053 .712 .832 .080 .475 .077  .090 .496 
N 16 16 16 16 15 15 16 15 15 
Bowel 
Movement 
Pearson Correlation -.366 -.309 -.116 -.273 .012 .172 .453 1 .723
**
 
Sig. (2-tailed) .179 .263 .680 .324 .966 .556 .090  .002 
N 15 15 15 15 14 14 15 15 15 
Toilet 
Time 
Pearson Correlation -.081 .100 .070 -.010 -.112 -.222 .191 .723
**
 1 
Sig. (2-tailed) .775 .722 .803 .971 .703 .446 .496 .002  
N 15 15 15 15 14 14 15 15 15 
Correlations estimated using the change score estimate (during – pre-intervention) **. Correlation is significant at the 0.01 level (2-tailed). 
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4.4 Exploration of the determinants of temporary response 
A range of baseline variables were explored as potential determinants of response due 
to temporary stimulation. Simple univariate analysis revealed no statistically 
significant differences in responders and non-responders to any of the baseline 
parameters.  However, the study is underpowered to identify potentially important 
factors. For example the response rate was 86% for men and 55% for women: a 30% 
change. To have adequate study power to detect this change would require 40 men and 
40 women. Consequently regression modelling of determinants was not attempted.  
Table 4-35 Determinants of temporary response 
  Response  
 N No Yes P 
Gender: Male:Female 18 1:5 6:6 0.32 
Age 18 53.7 53.3 0.82 
GA Constipation (pre) 16 4.08 3.68 0.33 
PAC SYM (pre) 16 1.37 1.26 0.81 
PAC QOL (pre) 16 2.18 1.71 0.33 
Laxative Score (pre) 15 0.31 1.99 0.76 
Bowel Movement (pre) 15 0.89 1.66 0.90 
Toilet Time (pre) 15 11.86 22.86 0.36 
Stimulation Threshold at insertion (V) 11 2.33 2.88 0.51 
Transit time (pre) (hours) 13 53.5 59.00 0.82 
* Continuous variables estimated using Mann-Whitney U; Gender estimated using an exact test 
on counts 
4.5 Summary  
Findings show a consistent pattern of positive response during temporary SNS, as seen 
with the global assessment of constipation, PAC-SYM and PAC-QOL measures.  
Improvement during the SNS phase was followed by consistent diminution towards 
baseline scores apparent 3 weeks after cessation of stimulation. There was a consistent 
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lack of response to measures of incontinence (global assessment of incontinence, diary 
and physiological measures); an unsurprising finding since less than half of patients 
had any incontinence at baseline. 
The coincidence of response and stimulation provides high attribution of improvement 
to the SNS process.  However, it is not able to differentiate between response due to 
active stimulation and the broader process of being treated which might include some 
form of placebo response. Any placebo response is likely to be transient and 
diminishing, consequently only long term SNS can definitively differentiate active and 
placebo response and this is explored in Chapter 5.  However, the chronic and stable 
nature of disease and substantial treatment history, together with consistent (rather 
than random) response in these patients provides some support in favour of active 
response. (See Figure 4-20). 
The potential for placebo response could be minimized by exploring the use of sham 
stimulation either within or between patients. The use of sham treatment was 
considered during the trial design. After discussion with all the stakeholders, it was 
decided that providing sham treatment for these patients was problematic because of: 
unnecessary procedures and use of anaesthetic; unwillingness of patients to 
participate; financial limitations in the use of expensive equipment; and, difficulty 
obtaining the relevant ethical approvals. Due to the small number of patients to be 
recruited, a within group off-on-off study design with multiple observations during 
each phase of the study was agreed upon as most efficient method to take the next step 
in understanding. 
The results from this study have helped inform subsequent trial design. A multi-centre 
study design has being developed to further improve the predictive long term 
performance of test stimulation and minimize placebo response.  Using a tined lead for 
test stimulation (not available when conducting the research for this thesis) allows a 
longer period of testing (up to six weeks). This can allow for identifying placebo 
responses, by using intermittent real or sham stimulation. The stimulation can be 
provided using subsensory settings so that the patient will not be able to differentiate 
between real and sham stimulation. 
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Figure 4-22: GA constipation: individual responses during temporary SNS  
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5. Long-term Data 
Twelve of the 18 patients (67%), who completed the trial, received an implantable 
pulse generator (IPG). These patients had a good temporary response after bilateral 
temporary SNS. There were 6 men and 6 women with an average age of 54 years 
(Range 38-69 years). Patients were assessed clinically for ongoing response to SNS, 
categorised as successful or unsuccessful. Categorisation took into account patient 
progression of symptoms, changes in laxative use, questionnaire scores and the 
clinician and patient overall assessment. 
We arranged follow-up appointments with these patients and asked them to complete 
additional questionnaires. We were not able to contact three patients to provide long 
term follow-up data, see Table 5-1 . Two further patients provided unusable 
questionnaire data but were clinically assessed for ongoing response. 
Table 5-1: Long term follow-up data 
 Pre-SNS Scores During SNS Long term SNS 
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Trial 
Number 
GA PAC-
SYM 
PAC-
QOL 
GA PAC-
SYM 
PAC-
QOL 
GA PAC-
SYM 
PAC-
QOL 
SNS002 3.00 1.18 1.63 2.00 0.63 1.04 3.00 1.00 1.50 27 No Yes 
SNS003 3.33 2.51 2.43 1.00 0.71 0.98 - - - 27 Yes No* 
SNS004 2.67 1.86 1.98 2.50 0.33 1.18 1.00 0.00 0.54 24 Yes Yes 
SNS005 4.17 1.75 2.15 1.00 0.25 0.14 1.00 0.25 0.43 27 Yes Yes 
SNS007 3.00 0.89 1.52 2.50 0.33 1.18 1.00 0.17 0.32 27 No Yes 
SNS008 5.00 2.50 2.77 4.00 2.00 2.43 - - - 24 No No 
SNS009 3.17 1.13 1.28 2.50 0.46 1.02 - - - 11 Yes Yes 
SNS013 4.00 2.13 2.48 3.00 1.25 1.75 4.00 2.25 2.64 18 Yes No 
SNS016 3.50 1.25 2.27 1.50 0.29 0.46 - - - 22 No Yes 
SNS017 3.50 1.92 1.82 2.00 1.67 1.52 3.00 2.00 1.28 12 Yes No 
SNS020 4.50 2.17 3.27 3.50 2.83 3.07 5.00 1.50 2.50 10 No No 
SNS021 4.33 1.29 2.18 2.00 0.50 0.75 - - - 8 No No 
Key:  * Pt. underwent colostomy for Sigmoid Volvulus 
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5.1 Response to permanent SNS 
The average length of follow-up was 20 months (range 8-27 months). Six of the 12 
patients (50%) who received IPGs failed to respond to the permanent implant. One 
patient suffered from sigmoid volvulus almost a year after receiving the permanent 
implant and proceeded to a colostomy. This patient had a good continuous response 
from her IPG until her operation. The overall response during long-term follow-up as 
determined by clinical assessment was 6/12 (50%, 95%CI: 21% to 79%).  
In subjects undergoing long term stimulation, there was a persistent improvement in 
the cumulative GA score for constipation, PAC-SYM and PAC-QOL scores when 
compared to the pre-intervention phase, although it had become borderline statistical 
significant, with some diminution of effect when compared to the early response 
recorded in the temporary SNS phase (see Table 5-2).  In subjects reporting long term 
response, there was a pattern of retaining or improving upon test phase scores, with 
one exception (patient SNS002). The pattern of long term scores in patients reporting 
cessation of response, showed a consistent return to baseline (pre-intervention) 
scores.  
 
Table 5-2: Long term outcome scores 
 GA PAC-SYM PAC-QOL 
 Int-Pre LT-Pre Int-Pre LT-Pre Int-Pre LT-Pre 
Mean -1.29 -0.98 -0.69 -0.67 -0.85 -0.80 
95% CI- -2.08 -2.21 -1.29 -1.38 -1.42 -1.44 
95% CI+ -0.50 0.26 -0.10 0.04 -0.27 -0.17 
p 0.006 0.10 0.028 0.060 0.010 0.022 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
LT: Long-term (Post IPG) 
7 subjects 
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5.2 Exploration of the determinants of long term response 
A range of baseline variables were explored as potential determinants of response due 
to permanent stimulation, following the approach used in 4.4. Given the lack of study 
power to determine response it was not-anticipated that any predictors of permanent 
implant response could be identified. Nonetheless potential variables are tabulated in 
Table 5-3. Consequently regression modelling of determinants was not attempted.  
 
Table 5-3 Determinants of permanent SNS response. 
  Response  
 N No Yes P 
Gender: Male: Female 12 2:3 4:3 >0.99 
Age 12 53.6 53.4 0.94 
GA Constipation (int-pre) 10 -1.44 -1.26 0.48 
PAC SYM (int-pre) 10 -0.72 -0.85 0.73 
PAC QOL (int-pre) 10 -0.83 -0.80 0.82 
Laxative Score (int-pre) 10 -0.04 -0.12 0.91 
Bowel Movement (int-pre) 9 -0.50 -0.47 0.36 
Toilet Time (int-pre) (min) 9 -15.13 -9.30 0.30 
Stimulation Threshold at removal (V) 8 7.40 7.33 0.87 
Stimulation Threshold change (V) 8 4.2 5.00 0.65 
* Continuous variables estimated using Mann-Whitney U; Gender estimated using an exact 
test on counts 
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6. Subgroup Analyses 
A subgroup analysis was carried out on patients suffering from Multiple Sclerosis (MS). 
There were 14 patients with MS recruited to the study, including 4 men and 10 women 
with an average age of 53 years (38-70 years). Of these, 3 patients dropped out and did 
not complete the trial. Bilateral SNS was carried out in 11 patients. Temporary SNS was 
successful in 8 of 11 patients (73%) in the MS subgroup. These patients went on to 
have a permanent implant. 
6.1 Primary Outcome  
6.1.1 Global Assessment of Constipation 
The mean GA score for constipation during the first six weeks was 3.64 (95% CI 3.26 to 
4.01). It improved during intervention (week 8-9) to 2.41 (95% CI 1.69 to 3.13) and 
post intervention increased to 3.55 (95% CI 2.85 to 4.24). The weekly mean scores and 
confidence intervals are given in Figure 6-1 and Table 6-21.  
There was an improvement in GA score for constipation during the intervention phase 
when compared to the pre-intervention stage (Table 6-2, p=0.004, paired t-test). There 
was a gradual washout of effect after the removal of stimulation. Symptoms returned to 
baseline at week 12.  
Figure 6-1: GA Constipation (MS) 
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Table 6-1: Weekly GA Scores (MS) 
Week 1 2 3 4 5 6 7 8 9 10 11 12 
Mean 3.64 3.82 3.82 3.55 3.55 3.45 2.45 2.55 2.27 2.91 3.36 3.55 
95%CI- 3.30 3.41 3.31 2.99 2.79 2.76 1.70 1.85 1.37 2.27 2.67 2.85 
95%CI+ 3.98 4.22 4.32 4.10 4.30 4.15 3.21 3.24 3.18 3.54 4.05 4.24 
 
 
Table 6-2: Mean GA Scores (MS) 
 Int-Pre End-Pre 
Mean -1.23 -0.09 
95% CI- -1.96 -0.65 
95% CI+ -0.50 0.47 
p 0.004 <0.001 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
End: Post-intervention (wk 12) 
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6.2  Secondary Outcomes  
6.2.1 Global Assessment of Faecal Incontinence 
The mean GA score for faecal incontinence during the first six weeks was 0.91 (95% CI 
0.16 to -1.66, during intervention (week 8-9) was 0.73 (95% CI -0.03 to 1.48) and post 
intervention was 0.45 (95% CI -0.17 to 1.09). The mean weekly scores and confidence 
intervals for GA FI are given in Figure 6-12 and Table 6-3. 
The mean GA score of FI slightly improved during the intervention phase of the study. 
There was no pattern of improvement that could be related to the intervention (Table 
6-3). There is a reduction in FI at week 12, but this may be a chance finding. The change 
in GA FI score for this subgroup was not expected to be significant as most of the 
patients did not suffer from any incontinence at baseline. 
 
Figure 6-2: GA Faecal Incontinence (MS) 
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Table 6-4: Mean scores for GA FI (MS) 
 Int-Pre End-Pre 
Mean -0.18 -0.45 
95% CI- -0.50 -0.86 
95% CI+ 0.14 -0.05 
p 0.23 0.03 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
End: Post-intervention (wk 12) 
 
6.2.2 Patient Assessment of Constipation Symptoms (PAC-SYM) 
The mean PAC-SYM score during the first six weeks was 1.64 (95% CI 1.30 to 1.97). It 
improved during intervention (week 8-9) to 0.80 (95% CI 0.39 to 1.20) and post 
intervention increased to 1.23 (95% CI 0.84 to 1.63). The mean weekly scores and 
confidence intervals for PAC-SYM are given in Figure 6-3 and Table 6-65. 
There was an improvement in PAC-SYM score during the intervention phase when 
compared to the pre-intervention stage (Table 6-6, p=0.001). PAC-SYM scores tended 
towards pre-stimulation values after removal of SNS. 
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Figure 6-3: PAC-SYM (MS) 
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6.2.3 Patient Assessment of Constipation (PAC-QOL) 
The mean PAC-QOL score during the first six weeks was 2.07 (95% CI 1.80 to 2.33). It 
improved during intervention (week 8-9) to 1.27 (95% CI 0.78 to 1.76) and post 
intervention increased to 2.01 (95% CI 1.60 to 2.41) almost returning to baseline value 
by the end of week 12. The mean weekly scores and confidence intervals for PAC-QOL 
are given in Figure 6-34 and Table 6-7. The improvement in PAC-QOL during SNS was 
statistically significant (Table 6-8, p=0.006).  
Figure 6-4: PAC-QOL (MS) 
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6.2.4  Euro QOL Health Questionnaire (EQ5D) 
The EQ5D pre-intervention score was 0.31 (95% CI 0.13 to 0.48), during intervention 
was 0.35 (95% CI 0.16 to 0.55) and post intervention was 0.36 (95% CI 0.16 to 0.56). 
The mean scores and confidence intervals are given in Figure 6-5and Table 6-9. There 
was no change apparent in EQ5D scores during the trial (Table 6-10). 
Figure 6-5: EQ5D (MS) 
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6.2.5 EuroQOL Visual Analogue Score (EQ-VAS) 
The pre-intervention score was 45.4 (95% CI 36.7 to 54.2) during intervention was 
47.3 (95% CI 32.2 to 62.3) and post intervention the score was 47.7 (95% CI 40.8 to 
54.7). The weekly mean scores and confidence intervals are given in Figure 6-6 and 
Table 6-11. There was no change apparent in EQ-VAS scores during the trial (Table 
6-12). 
Figure 6-6: EQ-VAS (MS) 
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6.3 Long-term Follow-up (MS) 
Eight of the 11 MS patients (73%) completing the trial received an implantable pulse 
generator (IPG). This section provides subgroup analyses of all patients reported in 
Chapter 5. Although it was possible to assess long term response in all patients, 4 
patients declined to provide questionnaire data.  
The average length of follow-up was 21 months (Range 11-27 months). Three of the 8 
patients (37.5%) who received IPGs failed to respond after the implant. One patient 
suffered from sigmoid volvulus almost a year after receiving the permanent implant 
and ended up having a colostomy. The overall response for long-term follow-up in the 
MS subgroup was 62.5% (5/8) as determined by patient symptom scores and overall 
clinical assessment.  
Table 6-13: Long-term Follow-up (MS) 
 Pre-SNS Scores During SNS Long term SNS 
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GA 
PAC-
SYM 
PAC-
QOL 
GA 
PAC-
SYM 
PAC-
QOL 
SNS003 3.33 2.51 2.43 1.00 0.71 0.98 - - - 27 yes no 
SNS004 2.67 1.86 1.98 2.50 0.33 1.18 1.00 0.00 0.54 24 yes yes 
SNS005 4.17 1.75 2.15 1.00 0.25 0.14 1.00 0.25 0.43 27 yes yes 
SNS007 3.00 0.89 1.52 2.50 0.33 1.18 1.00 0.17 0.32 27 no yes 
SNS009 3.17 1.13 1.28 2.50 0.46 1.02 - - - 11 yes yes 
SNS016 3.50 1.25 2.27 1.50 0.29 0.46 - - - 22 no yes 
SNS017 3.50 1.92 1.82 2.00 1.67 1.52 3.00 2.00 1.28 12 Yes no 
SNS021 4.33 1.29 2.18 2.00 0.50 0.75 - - - - no no 
 
Constipation GA, PAC-SYM and PAC-QOL scores were similar when comparing 
improvements from temporary SNS and long term with permanent SNS, although this 
comparison is limited by the small numbers completing long term questionnaire data.  
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The overall long-term response (5 of 8, 63%) suggests that patients with MS receiving 
permanent SNS may do better than other types (1 of 4, 25%), but small numbers 
preclude firm conclusions (p=0.30).  
Despite disease progression the response has been consistent in patients with MS over 
a period of time. A few minor adjustments in electrode settings were required for some 
patients during follow-up. Informal feedback during follow-up visits has shown that 
the improvement in quality of life has made a vast difference in the daily routines of 
patients responding to permanent SNS. 
Table 6-14: Mean Outcome Score (MS) 
 GA PAC-SYM PAC-QOL 
 Int-Pre LT-Pre Int-Pre LT-Pre Int-Pre LT-Pre 
Mean -1.58 -1.83 -1.01 -1.00 -1.05 -1.22 
95% CI- -2.47 -3.58 -1.46 -2.38 -1.64 -2.02 
95% CI+ -0.70 -0.09 -0.55 0.38 -0.46 -0.42 
p 0.003 0.04 0.001 0.10 0.004 0.01 
Int: Intervention (wks 8,9) 
Pre: Pre-intervention (wks1-6) 
LT: Long-term (Post IPG) 
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7. Discussion 
7.1 Principal Findings 
7.1.1 Temporary SNS 
Patient-assessed global assessment of constipation (GA-constipation), PAC-SYM and 
PAC-QOL scores improved significantly during temporary SNS, with 29%, 40% and 
30% improvements respectively. There was a clear pattern of diminishing benefit after 
removal of the electrodes. There was no pattern of change in faecal incontinence GA 
scores, consistent with prior expectation (faecal incontinence was largely absent from 
the group). There was no change in the EQ-VAS or EQ-5D scores during intervention: 
these measures were included to provide estimates of variance to help design future 
studies.  They were not anticipated to be adequately sensitive to show change within 
this trial. 
The majority of patients in the trial had ongoing mobility or independence issues due 
to the disabling nature of their disease, reflected in low EQ-VAS and EQ-5D scores. 
The use of SNS was expected (when decreasing constipation) to increase the frequency 
of bowel movements, although this was not found in this trial. A characteristic of 
patients with neuroconstipation is the experience of a high number of failed and 
incomplete evacuations.  It is possible that SNS caused patients to have improved (and 
thus fewer) bowel movements, although diary data from this trial did not record the 
completeness of the bowel movements. In support of this hypothesis, a number of 
patients reported verbally experiencing an improvement in their bowel function with 
better evacuations and less frequent toilet visits. 
Patients with neuroconstipation spend a significant amount of time in the toilet and 
have to use large amounts of laxatives to achieve a bowel movement. There was a 
significant reduction in toilet time per visit (33%) and use of laxatives during 
temporary SNS intervention. 
Neuroconstipation causes reduced colonic activity thus delaying transit times, as seen 
in the study patients (58.5 hours [mean] compared with less than 38 hours in a normal 
population). It would be anticipated to that colonic transit times would decrease with 
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SNS. However transit times were not altered during the intervention phase of this 
study.  The pathological processes affecting gut motility in neuroconstipation are 
different to idiopathic constipation which may explain the absence of any improvement 
in transit times in our patients. Kamm and colleagues reported an improvement in 
transit times after permanent SNS in idiopathic constipation (Kamm, Dudding et al. 
2010). The number of patients in our study may be inadequate to quantify the effect of 
SNS on colonic transit, or the temporary SNS period may be too short to capture 
change. Another limitation may be in the method of assessing transit times. Snapshot 
X-rays (rather than real-time scintigraphic studies) may be inadequately refined to 
capture the non-linear progress of stools through the bowel. A recent paper by Cowlam 
reported  that segmental colonic transit studies were not reliable in assessing 
idiopathic constipation (Cowlam, Khan et al. 2008). Another recent report on the effect 
of SNS on gastrointestinal motor function did not show any change in gastric emptying, 
small intestinal and colonic transit (Damgaard, Thomsen et al.). 
Laser Doppler mucosal flowmetry (LDFC) is a gut specific, quantitative measure of 
extrinsic autonomic nerve activity. Emmanuel and Kamm showed that patients with 
idiopathic constipation have impaired extrinsic gut nerve activity, and have a lower 
than normal rectal mucosal flux (Emmanuel and Kamm 2000). The mucosal circulation 
has been shown to increase and reach a plateau in response to voltage increments in 
patients with SNS. This was reported in sixteen patients with permanent SNS implants 
who were suffering from faecal incontinence (Kenefick, Emmanuel et al. 2003). We did 
not increase the voltage during LDFC measurement in our patients as LDFC was 
recorded at the end of the three week period of temporary stimulation and all patients 
were at the maximum temporary SNS voltage. In this study there was no apparent 
change in LDFC flux during treatment instead of the expected increase. However, the 
patients in our study suffered from constipation rather than faecal incontinence. The 
different pathophysiology in our patients, a low number of subjects in this study and 
the lack of study power may explain the lack of any change in the scores of rectal 
mucosal flux during SNS.  
7.1.2 Permanent SNS 
The initial response rate according to the global assessment of constipation during 
temporary SNS was 67% (12/18): these patients received a permanent implant and 
were followed-up long term (mean follow-up 20 months).  Six of 12 patients implanted 
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reported a long-term response. Thus the response rate was 50% (6/12 patients) for 
patients progressing to permanent SNS and from the initial cohort 33% (6/18) of 
patients overall were able to benefit. A formal exploration of the determinants of 
response was not feasible due to small numbers. Sub-group analyses suggested that 
patients with MS receiving permanent SNS may do better than other types (63% vs. 
25%, p=0.30) and that men may do better than women (86% vs. 55%, p=0.32) but the 
numbers are small and inconclusive. 
7.1.3 Patients with Multiple Sclerosis (MS) 
The global assessment of constipation, PAC-SYM and PAC-QOL scores for the patients 
with MS improved significantly during the intervention phase of the trial. There was a 
25% improvement in the GA score during SNS and 20 % improvement in both PAC-
SYM and PAC-QOL. The initial response rate for improvement during temporary SNS 
was 73%. These patients received a permanent implant and long term follow-up over 
21 months revealed a persistent effect in 63% (5/8 patients). There was a no change in 
the EQ-VAS and EQ-5D scores, although these were not anticipated to be sensitive to 
changes in bowel function in small numbers of patients.  
When compared with neurological constipation due to other or undefined causes there 
is a suggestion of a much higher response from permanent SNS although this needs to 
be confirmed in adequately powered studies.  For example an adequately powered 
study to demonstrate response rates of 63% (MS) and 25% (non-MS), recruiting at a 
ratio of 2:1, with 90% power and α=0.05 would require 60 MS patients and 30 non-MS 
patients, bigger than any current study of SNS in neuroconstipation.  
There were a few incidents when patients reported a decrease in the effect of SNS 
during an exacerbation of MS. This was rectified in most of the cases with 
reprogramming the stimulator by changing the electrode settings. Patients, who did 
not improve after re-programming, noticed a significant diminution in effect and ended 
up with failure of treatment. Despite disease progression there was generally a 
sustained response in patients with MS.  
MS offers an association plausibly related to better long-term response. It is likely that 
in most patients there are still functional ascending spinal pathways which might 
explain the better response in MS than in spinal cord injury patients. One patient in this 
study with a complete spinal cord injury did not have any motor response to 
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stimulation despite an intact bulbospongiosus reflex (signifying sacral sparing). 
Previously, it has been postulated that the effect of SNS may involve modulation of 
spinal pathways (Sheldon, Kiff et al. 2005)  and vagal afferents leading to cortical 
activation (Lundby, Møller et al. 2011): the results from this study support this 
hypothesis. 
7.2 Patient perspectives 
Although a formal qualitative analysis of the patient’s experience during the trial was 
not performed, it was possible to note patient perspectives and experiences within 
routine follow-up visits. Multi-source feedback from the principal investigators, 
research nurses and the patients over the course of two years has been helpful in 
providing the core of patient experience described.  
Patients experienced neuroconstipation as a chronic disabling condition which had 
proved refractory to most available therapies. The quality of life of these patients was 
very poor; having a non-functional gut exacerbated overall suffering caused by 
neurological disease. Patients reported having to adhere to a strict bowel regime on a 
daily basis. This could take up a significant amount of time every day and was one of 
the main issues that patients brought up during their initial consultation at the time of 
recruitment. 
Since the trial, patient feedback has been largely positive. Patients with a functioning 
IPG were followed up in clinic and reviewed on an annual basis. Patients assessed as 
responding to treatment reported a general improvement in their physical and 
psychological quality of life. One of the participants who worked as a psychotherapist 
was actively involved in our patient advisory group since receiving his implant. He 
noticed a significant improvement in his daily work life as he did not have to worry 
about his bowel function while working. He has provided advice and a narrative of his 
own experience to other patients considering SNS. One of the other patients who was 
wheelchair bound reported a significant improvement in her bowel function. She had 
severe refractory disease and was being considered for a stoma before receiving SNS. 
Conversely, patients who failed initial testing stage were disappointed and patients 
who failed to respond to permanent SNS after initial response were perhaps the most 
despondent. Generally, these patients were not prepared to accept any further surgical 
interventions and are being managed conservatively. 
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7.3 Relationship between current and previous findings  
7.3.1 Published evidence 
The National Institute of Clinical Excellence has approved SNS for use in faecal 
incontinence and voiding dysfunction (NICE 2002; NICE 2004) but has not considered 
its use in constipation. There is a limited body of evidence for the role of SNS in 
neurological bowel disease relating to neuroconstipation (Lombardi, Del Popolo et al. 
2010).  
There have been a number of small uncontrolled, mostly retrospective studies 
exploring the efficacy of SNS in idiopathic constipation (see Chapter 2 and Table 2-1). 
These studies suggest a significant response rate in idiopathic constipation although 
these case series are uncontrolled and patients are often poorly characterised. A 
randomized sham-controlled study in idiopathic constipation is underway in Australia 
but is likely to show similar results, i.e. SNS is effective in an as yet undefined sub-
group of patients with chronic constipation and that a two-week test stimulation is a 
poor predictor of long-term response (personal communication: P Dinning).   
7.3.2 Contribution of new findings  
This is the first prospective study reporting the efficacy of SNS in patients of varying 
aetiology with neuropathic constipation.  The potential value of treating patients with 
neuroconstipation has been demonstrated, although further research is needed to 
understand the mechanisms of benefit and influence of aetiology.   
The study by Kamm et al found a permanent response rate varying from 33% to 87% 
depending upon the definition of treatment success and is thus broadly in line with 
study findings reported here. Similarly, an audit of patients with chronic constipation 
treated in our clinics at Durham and Hull, found that 60% of patients stopped 
responding to treatment in the first 6 months after permanent stimulation, despite 
strongly positive responses to standard 2-week test stimulation.   
The one patient with complete spinal cord injury and thus no afferent response showed 
no response to SNS at the initial test stage, supporting the hypothesis that SNS requires 
an afferent pathway to work. Consequently SNS may be a misnomer: SNS works by 
stimulating the local nervous system and by modulating the local response by 
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stimulating afferent spinal pathways. Thus it is not (local) sacral nerve stimulation per 
se that is causing a treatment effect. 
Physiological assessments during temporary SNS (laser Doppler flow cytometry and 
transit time) were not informative in this study. This may be a consequence of an under 
powered study, the duration of temporary SNS being too short to capture change or 
because SNS modifies neuroconstipation through a different mechanism of action to 
than is understood to occur in idiopathic constipation.  
Temporary SNS correctly predicted 50% (95%CI: 21% to 79%) of subjects who 
reported long-term response.  Further research is needed to refine this estimate and 
identify patient sub-groups who benefit most, if this treatment to be economically 
viable. The tariff for permanent SNS is typically around £15,000 and use in neuro 
constipation does not generate the cost savings that occur when used in faecal 
incontinence (primarily due to reduced nursing care).  
The study has demonstrated the stability and responsiveness of a number of key 
outcome measures. The global assessment of constipation, PAC-SYM and PAC-QOL 
produced consistent findings and correlated with clinical assessments of response. 
Thus these measures would be useful and appropriate in future research.  Because of 
its simplicity and sensitivity, the global assessment of constipation measure appears 
most appropriate for clinical assessment of the temporary SNS phase.  
The off-on-off design permitted an exploration of the duration of, and time to response 
of, starting and ceasing stimulation. The study design reported in this thesis was 
chosen to permit all subjects to receive SNS, but could not differentiate genuine and 
placebo response during the temporary phase. If it were possible to do this then long-
term response to permanent stimulation might be achievable in a much higher 
proportion of patients. Knowledge of the time to response from changing stimulus, has 
informed the design of a crossover temporary SNS evaluation phase with washout 
period, where patients receive actual or sham stimulation in blinded sequence. Thus in 
future research it may be possible to differentiate sham and genuine response. On the 
basis of findings reported here a washout period of two weeks appears optimal. 
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7.4 Strengths and weaknesses of the study 
7.4.1 Study Design 
The performance of SNS has not been compared with a control, instead repeated 
measures have been made over time to improve the attribution of findings. Patients 
entering the study were characterised by long-term chronic constipation and this was 
verified in the six week pre-intervention phase (see Figure 4-20).  Thus changes 
observed during and after temporary stimulation are likely to be due to the process of 
SNS treatment but can't differentiate placebo and genuine response (i.e. the effect of 
needle insertion and signal versus the process of needle insertion). Theoretically, this 
problem could be managed by exposing patients to periods of both real and sham 
stimulation during the temporary phase. This was not possible within the study 
because the response and washout times were previously unknown. For the process to 
be viable the temporarily inserting needles need to be in place throughout the entire 
real-washout-sham period, although the risk of infection or lead migration increases 
with time. In the light of the new findings presented in this thesis it would be realistic 
to have two-week stimulation period separated by a two-week washout (6 weeks in 
total) as a viable design. Although limited in its attribution and examination of 
aetiology, this study has substantially augmented current understanding of SNS in 
neuroconstipation and informed the design of a subsequent larger trial using crossover 
temporary SNS to explore the determinants of response to permanent SNS. 
7.4.2 Why bilateral SNS? 
Unilateral lead placement is usually sufficient for treating faecal incontinence and 
idiopathic constipation. Expert opinion was sought regarding the optimum placement 
of electrodes for study patients. Bilateral wire placement was performed in all patients 
to reduce the chance of electrode displacement and laterality bias in the final analysis. 
There was no available evidence addressing this specific issue, therefore, this decision 
was reached after consensus within the clinical team. In a proof of concept study it was 
decided it was important to maximise the potential to demonstrate a therapeutic 
response. Two patients received a unilateral lead as they did not have any motor 
response in the contralateral sacral foramina during electrode placement. 
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7.4.3 Selection of outcome measures 
There are no universally accepted severity assessments for constipation. Most 
measures used have been validated in chronic constipation. It is likely, though not 
certain, that they will be sensitive to changes in neuroconstipation. 
We decided to use the global assessment of constipation as the primary outcome 
measure. This has been used in many randomized controlled trials in functional bowel 
disease and has shown been shown to be reliable (Camilleri et al. 2000; Kellow et al. 
2003; Nyhlin et al. 2004; S A Müller-Lissner et al. 2001). A validation analysis 
compared to a visual analogue scale has been reported (Müller-Lissner et al. 2003). 
Although the scale has been shown to be reliable in functional constipation, it has not 
been used in patients with neuroconstipation before. 
PAC-SYM and PAC-QOL have been well validated and show considerable stability and 
responsiveness (Frank et al. 1999; Marquis et al. 2005). This has been observed in this 
study as well (see 4.3.2 and 4.3.3). Despite being reliable and stable during the study, 
PAC scores have not been used in this patient subgroup before. Further work is needed 
to formally validate these scores in neuro-constipation.  
Secondary outcome measures like transit times and LDFC were selected to explain the 
mechanism of action and the anticipated physiological effects during the intervention 
(Blanchard, Schwarz, et al. 1992; Blanchard, Scharff, et al. 1992). Others (stimulation 
thresholds, EuroQOL) provided the data for exploratory analyses and estimation of 
variance in these patients.  
The diary cards did not record spontaneous complete bowel movements (SCBM) 
during the study. The completeness of the bowel movements was also difficult to 
record. The lack of reporting SCBMs during intervention is a potential weakness of the 
study. The diary cards during week 4 to week 9 included items for frequency, 
incontinence, time spent toileting and laxative use. 
7.5 Comparison with other interventions 
Most patients with neuroconstipation are managed conservatively. This includes 
establishing a scheduled pattern for bowel movements, dietary and lifestyle 
modification, use of laxatives and/or suppositories. These measures work in a majority 
of patients and only a few require intervention. The options for intervention in 
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neuroconstipation include transanal irrigation (TAI), percutaneous endoscopic 
colostomy (PEC), antegrade continence enema (appendicostomy, ACE) or faecal 
diversion through stomas. 
Faaborg et al. reported the outcome of TAI in a series of 211 patients with neurogenic 
bowel dysfunction(Faaborg, Christensen et al. 2009). The authors reported a success 
rate of 46% at 19 months follow-up which decreased to 35% at 3 years. TAI was 
considered safe (risk of perforation: 1 in 50000) but side effects were seen in up to 
48% of patients. TAI is effective but a labour intensive modality for treatment. Studies 
reporting the outcome after ACE procedures have shown a success rate of 80% in 
children but evidence in neuroconstipation is limited. The stenosis rate is high (30%) 
requiring further surgery (Malone 2004).  
A case series of 31 patients (6 with neurogenic aetiology) receiving PEC was reported 
in 2007. There was significant morbidity associated with PEC (infection rate 77%) and 
two deaths due to faecal peritonitis. A high percentage of patients (44%) ended up 
having the PEC removed (Cowlam, Watson et al. 2007). Similarly, surgery for diversion 
carries a significant risk of early or late complications. A retrospective study in 32 
patients with SCI recorded increased patient satisfaction and a decrease in toileting 
time (from 10.3 hrs/week to 1.9 hrs/week). However, 44% of patients suffered from 
complications (6% early, 37.5% late). These included diversion colitis, faecal fistula, 
parastomal hernias and adhesional bowel obstruction. (Branagan, Tromans et al. 2003) 
In contrast, SNS offers a minimally invasive and safe alternative. This study has shown 
that 67% of patients have a good response after T-SNS. Long term response is limited 
(33%) but patients with MS seem to respond better (63%) than patients with other 
aetiology. 
7.6 Dissemination of findings 
To date, response and physiological findings have been presented at two major 
international conferences in the form of a poster. Details in Appendix B.  Thesis 
findings will be disseminated through peer-reviewed publication. 
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7.7 Future Research Directions 
The main challenge faced in this field of research is the need to identify those patients 
who will benefit from permanent SNS. The initial response to temporary stimulation 
was 67% but only half of patients demonstrated persistent benefit (after a mean of 27 
months follow-up).  
The standard method of predicting response, across all studies of SNS for incontinence 
and constipation, has been to use 2 or 3-week test stimulation. However, this approach 
does not seem as effective in neuroconstipation as in faecal incontinence and bladder 
dysfunction.  Within the research reported here, simple helical leads were used during 
the temporary phase but some recent studies have used the same tined leads used in 
permanent SNS.  
The success rate for subsequent permanent implantation when using quadripolar or 
tined leads during the diagnostic phase has been reported to be between 63% to 80% 
when compared to 50% for conventional testing (Donato F Altomare et al. 2009; Seif et 
al. 2006; Sievert et al. 2007; Spinelli et al. 2003). Consequently, the future planned 
study with active sham temporary phase stimulation will also employ tined leads. 
The lack of an accurate test phase to reliably predict long term benefit poses a major 
barrier to the viability of the treatment in this condition, both from a patient 
perspective and an economic one.  It is probable that the current predictive value of 
test stimulation is inadequate to allow any consensus for approval of SNS in 
constipation.  The reasons for the poor predictive performance of the temporary-wire 
test stimulation in constipation are unknown.  A placebo effect, if present, is most likely 
to be strongest following commencement of treatment, and reduce with time (Bland 
and Altman 1994).  There is a possibility that the lead position may be more critical in 
chronic constipation, thus a test procedure is only effective at predicting the outcome 
of a lead in that specific position, but once that lead is changed for a permanent (tined) 
lead the small change in position results in a change in efficacy.   
7.8 Conclusions 
Temporary SNS may accurately predict about half of patients who will benefit long 
term from permanent SNS.  Nonetheless, in patients in whom other management 
options have been exhausted, SNS offers a potentially valuable alternative to invasive 
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surgical procedures. Further research is needed to refine estimates of long term 
benefit, prediction of which patients and sub-groups benefit most and develop 
understanding of the underlying physiological mechanism of benefit. Findings from 
this study provide important insights in the design of future research. 
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Appendix A  
Table_Apx 1: Weekly GA Constipation scores 
 con1 con2 con3 con4 con5 con6 con7 con8 con9 con10 con11 con12 
SNS002 3 3 3 3 3 3 2 2 2 2 3 3 
SNS003 3 3 4 3 4 3 3 2 0 3 4 5 
SNS004 4 4 4 2 1 1 2 3 2 1 1 1 
SNS005 4 4 5 4 4 4 1 1 1 2 4 4 
SNS006 4 4 4 4 4 4 - - - - - - 
SNS007 3 3 3 3 3 3 2 3 2 3 3 3 
SNS008 5 5 5 5 5 5 4 4 4 2 3 4 
SNS009 3 4 3 3 3 3 2 2 3 2 4 4 
SNS010 4 5 4 4 4 4 4 4 4 4 4 4 
SNS011 4 4 4 4 5 4 4 3 4 3 4 4 
SNS012 4 4 4 4 4 4 4 4 4 4 4 4 
SNS013 4 4 4 4 4 4 3 3 3 4 3 4 
SNS016 3 4 3 4 3 4 1 1 2 3 3 3 
SNS017 4 4 4 3 3 3 2 2 2 3 2 3 
SNS020 4 4 5 5 5 4 4 3 4 3 4 4 
SNS021 4 3 5 5 4 5 2 3 1 4 4 4 
SNS018 4 4 3 4 5 4 4 4 4 4 4 4 
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Table_Apx 2: Weekly GA FI scores 
 con1 con2 con3 con4 con5 con6 con7 con8 con9 con10 con11 con12 
SNS002 0 0 0 0 0 0 0 0 0 0 0 0 
SNS003 0 0 0 0 0 2 0 0 0 0 0 0 
SNS004 2 2 0 2 1 1 2 3 0 2 0 1 
SNS005 3 1 2 1 1 1 1 1 1 1 1 1 
SNS006 0 0 0 2 2 1 - - - - - - 
SNS007 0 0 0 0 0 0 0 0 0 1 0 0 
SNS008 0 0 0 3 4 5 3 3 4 2 1 4 
SNS009 0 0 0 3 0 0 0 0 0 0 0 0 
SNS010 0 0 0 0 0 0 0 0 0 0 0 0 
SNS011 0 0 0 0 0 0 0 0 0 0 0 0 
SNS012 4 4 4 4 0 4 4 4 3 0 3 3 
SNS013 3 3 2 2 2 3 2 3 0 3 4 4 
SNS016 3 0 0 0 0 0 0 0 0 0 0 0 
SNS017 4 4 4 3 3 3 1 3 2 3 2 3 
SNS020 0 4 4 4 5 0 4 3 0 3 4 4 
SNS021 1 0 0 0 0 0 0 0 0 0 0 0 
SNS018 1 5 4 0 0 3 3 2 4 2 2 0 
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Table_Apx 3: Weekly scores for PAC-SYM 
 
pacs
ym1 
pacs
ym2 
pacs
ym3 
pacs
ym4 
pacs
ym5 
pacs
ym6 
pacs
ym7 
pacs
ym8 
pacs
ym9 
pacs
ym1
0 
pacs
ym1
1 
pacs
ym1
2 
SNS002 1.00 1.33 1.25 1.33 0.92 1.25 1.17 0.58 0.67 0.42 1.08 1.08 
SNS003 3.17 2.50 2.36 2.64 2.50 1.92 2.17 0.83 0.58 0.92 1.09 2.00 
SNS004 2.17 2.08 1.58 2.17 2.25 0.92 0.50 0.42 0.25 0.92 0.67 0.83 
SNS005 1.50 2.00 1.67 1.92 1.75 1.67 0.33 0.33 0.17 0.58 1.75 1.67 
SNS006 1.33 1.00 1.00 1.08 0.92 1.08 - - - - - - 
SNS007 0.83 0.83 0.92 1.00 0.83 0.92 0.50 0.42 0.25 0.42 0.67 0.83 
SNS008 2.33 2.25 2.58 2.50 2.67 2.67 1.67 2.08 1.92 1.25 1.08 2.17 
SNS009 1.00 0.92 2.00 1.17 0.83 0.83 0.75 0.50 0.42 0.33 0.92 0.83 
SNS010 1.75 2.25 1.92 1.25 1.17 1.67 0.75 0.92 0.67 1.33 1.25 1.50 
SNS011 2.58 2.08 2.42 2.33 2.33 2.08 2.17 1.75 1.67 1.83 1.92 2.33 
SNS012 3.58 3.42 3.50 2.83 3.08 3.50 2.83 2.50 1.92 2.42 2.17 2.17 
SNS013 1.83 1.83 1.75 2.83 2.25 2.25 0.75 1.25 1.25 1.75 2.33 2.67 
SNS016 1.25 1.17 1.33 1.17 1.25 1.33 0.17 0.17 0.42 0.42 0.42 0.42 
SNS017 2.17 2.17 1.92 1.17 2.08 2.00 1.75 1.67 1.67 0.75 0.50 0.92 
SNS020 1.17 2.75 2.83 2.42 1.92 1.92 2.42 2.83 2.83 1.75 1.75 2.92 
SNS021 1.33 1.00 1.17 1.92 1.00 1.33 0.58 0.67 0.33 0.92 0.92 0.92 
SNS018 1.33 1.50 1.42 1.17 1.67 1.50 1.50 1.75 1.67 1.58 1.25 1.33 
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Table_Apx 4: PAC-SYM Abdominal domain 
 
pacs
ym1 
pacs
ym2 
pacs
ym3 
pacs
ym4 
pacs
ym5 
pacs
ym6 
pacs
ym7 
pacs
ym8 
pacs
ym9 
pacs
ym1
0 
pacs
ym1
1 
pacs
ym1
2 
SNS002 0.80 0.80 0.80 1.20 0.60 0.80 0.80 0.40 0.40 0.20 0.80 0.80 
SNS003 3.40 2.80 1.25 2.40 2.60 1.60 2.60 0.40 0.40 0.80 0.50 3.20 
SNS004 2.80 2.40 1.60 2.80 2.40 0.80 0.40 0.20 0.20 0.80 0.40 0.60 
SNS005 1.40 2.00 1.80 2.00 1.60 1.40 0.60 0.20 0.20 0.60 1.60 1.40 
SNS006 1.40 1.00 1.20 1.40 1.20 1.40 - - - - - - 
SNS007 0.80 0.80 1.00 0.80 0.60 0.80 0.40 0.20 0.20 0.20 0.40 0.60 
SNS008 2.40 2.20 2.60 2.80 2.80 2.80 1.60 1.80 1.60 1.20 1.00 2.20 
SNS009 1.40 1.80 2.20 1.40 1.20 1.40 1.80 0.80 0.80 0.40 1.40 1.40 
SNS010 2.00 3.20 3.20 2.00 1.80 2.40 0.80 1.00 1.00 1.60 1.60 1.60 
SNS011 2.20 1.40 2.20 2.20 2.40 1.80 2.20 1.40 1.20 2.00 2.00 2.40 
SNS012 3.80 4.00 3.80 3.40 3.40 4.00 3.00 2.60 3.20 2.60 2.80 2.20 
SNS013 3.00 2.80 2.60 3.60 3.20 2.80 1.20 1.40 1.60 2.40 2.80 3.00 
SNS016 1.60 1.60 1.60 1.60 1.60 1.60 0.40 0.40 1.00 0.60 0.60 0.60 
SNS017 2.80 2.60 2.40 1.60 2.80 2.80 2.40 2.00 2.20 1.40 1.20 1.00 
SNS020 0.80 2.80 2.80 1.80 0.80 2.60 1.40 3.20 3.20 2.60 2.60 3.00 
SNS021 0.80 1.20 1.20 2.20 1.40 1.80 0.40 0.20 0.40 1.00 0.80 1.00 
SNS018 1.09 1.45 1.27 1.00 1.64 1.45 1.36 1.73 1.55 1.45 1.18 1.27 
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Table_Apx 5:PAC-SYM Rectal domain 
 
pacs
ym1 
pacs
ym2 
pacs
ym3 
pacs
ym4 
pacs
ym5 
pacs
ym6 
pacs
ym7 
pacs
ym8 
pacs
ym9 
pacs
ym1
0 
pacs
ym1
1 
pacs
ym1
2 
SNS002 0.67 1.00 1.00 1.00 0.67 1.00 0.67 0.33 0.33 0.33 0.67 0.67 
SNS003 3.00 2.00 3.33 3.00 3.00 3.00 1.33 1.33 0.67 1.00 1.00 - 
SNS004 3.00 1.67 1.67 3.00 2.33 0.67 0.67 0.33 0.33 0.33 1.00 1.00 
SNS005 2.00 2.00 1.67 2.00 2.33 2.00 - 0.33 0.33 - 1.67 2.33 
SNS006 1.00 1.00 0.67 0.67 0.67 0.67 - - - - - - 
SNS007 0.67 0.67 1.00 1.00 1.00 0.67 0.67 0.33 0.33 0.33 1.00 1.00 
SNS008 1.33 1.33 2.00 1.00 1.67 2.00 0.67 1.33 1.00 0.67 1.00 2.00 
SNS009 0.33 0.33 1.33 0.67 0.33 0.33 - - - 0.33 - - 
SNS010 1.00 1.00 1.00 0.67 1.00 0.67 0.67 0.67 0.33 0.67 0.67 0.67 
SNS011 1.33 1.33 1.00 1.33 1.00 1.00 1.00 1.00 1.00 0.67 0.67 1.00 
SNS012 2.67 1.67 2.67 2.00 1.67 3.33 3.00 1.67 0.67 1.33 1.00 2.00 
SNS013 1.00 1.00 1.33 2.67 1.33 1.67 0.33 1.00 1.00 1.33 2.33 3.00 
SNS016 1.33 1.33 1.33 1.33 1.33 1.33 - - - 0.67 0.67 0.67 
SNS017 0.67 1.33 0.67 0.67 1.00 1.00 0.67 0.67 1.00 - - 0.33 
SNS020 1.33 2.33 2.00 2.67 2.00 2.00 3.00 3.00 2.67 1.00 1.00 1.67 
SNS021 1.00 0.67 0.67 1.00 0.33 1.00 - 0.67 0.33 0.67 0.67 1.00 
SNS018 0.67 1.33 1.00 0.67 1.00 1.00 1.00 1.33 1.00 1.00 0.67 1.00 
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Table_Apx 6: PAC-SYM stool domain 
 
pacs
ym1 
pacs
ym2 
pacs
ym3 
pacs
ym4 
pacs
ym5 
pacs
ym6 
pacs
ym7 
pacs
ym8 
pacs
ym9 
pacs
ym1
0 
pacs
ym1
1 
pacs
ym1
2 
SNS002 1.50 2.25 2.00 1.75 1.50 2.00 2.00 1.00 1.25 0.75 1.75 1.75 
SNS003 3.00 2.50 2.75 2.75 2.00 1.50 2.25 1.00 0.75 1.00 1.75 2.00 
SNS004 0.75 2.00 1.50 0.75 2.00 1.25 0.50 0.75 0.25 1.50 0.75 1.00 
SNS005 1.25 2.00 1.50 1.75 1.50 1.75 0.25 0.50 - 1.00 2.00 1.50 
SNS006 1.50 1.00 1.00 1.00 0.75 1.00 - - - - - - 
SNS007 1.00 1.00 0.75 1.25 1.00 1.25 0.50 0.75 0.25 0.75 0.75 1.00 
SNS008 3.00 3.00 3.00 3.25 3.25 3.00 2.50 3.00 3.00 1.75 1.25 2.25 
SNS009 1.00 0.25 2.25 1.25 0.75 0.50 - 0.50 0.25 0.25 1.00 0.75 
SNS010 2.00 2.00 1.00 0.75 0.50 1.50 0.75 1.00 0.50 1.50 1.25 2.00 
SNS011 4.00 3.50 3.75 3.25 3.25 3.25 3.00 2.75 2.75 2.50 2.75 3.25 
SNS012 4.00 4.00 3.75 2.75 3.75 3.00 2.50 3.00 1.25 3.00 2.25 2.25 
SNS013 1.00 1.25 1.00 2.00 1.75 2.00 0.50 1.25 1.00 1.25 1.75 2.00 
SNS016 0.75 0.50 1.00 0.50 0.75 1.00 - - - - - - 
SNS017 2.50 2.25 2.25 1.00 2.00 1.75 1.75 2.00 1.50 0.50 - 1.25 
SNS020 1.50 3.00 3.50 3.00 3.25 1.00 3.25 2.25 2.50 1.25 1.25 3.75 
SNS021 2.25 1.00 1.50 2.25 1.00 1.00 1.25 1.25 0.25 1.00 1.25 0.75 
SNS018 2.25 1.75 2.25 1.75 2.00 2.25 2.50 2.00 2.00 1.50 1.00 1.25 
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Table_Apx 7: Weekly PAC-QOL Scores 
 
pacq
ol1 
pacq
ol2 
pacq
ol3 
pacq
ol4 
pacq
ol5 
pacq
ol6 
pacq
ol7 
pacq
ol8 
pacq
ol9 
pacq
ol10 
pacq
ol11 
pacq
ol12 
SNS002 1.89 1.68 1.68 1.71 1.46 1.32 1.29 1.00 1.07 0.71 1.32 1.36 
SNS003 2.79 2.11 2.79 2.36 2.29 2.25 1.50 1.39 0.57 1.54 2.22 3.04 
SNS004 2.14 2.07 2.33 2.14 2.14 1.04 1.54 1.29 1.07 1.14 1.25 1.54 
SNS005 1.79 2.25 2.18 2.39 2.18 2.11 0.29 0.14 0.14 0.75 1.54 1.75 
SNS006 2.57 2.32 2.43 2.43 2.71 2.68 - - - - - - 
SNS007 1.71 1.75 1.61 1.57 1.43 1.04 1.54 1.29 1.07 1.14 1.25 1.54 
SNS008 3.00 2.96 3.00 2.50 2.61 2.54 2.39 2.57 2.29 1.54 2.04 2.46 
SNS009 1.04 1.32 1.43 1.32 1.29 1.29 1.39 1.14 0.89 0.71 2.14 2.18 
SNS010 2.04 2.93 2.61 2.21 2.25 2.39 2.43 2.14 2.64 2.57 2.57 2.61 
SNS011 2.82 2.54 2.43 2.64 2.89 1.96 2.64 2.18 2.07 1.61 2.50 2.64 
SNS012 3.82 3.61 3.21 2.89 2.71 3.25 2.89 2.86 3.18 2.61 2.71 2.68 
SNS013 2.86 2.21 2.46 2.32 2.68 2.32 1.79 1.71 1.79 2.36 2.46 2.79 
SNS016 2.50 2.18 2.14 2.18 2.50 2.14 0.68 0.32 0.61 1.29 1.29 1.29 
SNS017 2.18 2.04 1.57 1.57 1.75 1.82 1.43 1.43 1.61 1.68 1.25 1.18 
SNS020 3.64 3.50 3.39 3.18 2.46 3.46 3.36 3.07 3.07 2.96 3.32 3.18 
SNS021 2.32 1.96 2.18 2.39 2.11 2.14 0.96 0.96 0.54 1.68 1.86 2.14 
SNS018 2.21 2.29 2.18 2.21 1.93 2.00 2.21 2.25 2.25 1.96 2.18 2.21 
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Table_Apx 8: PAC-QOL Physical discomfort domain 
 
pacq
ol1 
pacq
ol2 
pacq
ol3 
pacq
ol4 
pacq
ol5 
pacq
ol6 
pacq
ol7 
pacq
ol8 
pacq
ol9 
pacq
ol10 
pacq
ol11 
pacq
ol12 
SNS002 2.25 2.25 2.25 2.25 1.75 2.00 1.25 1.00 1.00 0.50 1.75 1.75 
SNS003 2.75 2.75 2.00 2.50 2.25 1.50 1.50 1.00 0.50 1.50 0.67 3.75 
SNS004 2.50 2.75 2.00 2.50 2.25 1.00 0.75 0.75 0.50 0.50 0.75 1.00 
SNS005 1.75 3.50 3.25 3.00 2.75 2.75 0.25 - - 0.50 2.25 2.50 
SNS006 2.00 2.25 1.75 2.25 2.75 2.50 - - - - - - 
SNS007 0.75 1.00 0.75 0.75 0.50 1.00 0.75 0.75 0.50 0.50 0.75 1.00 
SNS008 2.50 2.25 2.25 1.50 1.50 1.75 1.50 1.75 1.50 1.00 1.25 1.75 
SNS009 1.25 1.50 1.50 1.75 1.75 1.75 2.00 1.50 0.75 0.25 2.75 2.50 
SNS010 3.00 3.50 3.50 2.75 2.75 3.25 2.25 2.25 2.50 3.00 3.00 3.00 
SNS011 3.75 2.75 2.50 3.00 3.00 1.75 3.25 2.75 2.75 2.00 2.75 3.25 
SNS012 4.00 4.00 4.00 3.00 3.75 4.00 3.00 3.75 3.25 3.25 3.50 3.25 
SNS013 3.00 2.75 2.75 2.50 2.50 3.00 1.50 1.75 2.25 2.75 2.50 3.25 
SNS016 2.75 3.50 3.00 3.50 2.75 3.00 0.25 - 1.50 2.25 2.25 2.25 
SNS017 3.75 3.25 3.00 2.00 2.50 1.75 2.25 1.75 2.50 2.25 1.00 0.25 
SNS020 3.75 3.75 3.50 3.25 3.75 4.00 3.25 3.25 3.25 2.75 3.25 2.75 
SNS021 3.00 2.50 3.00 3.00 2.50 2.50 1.00 1.00 0.25 1.50 2.25 2.75 
SNS018 2.00 1.75 1.75 1.50 1.75 1.50 1.75 2.00 2.50 1.75 2.75 2.00 
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Table_Apx 9: PAC-QOL Psychosocial discomfort domain 
 
pacq
ol1 
pacq
ol2 
pacq
ol3 
pacq
ol4 
pacq
ol5 
pacq
ol6 
pacq
ol7 
pacq
ol8 
pacq
ol9 
pacq
ol10 
pacq
ol11 
pacq
ol12 
SNS002 0.50 0.13 - 0.63 0.25 0.25 - - - - 0.13 0.13 
SNS003 2.25 0.63 2.13 1.25 1.38 1.13 1.00 1.00 0.38 1.13 2.00 2.00 
SNS004 1.75 0.88 1.63 1.75 1.38 1.13 1.13 1.38 1.13 1.13 0.75 1.13 
SNS005 0.63 0.75 0.38 0.75 0.63 0.50 - - - - - - 
SNS006 2.50 2.38 2.50 3.00 3.13 2.88       
SNS007 1.13 1.13 1.13 1.25 1.13 1.13 1.13 1.38 1.13 1.13 0.75 1.13 
SNS008 2.50 2.50 2.75 2.00 2.13 2.25 2.13 2.13 2.13 2.00 1.63 2.25 
SNS009 0.25 0.50 0.50 - 0.25 0.13 0.38 0.13 - 0.25 0.38 0.25 
SNS010 1.38 2.63 3.00 2.38 2.88 2.25 2.63 2.50 2.38 2.63 2.63 2.63 
SNS011 1.00 0.63 0.75 1.00 1.50 0.50 0.88 0.63 0.38 0.25 0.75 1.00 
SNS012 3.38 3.13 2.63 1.88 1.88 2.00 2.00 2.00 2.00 2.63 1.63 1.50 
SNS013 3.00 1.75 2.88 2.50 2.88 2.50 2.13 1.50 1.38 2.50 3.00 3.25 
SNS016 1.50 1.38 1.50 1.38 1.50 1.50 - - 0.25 - - - 
SNS017 0.88 0.25 - 0.25 - - - - - - - 0.38 
SNS020 3.25 3.38 3.13 2.50 1.25 2.75 2.75 2.88 2.88 2.75 2.50 2.38 
SNS021 1.50 1.13 1.75 1.75 1.75 1.50 1.00 1.13 0.50 1.38 1.00 1.13 
SNS018 2.00 2.13 2.00 1.88 1.63 1.88 2.00 2.00 2.13 1.50 1.88 2.25 
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Table_Apx 10: PAC-QOL Worries and concerns domain 
 
pacq
ol1 
pacq
ol2 
pacq
ol3 
pacq
ol4 
pacq
ol5 
pacq
ol6 
pacq
ol7 
pacq
ol8 
pacq
ol9 
pacq
ol10 
pacq
ol11 
pacq
ol12 
SNS002 2.18 2.09 2.18 1.82 1.64 1.36 1.73 1.36 1.36 0.82 1.45 1.55 
SNS003 2.73 2.36 3.18 2.64 2.64 2.82 2.09 1.36 0.64 1.45 2.36 3.36 
SNS004 2.18 2.09 2.50 2.18 2.55 1.27 1.55 1.00 0.82 1.00 1.18 1.45 
SNS005 2.18 2.09 2.36 2.64 2.36 2.27 0.64 0.36 0.36 1.09 1.36 2.09 
SNS006 2.73 2.45 2.45 2.27 2.55 2.64       
SNS007 1.82 1.91 1.73 1.55 1.36 1.27 1.55 1.00 0.82 1.00 1.18 1.45 
SNS008 3.27 3.27 3.18 2.64 2.82 2.55 2.36 2.64 2.09 1.91 2.09 2.55 
SNS009 0.73 1.09 1.09 1.00 0.91 0.91 1.18 0.91 0.82 0.55 2.36 2.64 
SNS010 1.73 2.55 1.91 1.73 1.64 2.00 1.91 1.64 2.36 1.91 1.91 2.00 
SNS011 3.36 3.27 3.00 3.09 3.36 2.27 3.09 2.45 2.27 2.64 3.09 3.00 
SNS012 4.00 3.73 3.82 3.45 3.36 3.91 3.36 3.00 3.82 1.91 3.00 3.18 
SNS013 2.27 1.73 1.55 1.91 2.27 1.55 1.18 1.36 1.36 1.73 1.55 1.82 
SNS016 2.82 1.55 1.64 1.55 2.82 1.64 0.91 0.64 0.64 1.09 1.09 1.09 
SNS017 2.00 2.36 2.00 1.45 2.00 2.36 1.82 2.18 2.36 1.91 1.36 1.27 
SNS020 3.82 3.64 3.64 4.00 3.09 3.91 3.64 3.82 3.82 2.91 3.73 3.64 
SNS021 2.45 2.45 2.27 2.55 2.27 2.82 1.00 1.09 0.82 1.82 2.27 2.09 
SNS018 2.27 2.36 2.27 2.82 2.00 1.91 2.27 2.36 2.45 2.18 2.00 2.09 
 
  
  
161 
 
Table_Apx 11: PAC-QOL dissatisfaction domain 
 
pacq
ol1 
pacq
ol2 
pacq
ol3 
pacq
ol4 
pacq
ol5 
pacq
ol6 
pacq
ol7 
pacq
ol8 
pacq
ol9 
pacq
ol10 
pacq
ol11 
pacq
ol12 
SNS002 3.20 2.80 2.80 2.80 2.80 2.40 2.40 1.80 2.20 1.80 2.60 2.60 
SNS003 3.80 3.40 3.60 3.40 3.00 3.40 1.00 2.40 0.80 2.40 3.20 3.40 
SNS004 2.40 3.40 3.40 2.40 2.40 0.40 2.80 2.20 2.00 2.00 2.60 2.80 
SNS005 2.80 4.00 3.80 4.00 3.80 3.80 - - - 1.40 3.80 3.20 
SNS006 2.80 2.00 2.80 2.00 2.40 2.60 - - - - - - 
SNS007 3.20 3.00 2.80 2.80 2.80 0.40 2.80 2.20 2.00 2.00 2.60 2.80 
SNS008 3.60 3.60 3.60 3.80 3.80 3.60 3.60 3.80 3.60 0.40 3.20 3.20 
SNS009 2.80 3.00 3.60 3.80 3.40 3.60 3.00 3.00 2.60 2.20 4.00 4.00 
SNS010 3.00 3.80 2.80 2.60 2.20 2.80 3.40 2.60 3.80 3.60 3.60 3.60 
SNS011 3.80 3.80 3.80 4.00 4.00 3.80 4.00 3.60 3.80 1.20 3.80 4.00 
SNS012 4.00 3.80 2.20 3.20 1.80 3.20 3.20 3.20 3.60 3.60 3.20 3.00 
SNS013 3.80 3.60 3.60 2.80 3.40 3.20 2.80 2.80 3.00 3.20 3.60 3.80 
SNS016 3.20 3.80 3.60 3.80 3.20 3.60 1.60 0.40 0.40 3.00 3.00 3.00 
SNS017 3.40 3.20 2.00 3.60 3.40 3.60 2.20 1.80 1.80 3.40 3.20 3.00 
SNS020 3.80 3.20 3.20 2.40 2.00 3.20 3.80 1.60 1.60 3.60 3.80 3.80 
SNS021 2.80 1.80 2.00 2.60 2.00 1.40 0.80 0.40 0.20 2.00 2.00 3.40 
SNS018 2.60 2.80 2.60 2.00 2.40 2.80 2.80 2.60 1.80 2.40 2.60 2.60 
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Table_Apx 12: EQ-VAS scores 
 eqvas3 eqvas6 eqvas9 eqvas12 
SNS003 75 45 95 50 
SNS004 50 50 50 60 
SNS005 39 30 80 50 
SNS006 40 30 - - 
SNS007 50 50 50 50 
SNS008 70 40 70 55 
SNS009 55 65 45 60 
SNS010 30 40 20 30 
SNS011 50 50 30 40 
SNS012 20 70 20 40 
SNS013 35 20 45 20 
SNS016 20 20 40 40 
SNS017 35 30 25 35 
SNS020 50 60 60 35 
SNS021 55 60 45 60 
SNS018 50 50 40 50 
0-100 (0 worst state of health, 100 best state of health) 
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Table_Apx 13: EQ-5D Scores 
 eq5d3 eq5d6 eq5d9 eq5d12 
SNS003 0.587 0.516 0.746 -0.181 
SNS004 0.273 0.273 0.273 0.312 
SNS005 0.587 0.623 0.587 0.691 
SNS006 0.516 -0.056   
SNS007 0.620 0.691 0.691 0.691 
SNS008 0.088 -0.135 0.030 0.088 
SNS009 -0.037 0.073 0.073 0.587 
SNS010 -0.086 0.159 -0.003 0.159 
SNS011 0.516 0.516 0.088 0.516 
SNS012 -0.181 0.082 -0.077 -0.181 
SNS013 -0.074 -0.003 0.260 -0.003 
SNS016 -0.095 -0.095 0.073 0.073 
SNS017 0.088 0.620 0.159 0.691 
SNS020 0.222 -0.077 0.689 -0.077 
SNS021 0.620 0.088 0.691 0.159 
SNS018 0.205 -0.016 0.516 0.260 
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Daily Diary 
Table_Apx 14: Weekly Bowel Movements 
Bowel 
Movements 
wk 4 wk 5 wk 6 wk 8 wk 9 
SNS002 2.43 2.14 1.71 1.71 1.14 
SNS003 0.43 0.29 0.57 0.71 0.71 
SNS004 1.43 1.29 1.50 2.00 - 
SNS005 0.29 0.29 0.29 0.71 0.57 
SNS006 4.14 3.29 3.57 - - 
SNS007 6.14 5.71 1.71 1.43 1.71 
SNS008 5.29 5.71 5.57 4.14 5.57 
SNS009 0.29 0.43 0.29 0.43 0.29 
SNS010 1.29 0.71 0.71 1.00 0.57 
SNS011 0.43 0.86 0.43 0.71 0.43 
SNS012 0.86 1.43 1.14 0.29 1.14 
SNS013 2.00 1.71 2.00 2.43 0.57 
SNS016 0.14 0.29 0.14 0.43 0.29 
SNS017 0.29 0.71 0.29 0.71 0.71 
SNS020 0.86 0.71 0.86 1.00 0.86 
SNS021 1.86 1.71 1.71 1.57 1.14 
SNS018 1.00 1.00 0.85 0.72 0.72 
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Table_Apx 15: Faecal Incontinence Episodes 
FI wk 4 wk 5 wk 6 wk 8 wk 9 
SNS002 0 0 0 0 0 
SNS003 0 0 0 0 0 
SNS004 0 0 0 0 0 
SNS005 0 0 0 0 0 
SNS006 0 0 0 - 0 
SNS007 0 0 0 0 0 
SNS008 15 6 5 0 0 
SNS009 0 0 0 0 0 
SNS010 0 0 0 0 0 
SNS011 0 0 0 0 0 
SNS012 0 0 0 0 0 
SNS013 0 0 0 0 0 
SNS016 0 0 0 0 0 
SNS017 0 9 8 0 0 
SNS020 0 0 0 0 0 
SNS021 0 0 0 0 0 
SNS018 0 1 0 0 0 
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Table_Apx 16: Mean toileting time 
Toileting Time wk 4 wk 5 wk 6 wk 8 wk 9 
SNS002 16.57 16.43 12.14 16.00 10.71 
SNS003 11.43 8.57 11.43 12.14 5.71 
SNS004 20.00 16.43 20.00 12.86 - 
SNS005 12.86 18.57 18.57 10.00 8.57 
SNS006 77.14 45.71 54.29 - - 
SNS007 72.14 76.43 26.43 25.00 16.43 
SNS008 20.43 20.29 19.71 10.14 14.29 
SNS009 26.43 30.00 24.29 22.14 21.43 
SNS010 12.86 8.57 8.57 12.43 4.57 
SNS011 6.57 6.71 5.71 8.57 3.57 
SNS012 2.86 1.71 2.86 1.43 5.71 
SNS013 107.14 65.00 58.57 55.00 32.14 
SNS016 6.43 12.86 6.43 12.86 4.29 
SNS017 1.00 3.00 2.86 4.71 4.43 
SNS020 8.43 7.71 9.43 7.14 5.00 
SNS021 9.57 6.86 6.86 4.43 2.86 
SNS018 28.33 28.89 28.70 28.98 30.00 
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Table_Apx 17: Mean Laxative score 
Laxative Score wk 4 wk 5 wk 6 wk 8 wk 9 
SNS002 0.14 0.00 0.00 0.00 -0.57 
SNS003 0.57 0.29 0.43 0.71 0.43 
SNS004 0.57 0.29 0.43 0.71 0.43 
SNS005 0.00 0.00 0.00 0.00 0.00 
SNS006 0.00 0.00 0.00 0.00 0.00 
SNS007 0.29 -0.71 -1.00 -1.00 -1.00 
SNS008 0.00 0.00 0.00 0.00 0.00 
SNS009 0.29 0.29 0.29 0.00 0.00 
SNS010 -0.14 0.29 1.00 -0.71 -0.14 
SNS011 0.14 -0.14 -0.29 -0.29 0.00 
SNS012 1.00 0.00 0.57 0.00 0.00 
SNS013 0.14 0.00 0.00 0.00 -0.14 
SNS016 0.00 0.00 0.29 0.00 0.00 
SNS017 0.00 0.00 0.00 0.00 0.00 
SNS020 0.00 0.00 0.00 0.00 0.00 
SNS021 0.00 0.00 0.00 0.00 0.00 
SNS018 -0.72 0.28 0 -0.43 0.00 
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Table_Apx 18: Transit times 
 TSM Pre SNS TSM SNS 
SNS002 - 69 
SNS003 72 59 
SNS004 54 61 
SNS005 62 67 
SNS006 69 - 
SNS007 10 17 
SNS008 63 71 
SNS009 66 72 
SNS010 55 62 
SNS011 70 72 
SNS012 72 65 
SNS013 62 72 
SNS016 72 72 
SNS017 40 64 
SNS020 63 - 
SNS021 47 46 
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Table_Apx 19: LDFC Scores 
 LDFC Pre SNS LDFC SNS 
SNS002 38.95 55.15 
SNS003 119.375 56 
SNS005 45.825 35.325 
SNS007 30.55 24.875 
SNS008 48.5 72.3 
SNS009 42.975 52.175 
SNS010 31.425 30.35 
SNS011 60.575 34.1 
SNS012 32 32.6 
SNS013 60.525 52.025 
SNS016 24.175 28.3 
SNS017 90.25 66.225 
SNS020 25.65 32 
SNS021 54.75 55.3 
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Appendix B  
 
Figure_Apx 1: Poster (ASGBI,  Bournemouth 2011) 
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Figure_Apx 2: Poster (BSG, Birmingham 2011) 
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Figure_Apx 3: Search Strategy Medline 
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Figure_Apx 4:  Searh Strategy Embase 
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Figure_Apx 5: Search Strategy CINAHL 
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Ethics Application for the study 
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LETTER TO THE GP 
Dr Y Yiannakou Secretary, University Hospital North Durham Tel 0191 3332 889 
Department of Gastroenterology, University Hospital North Durham Tel 0191 333 
2248 
Dear Doctor  
 
Patient: 
 
 
 
 
 
 
 
Date…………….. 
 
Your patient has agreed to be included in a study to examine the effectiveness of 
sacral nerve stimulation (SNS) for the management of neurological constipation. 
 
Patients referred to the Specialist Constipation Clinic at the University Hospital of 
North Durham will be invited to take part. The study involves assessment of 
subjective and objective measures pre and post SNS insertion to investigate the 
effectiveness of this procedure for the management of neuro-constipation. These 
measures involve Pre and Post Transit Study with Abdominal X-Ray (following 
ingestion of radio opaque markers), a daily defaecation and laxative diary, weekly 
self-administered questionnaires to measure symptoms (PAC-SYM) and quality of 
life (PAC-QOL); and laser Doppler flowcytometry.  
 
The decision to insert SNS is made on compassionate grounds and offered to patients 
as an alternative to surgical management for their constipation. The decision to offer 
SNS to patients does not form part of the research protocol and inclusion in the study 
is completely voluntary. Information pertaining to SNS (irrespective of whether they 
are involved in the study or not) will be provided to GP’s via the normal channels. 
 
The results of the assessments made as part of the study will be available to the 
clinicians in Dr Yiannakou’s Constipation Clinic who will correspond with the 
patient’s GP in the usual manner.  
 
Yours Faithfully 
 
Mr U Khan and Dr Y Yiannakou  
Principle Investigators 
AFFIX ADDRESSOGRAPH  
V1 03/03/2007 
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(Form to be on headed paper)  
 
 
 
CONSENT FORM 
Copies of this form must be a) supplied to the subject b) included in the medical notes 
 
A study to examine the short-term efficacy of sacral nerve stimulation 
(SNS) in neurological constipation 
 
 
 
 
 
 
 
 
I understand the nature and the purpose of the proposed study as explained to me by 
the chief investigator, Dr Y Yiannakou. 
 
I understand that I am free to ask any questions at any time during my participation 
in the study. I confirm that I have been given full written information (or equivalent 
non written information if required) about this study and have been informed of 
potential problems or side effects that might occur as part of my participation. I will 
report any problems or side effects that I experience as part of my involvement. 
 
I am aware that I am free to withdraw from the study at any time and without stating 
a reason. This will not affect my future health care. 
 
I am aware that in the event of health deteriorating in any way as a result of my 
taking part in this study, I may submit a claim to the County Durham and Darlington 
Acute Hospitals NHS Trust for compensation to be considered. I understand that I do 
not necessarily have to prove that anyone involved in the research project has been 
negligent before submitting a claim. If negligence can be established, I understand 
that my claim would be dealt with in accordance with the legal principles affecting 
claims for damages for personal injuries. If negligence cannot be established, the 
County Durham and Darlington Acute Hospitals NHS Trust will consider any claims 
on their merits and in appropriate circumstances, may decide to offer an ex-gratis 
payment. 
 
I declare that I am not taking part in any other trials at this time. 
Patient identification Addressograph 
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(Form to be on headed paper)  
 
CONSENT FORM 
 
Patient Identification (addressograph): 
 
Title of Project:  
A study to examine the short-term efficacy of sacral nerve stimulation (SNS) in 
neurological constipation 
 
Name of Researcher: Dr Y Yiannakou, Consultant Gastroenterologist 
 
Please initial box 
 
1) I confirm that I have read and understand the information sheet dated .............. 
(Version ............) for the above study and have had the opportunity to ask  
questions. 
 
2) I understand that my participation is voluntary and that I am free to withdraw at  
any time, without giving any reason, without my medical care or legal rights  
being affected. 
 
3) I understand that sections of any medical notes may be looked at by responsible  
individuals from County Durham and Darlington Acute Hospitals NHS Trust  
 or from regulatory authorities where it is relevant to my taking part in research.  
 I give permission for these individuals to have access to my records. 
 
4) I understand that the investigators would like to inform my GP of my  
 participation in the study. I give permission for my GP to be informed. 
 
 
5) I agree to take part in the above study. 
    
 
________________________ ___________ ___                  ________________ 
Name of Patient Date Signature 
 
_________________________ ______________                  ________________ 
Name of Person taking consent Date Signature 
(If different from researcher) 
 
 
_________________________ _________________             ________________ 
Researcher Date Signature 
 
 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
V1 03/03/2007 
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PROCEDURE INFORMATION SHEET  
(Given to all patients undergoing SNS even if not participating in the study) 
 
SACRAL NERVE STIMULATION (SNS) 
 
 
 
 
 
 
 
 
 
SNS is a two-stage procedure with a test (diagnostic) stage and permanent 
(therapeutic) stage. It involves placement of wire inside the sacrum bone in the lower 
back of a patient, which is connected to an external stimulator worn on a belt for a 
short period of time. Over a period of two to three weeks the symptoms of the patient 
are assessed. This test stage helps in identifying patients who may potentially benefit 
from a permanent implant. This temporary wire can later be replaced with a 
permanent one and a stimulator placed in the buttocks (under a general anaesthetic). 
 
The procedure to insert the test wire is relatively simple. The patient is put under a 
general anaesthetic in theatre. They are positioned face down on the table. The 
surgeon puts a needle into a small opening in the sacrum bone in the lower back. 
This is where the nerves supplying the bowel originate. After placing the needle its 
position is checked with x-rays. The wire is passed through the needle close to the 
nerves and the needle is removed. The wire is secured with tape and then connected 
to a stimulator, which the patient wears on a belt. The doctors who insert SNS in 
Durham are all experienced in this procedure and the whole procedure takes 10-15 
minutes. 
 
SNS involves the use of chronic low-level stimulation of sacral nerves by a small 
electrical current to produce a beneficial effect on the hindgut, pelvic floor and the 
anal sphincters. It has been shown to be safe and effective in faecal incontinence and 
bladder dysfunction. Using SNS to treat constipation is relatively new but it is being 
done more and more in the UK.  
 
Your symptoms of constipation are severe and have not responded to simple 
treatments like changes to diet, laxatives or enemas. For some of our patients other 
treatments can be offered but may involve surgery to remove part of the colon (large 
bowel). 
This would involve a major operation with risks of complications that although 
infrequent, can be significant and serious. 
You are invited to consider an alternative treatment called Sacral Nerve Stimulation (SNS). This 
is a minimally invasive procedure that should benefit patients with severe constipation.  
  
181 
 
SNS is a very safe procedure but you should be aware that there are some small risks 
that can happen when test wire is inserted. These can include bleeding and 
infection. These risks are explained below. 
 
At the time of wire insertion minor bleeding can occur due to the needle. The 
surgeon can easily control this bleeding during the operation. 
 
Infection can sometimes develop at the site where the wire is inserted. Every 
necessary precaution including strict aseptic measures is taken to prevent infection. 
If the infection does not settle, it maybe necessary to remove the wire. After removal 
the infection will improve. There is a small chance of the wire falling out but every 
necessary precaution is taken to prevent that at the time of the procedure. 
 
We plan for a hospital stay of 12 hours. The wire and stimulator settings will be set 
and explained by a representative from Medtronic (the company that makes this 
equipment) to the patients before discharge. Patients will be seen and assessed in 
clinic after three weeks of SNS. 
 
Before SNS is inserted you will be able to discuss the procedure with the surgeons in 
the outpatient clinic. You will also have the opportunity to speak to some the patients 
who have already had SNS inserted.  You will be able to talk to them about their 
experiences.  
 
Before the procedure you will be asked by Mr Jag Varma or Ms Susan Green to sign 
a form to give consent.  Should you have any questions at any time we will be happy 
to answer them. 
 
Mr. Jag Varma      Ms Susan Green 
Consultant Colorectal Surgeon    Consultant Colorectal 
Surgeon 
 
 
 
 
 
 
 
 
 
 
 
 
 
University Hospital North Durham 
Durham DH1 5TW 
0191 3332888  
V1 03/03/2007 
  
182 
 
STUDY INFORMATION SHEET 
(Given to patient participating in the study) 
 
A STUDY TO EXAMINE THE SHORT-TERM EFFICACY OF SACRAL 
NERVE STIMULATION (SNS) IN NEUROLOGICAL CONSTIPATION 
 
 
 
 
 
 
 
Introduction 
Your Doctor (either a hospital specialist or your GP) has referred you to the 
Constipation Clinic at the University Hospital of North Durham. At the clinic tests 
are performed to understand why you have constipation and how severe the problem 
is. 
In patients with neurological problems like multiple sclerosis (MS) or spinal cord 
diseases, constipation can be a severe predicament. Often treatment with laxatives or 
enemas is ineffective. For some of our patients other treatments can be offered but 
may involve surgery to remove part of the colon (large bowel).  
An alternative to surgery is SNS, which stimulates the large bowel to improve 
constipation.  Information is available about SNS from the doctors in the 
Constipation Clinic (Dr Yan Yiannakou and Mr Usman Khan).  
SNS is being used more and more in the UK to treat constipation. The technique has 
been shown to be successful and is an alternative to surgery. We feel that it is 
important to gather detailed information about how useful SNS is to treat patients 
with neurological constipation. 
 
What is the purpose of the study? 
The purpose of the study is to look at how effective SNS is for treating neurological 
constipation in patients only during the testing stage. To do this we need to gather 
detailed information about how severe the constipation is before and after the SNS.  
 
Why have I been chosen? 
You have been invited to take part because you have severe neurological 
constipation that has not responded well to standard treatments (laxatives and 
enemas). Because your symptoms have not responded well to laxatives and enemas 
and you have agreed to have SNS you have been invited to take part.  
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with friends, relatives and your GP if 
you wish. Ask us if there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part.  
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Deciding that you would like to have SNS does not automatically mean that you will 
be involved in the study. To become part of the study you will have to make a 
separate decision to take part or not. 
 
What will happen to me if I take part?  
The study will last 12 weeks for each person taking part in the study. Each person 
taking part in the study will be asked to fill in a daily diary during the trial. For the 
first three weeks that will involve a weekly assessment of your constipation or faecal 
incontinence by filling in one box in the diary with the help of a rating scale that will 
be provided. During the next six weeks you will also have to provide information 
about your bowel habits and intake of laxatives in addition to the above and during 
the last three weeks you will revert back to filling one box weekly about your 
constipation or faecal incontinence. We will also ask you to fill in weekly short 
questionnaires about your symptoms and quality of life in addition to the diary.  
We will ask everyone taking part in the trial to come to the hospital for a three 
weekly visit (at week three, six and nine) for a laser Doppler test of the back passage 
lasting 10-15 minutes. This will involve passing a small telescope in the back 
passage to take laser Doppler measurements. During that visit you will be asked to 
fill in a health related questionnaire and your diary cards will be collected and 
analysed.  
At week nine during the period of stimulation you will be asked to have a Transit 
Study. This will involve swallowing small capsules full of markers and then having 
an X-ray of the abdomen. By counting the number of markers in the bowel we will 
be able to work out how fast the bowel is working. You will already have had a 
Transit Study done when you were first referred to Dr Yiannakou’s clinic. 
 
Will my taking part in the study be kept confidential? 
The results and information collected in the study will not be disclosed outside of the 
hospital. Any information about you will have the name and address removed so that 
you cannot be recognised by it.  
 
What will happen to the results of my tests? 
The results of your investigations will be kept confidentially in your medical records. 
The results will be available to the doctors in the Constipation Clinic, your hospital 
doctor and GP. We will analyse the results of tests and questionnaires and discuss 
the results with you in clinic. We will provide you with a written summary of the 
project upon completion of the study. 
We may write a report about our findings and attempt to publish this in a medical 
journal. In the report the results will be anonymous with no personal details such as 
name or address. If you decide to withdraw from the study, we will ask your 
permission to keep the results of your investigations. Any results from the study will 
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be kept securely and confidentially in the hospital for a maximum of three years. 
After this, the results will be destroyed. 
 
What are the benefits of taking part in the study? 
The experience in other hospitals around the world suggests that investigations such 
as these give extra information about neurological constipation. It is hoped that such 
information will help patients now and in the future who have similar problems.  
 
What are the disadvantages of taking part in the study? 
We understand that filling in diaries and questionnaires can be a little tedious but 
they are designed to be very simple and can be filled by marking off the boxes in a 
few minutes.  
If you take part in the study you will have two transit studies done, one before the 
SNS and one after. This means that in addition to the routine abdominal X-ray that 
we request for all of our patients in the clinic, you will be asked to have another 
Abdominal X-ray as part of the study.  
We do not believe that the extra radiation exposure during the second abdominal X-
ray will cause any problems to our patients either now or in the future. This is 
because the amount of X-ray radiation used for the Transit study is minimal.  
However, extra radiation is not recommended in special situations (such as 
pregnancy) and you are encouraged to discuss having the X-rays with the doctors in 
the clinic to make sure no special situations affect them. There are no reports in the 
medical literature that the markers we ask the patients to swallow for the transit 
study cause any side effects. 
We believe that the only disadvantage of being involved is that you may have to 
spend a little longer visiting hospital during your three weekly visits for laser 
Doppler testing.  The laser Doppler procedure is an additional but essential element 
of this study and is not part of standard treatment for patients coming to the 
constipation clinic. 
 
Do I have to take part in the study? 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep. You will be asked to sign a consent 
form.  
If you decide to take part you are still free to withdraw at any time and without 
giving a reason. This will not affect the standard of care you receive now or in the 
future. Being involved in the study is completely voluntary. 
 
What if I am upset or inconvenienced by taking part in the study? 
If you feel upset at any time during your involvement or you wish to complain about 
any aspect of the way you have been approached or treated during the study, the 
normal National Health Service complaints processes will be available to you.  
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In addition you will be able to discuss any concerns you have at any time before or 
after the tests with Dr Yan Yiannakou or Mr Usman Khan. 
 
Who is co-ordinating the study? 
Dr Yan Yiannakou and Mr Usman Khan are co-ordinating the study. Both are based 
at the University Hospital of North Durham. If you wish to ask questions please do 
not hesitate to telephone Dr Yiannakou’s secretary on 0191 3332889. 
 
Has the design of this study been checked by other Doctors or Scientists? 
Members of the Local Ethics Committee have checked the aims and design of this 
study. This committee is made up of doctors, scientists and lay people. Their job is 
to make certain that any studies involving patients in the UK are carried out safely 
and sensibly and in away that will be beneficial to patients now and in the future.  
 
What do I do now? 
If you would like to help with the study please sign the consent form. Please keep 
this information sheet. 
 
Thank you for your cooperation. 
 
 
 
V1 03/03/2007 
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Over next six weeks you will also 
have to provide information about 
your bowel habits and intake of 
laxatives in a daily diary 
 
During the last three weeks you will 
revert back to filling one box weekly 
about your bowel movements 
 
a.  
b.  
c.  
d.  
e.  
f.  
 
g.  
 
h.  
i.  
j.  
 
k.  
l.  
 
m.  
n.  
o.  
p.  
q.  
r.  
s.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
You have been asked to take part 
because your symptoms have not 
responded to the normal treatments 
(laxatives or enemas) and you have 
agreed to have SNS 
 
You have been asked to 
take part because you 
have neurological 
constipation. 
You will already have had routine 
investigations when you were referred to 
the clinic including a Transit study (X ray of 
the abdomen after taking capsules) 
 
What will happen if I agree to take part in the study? 
 
 
The study will last 12 weeks for 
persons taking part in the study 
and you will be asked to do the 
following things 
 
We will ask you to fill in short 
questionnaires on a weekly basis 
about your symptoms and quality of 
life 
You will have to come to the 
hospital on three weekly visits 
(weeks 3, 6 & 9) for a laser Doppler 
test of the back passage 
During those visits you will fill a 
questionnaire about your health 
and your diary will be collected and 
analysed 
 
You will also be asked to fill in 
daily diary cards 
For the first three weeks this will 
involve a weekly assessment of your 
bowel movements by filling in a 
diary with the help of a rating scale 
that will be provided 
 
It is important that you read the full information 
leaflet about this study. Please contact the study 
coordinators (Mr Khan & Dr Yiannakou) if you have 
any questions. University Hospital of North Durham  
0191 3332889 
 
A STUDY TO EXAMINE THE SHORT-TERM EFFICACY OF SACRAL NERVE 
STIMULATION (SNS) IN NEUROLOGICAL CONSTIPATION 
 
At week 9 during the period of 
stimulation you will be asked to 
have a Transit Study (x-ray of the 
abdomen after taking capsules) 
 
V1 03/03/2007 
  
187 
 
CARER INFORMATION 
 
A STUDY TO EXAMINE THE SHORT-TERM EFFICACY OF SACRAL 
NERVE STIMULATION (SNS) IN NEUROLOGICAL CONSTIPATION 
 
 
 
 
 
 
 
Introduction 
The person you care for has been referred by their Doctor (either a hospital specialist 
or your GP) to the Constipation Clinic at the University Hospital of North Durham. 
At the clinic tests are performed to understand why patients have constipation and 
how severe the problem is.  
In patients with neurological problems like multiple sclerosis (MS) or spinal cord 
diseases, constipation can be a severe predicament. Often treatment with laxatives or 
enemas is ineffective. For some of our patients other treatments can be offered but 
may involve surgery to remove part of the colon (large bowel).  
An alternative to surgery is SNS, which stimulates the large bowel to improve 
constipation.  Information is available about SNS from the doctors in the 
Constipation Clinic (Dr Y Yiannakou and Mr U Khan).  
SNS is being used more and more in the UK to treat constipation. The technique has 
been shown to be successful and is an alternative to surgery. We feel that it is 
important to gather detailed information about how useful SNS is to treat patients 
with neurological constipation. 
 
What is the purpose of the study? 
The purpose of the study is to look at how effective SNS is for treating neurological 
constipation in patients. To do this we need to gather detailed information about how 
severe the constipation is before and after the SNS. 
 
Why has the person you care for been chosen? 
The person you care for has been invited to take part because they have severe 
neurological constipation that has not responded well to standard treatments 
(laxatives and enemas). They have been invited to take part because they have 
agreed to have SNS.  
Deciding that they would like to have SNS does not automatically mean that they 
will be involved in the study. To become part of the study the person you care for 
will have to make a separate decision to take part or not. 
The person you care for has been invited to take part in a research study. Their involvement 
in the study may have an effect on your role as a carer. It is important for you and the person 
you care for to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully. Ask us if there is anything that is not 
clear or if you would like more information.  
Take time to decide whether or not you wish to take part.  
 
  
188 
 
 
What will happen to the person you care for if they take part?  
The study will last 12 weeks for each person taking part in the study. Each person 
taking part in the study will be asked to fill in a daily diary during the trial. For the 
first three weeks that will involve a weekly assessment of their constipation or faecal 
incontinence by filling in one box in the diary with the help of a rating scale that will 
be provided. During the next six weeks the person you care for will also have to 
provide information about their bowel habits and intake of laxatives in addition to 
the above and during the last three weeks they will revert back to filling one box 
weekly about your constipation or faecal incontinence. We will also ask them to fill 
in weekly short questionnaires about their symptoms and quality of life in addition to 
the diary.  
We will ask everyone taking part in the trial to come to the hospital for a three 
weekly visit (at week three, six and nine) for a laser Doppler test of the back passage 
lasting 10-15 minutes. This will involve passing a small telescope in the back 
passage to take laser Doppler measurements. During that visit the person you care 
for will be asked to fill in a health related questionnaire and their diary cards will be 
collected and analysed. 
At week 9 during the period of stimulation they will be asked to have a Transit 
Study. This will involve swallowing small capsules full of markers and then having 
an X-ray of the abdomen. By counting the number of markers in the bowel we will 
be able to work out how fast the bowel is working. The person you care for will 
already have had a Transit Study done when they were first referred to Dr 
Yiannakou’s clinic.  
 
What are the benefits of taking part in the study? 
The experience in other hospitals around the world suggests that investigations such 
as these give extra information about neurological constipation. It is hoped that such 
information will help patients now and in the future who have similar problems.  
 
What are the disadvantages of taking part in the study? 
We understand that filling in diaries and questionnaires can be a little tedious but 
they are designed to be very simple and can be filled by marking off the boxes in a 
few minutes. 
If the person you care for takes part in the study they will have two transit studies 
done, one before the SNS and one after. This means that in addition to the routine 
abdominal X-ray that we request for all of our patients in the clinic, they will be 
asked to have another Abdominal X-ray as part of the study.  
We do not believe that the extra radiation exposure during the second abdominal X-
ray will cause any problems to our patients either now or in the future. This is 
because the amount of X-ray radiation used for the Transit study is minimal.  
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However, extra radiation is not recommended in special situations (such as 
pregnancy) and the person you care for is encouraged to discuss having the X-rays 
with the doctors in the clinic to make sure no special situations affect them. There 
are no reports in the medical literature that the markers we ask the patients to 
swallow for the transit study cause any side effects. 
We believe that the only disadvantage of being involved is that the person you care 
for may have to spend a little longer visiting hospital during their three weekly visits 
for laser Doppler testing. The laser Doppler procedure is an additional but essential 
element of this study and is not part of standard treatment for patients coming to the 
constipation clinic. 
 
Does the person I care for have to take part in the study? 
It is up to the person you care for to decide whether or not to take part. To help them 
make this decision they may want to talk to the doctors in the Constipation Clinic, 
their GP, friends, family and carers.  If the person you take care of decides to take 
part you will be given this information sheet to keep.  
The person you care for will be asked to sign a consent form. If they decide to take 
part they are still free to withdraw at any time and without giving a reason. This will 
not affect the standard of care they receive now or in the future. Being involved in 
the study is completely voluntary. 
 
What if the person I care for is upset or inconvenienced by taking part in the 
study? 
If the person you care for feels upset at any time during their involvement or they 
wish to complain about any aspect of the way they have been approached or treated 
during the study, the normal National Health Service complaints processes will be 
available to them. In addition they will be able to discuss any concerns they have at 
any time before or after the tests with Dr Yan Yiannakou or Mr Usman Khan. 
 
Who is co-ordinating the study? 
Dr Yan Yiannakou and Mr Usman Khan are co-ordinating the study. Both are based 
at the University Hospital of North Durham. If you or the person you care for wish to 
ask questions please do not hesitate to telephone Dr Yiannakou’s secretary on 0191 
3332889. 
 
 
Thank you for your cooperation. 
 
 
 
V1 03/03/2007 
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PAC-SYM  
PATIENT ASSESSMENT OF CONSTIPATION 
 
This questionnaire asks you about your constipation symptoms in the past week. Answer each question 
according to your symptoms, as accurately as possible. There are no right or wrong answers. 
For each symptom below, please indicate how severe your symptoms have been during the past week. If 
you have not had the symptom during the past week, tick 0.  If the symptom seemed mild, tick 1.  If the 
symptom seemed moderate, tick 2.  If the symptom seemed severe, tick 3.  If the symptom seemed very 
severe, tick 4.  Please be sure to answer every question. 
 
How severe have each of these symptoms been 
in the past week? 
 
Absent 
0 
 
Mild 
1 
 
Moderate 
2 
 
Severe 
3 
Very 
severe 
4 
1. discomfort in your stomach      
2. pain in your stomach      
3. bloating in your stomach      
4. stomach cramps      
5. painful bowel movements      
6. rectal burning during or after a bowel 
movement 
     
7. rectal bleeding or tearing during or after a 
bowel movement 
     
8. incomplete bowel movement, as though you 
didn’t “finish” 
     
9. stools that were too hard      
10. stools that were too small      
11. straining or squeezing to try to pass stools      
12. feeling like you had to pass a stool but you 
couldn’t (false alarm) 
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PAC-QOL  
PATIENT ASSESSMENT OF CONSTIPATION 
 
The following questions are designed to measure the impact constipation has had on your daily life during 
the past week. For each question, please tick one box. 
 
The following questions ask you about 
the intensity of your symptoms. To 
what extent, during the past week... 
 
 
Not at all 
0 
 
 
A little bit 
1 
 
 
Moderately 
2 
 
 
Quite a bit 
3 
 
 
Extremely 
4 
1. have you felt bloated to the point of 
bursting? 
     
2. have you felt heavy because of your 
constipation? 
     
 
 
The next few questions ask you about 
the effects of constipation on your 
daily life. How much of the time, during 
the past week... 
None of 
the time 
0 
A little of 
the time 
1 
Some of 
the time 
2 
Most of 
the time 
3 
All of  
the time 
4 
3. have you felt any physical 
discomfort? 
     
4. have you felt the need to open your 
bowel but not been able to? 
     
5. have you been embarrassed to be 
with other people? 
     
6. have you been eating less and less 
because of not being able to have 
bowel movements? 
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The next few questions ask you about 
the effects of constipation on your 
daily life. To what extent, during the 
past week... 
 
 
Not at all 
0 
 
 
A little bit 
1 
 
 
Moderately 
2 
 
 
Quite a 
bit 
3 
 
 
Extremely 
4 
7. have you had to be careful about 
what you eat? 
     
8.  have you had a decreased 
appetite? 
     
9. have you been worried about not 
being able to choose what you eat 
(for example, at friend’s)? 
     
10. have you been embarrassed about 
staying in the toilet for so long when 
you were away from home? 
     
11. have you been embarrassed about 
having to go to the toilet so often 
when you were away from home? 
     
12. have you been worried about 
having to change your daily routine 
(for example, travelling, being away 
from home)? 
     
 
The next few questions ask you about 
your feelings. How much of the time, 
during the past week... 
None of 
the time 
0 
A little of 
the time 
1 
Some of 
the time 
2 
Most of 
the time 
3 
All of the 
time 
4 
13. have you felt irritable because of 
your condition? 
     
14. have you been upset by your 
condition? 
     
15.  have you felt obsessed by your 
condition? 
     
16. have you felt stressed by your 
condition? 
     
17. have you been less self-confident 
because of your condition? 
     
18. have you felt in control of your 
situation? 
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The next questions ask you about your 
feelings. To what extent, during the 
past week.. 
 
Not at all 
0 
 
A little bit 
1 
 
Moderately 
2 
 
Quite a bit 
3 
 
Extremely 
4 
19. have you been worried about not 
knowing when you are going to be 
able to open your bowels? 
     
20.  have you been worried about not 
being able to open your bowels when 
you needed to? 
     
21. have you been more and more 
bothered by not being able to open 
your bowels? 
     
 
The next questions ask about your life 
with constipation.  How much of the 
time, during the past week... 
None of 
the time 
0 
A little of 
the time 
1 
Some of 
the time 
2 
Most of 
the time 
3 
All of the 
time 
4 
22. have you been afraid that your 
condition will get worse? 
     
23. have you felt that your body was not 
working properly? 
     
24. have you had fewer bowel 
movements than you would like? 
     
 
The next questions ask you about how 
satisfied you are. To what extent, 
during the past week... 
 
Not at all 
0 
 
A little bit 
1 
 
Moderately 
2 
 
Quite a bit 
3 
 
Extremely 
4 
25. have you been satisfied with how 
often you open your bowels? 
     
26. have you been satisfied with the 
regularity with which you open your 
bowels? 
     
27. have you been satisfied with your 
bowel function? 
     
28. have you been satisfied with your 
treatment? 
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EuroQOL Health Questionnaire 
(English version for the UK) 
(Validated for use in Eire) 
 
By placing a tick in one box in each group below, please indicate which statements best 
describe your own health state today. 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed   
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To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 
and the worst state you can imagine is marked 0. We 
would like you to indicate on this scale how good or bad 
your own health is today, in your opinion. Please do this 
by drawing a line from the box below to whichever point 
on the scale indicates how good or bad your health 
state is today. 
 
 
 
 
 
 
Your own 
health state 
today 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
Worst 
imaginable 
health state 
0 
Best  
imaginable 
health state 
